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ABSTRACT 
The number of people having diabetes mellitus is increasing worldwide at an alarming 
rate. An unbalanced diet rich in carbohydrates and saturated fats, obesity and lack of 
physical activity, are being blamed. The worldwide prevalence of diabetes for all age-
groups has been estimated to be 2.8% in 2000 and projected to be 4.4% by the year 2030. 
The pathogenesis of diabetes, especially the recent epidemic increase in type 2 diabetes, 
is still far from clear. Endothelial dysfunction, commonly defined as reduced 
endothelium-dependent relaxation due to reduced availability of the vasodilator mediator 
nitric oxide (NO), is a hallmark of diabetes mellitus. Methylglyoxal (MG) is a highly 
reactive dicarbonyl compound mainly formed as an intermediate during glycolysis. MG 
is also formed to a lesser extent from protein and amino acid metabolism. However, the 
relative contribution of various metabolic precursors to MG formation is not known. 
Levels of MG have been found to be elevated in diabetic and hypertensive conditions but 
it is not known whether MG is the cause or the effect of these pathological conditions. 
The aim of my project was (i) to quantify the amount of MG and oxidative stress 
produced from various substrates in cultured A10 vascular smooth muscle cells 
(VSMCs), (ii) to investigate the acute in vivo effects of a single dose of MG on glucose 
tolerance in male Sprague-Dawley (SD) rats, (iii) to investigate the effects of MG on 
endothelial function and (iv) to investigate the effects, and the underlying molecular 
mechanisms, of chronic administration of MG on glucose homeostasis in male SD rats. 
The results show that aminoacetone, a protein metabolism intermediate, is the most 
potent substrate for MG formation on a molar basis, whereas D-glucose and fructose are 
equipotent. I also established optimum sample preparation protocols for reproducible 
 ii
measurement of MG in biological samples by high performance liquid chromatography 
(HPLC). In normal SD rats a single acute dose of MG induced glucose intolerance, 
reduced adipose tissue glucose uptake and impaired the insulin signalling pathway, which 
was prevented by the MG scavenger and advanced glycation end product (AGE) breaking 
compound, alagebrium (ALT-711). MG and high glucose (25 mM) induced endothelial 
dysfunction in rat aortic rings and cultured endothelial cells by reducing endothelial nitric 
oxide synthase (eNOS) phosphorylation at Ser-1177, activity and NO production. MG 
and high glucose also increased oxidative stress and further reduced NO availability in rat 
aortic rings and cultured endothelial cells. Chronic administration of MG in normal SD 
rats by continuous infusion with a subcutaneously implanted minipump for 28 days (60 
mg/kg/day), induced metabolic and biochemical abnormalities of glucose homeostasis 
and insulin regulation that are characteristic of type II diabetes. In MG treated rats, 
insulin stimulated glucose uptake in adipose tissue, and glucose stimulated insulin release 
from freshly isolated pancreas, were significantly reduced as compared to saline treated 
control rats. At a molecular level, insulin gene transcription was significantly impaired 
and apoptosis and DNA fragmentation were more prevalent in the pancreas of MG 
treated rats as compared to untreated control rats. All of these in vivo effects of MG were 
attenuated by the MG scavenger, alagebrium. Our data strongly indicate that MG is a 
causative factor in the pathogenesis of endothelial dysfunction and type 2 diabetes 
mellitus. 
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CHAPTER 1 
 
INTRODUCTION AND LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
1 
 
1.1 Diabetes mellitus 
 
Diabetes mellitus (DM), as defined in Harrison’s Principles of Internal Medicine, is “a 
group of common metabolic disorders that share the phenotype of hyperglycemia” (page-
2275). DM is usually characterized by abnormally high blood glucose levels (hyperglycemia), 
glycosuria (glucose in urine), hyperlipidemia and sometimes ketonemia. Because of the 
constant exposure to high concentrations of glucose, there is increased nonenzymatic 
glycosylation of proteins which is considered to be a causative factor in the pathological 
changes of diabetes (Harrison’s Principles of Internal Medicine). As DM progresses, there is 
increased thickening of capillary basement membrane, and increased cellular proliferation, 
which result in vascular complications such as atherosclerosis, retinopathy, neuropathy and 
peripheral vascular insufficiency. Insulin enables the cells to absorb glucose and convert it into 
energy. In case of DM, there is either a deficiency of insulin or high insulin levels due to the 
body’s inability to properly respond to insulin to meet its needs. This phenomenon creates a 
vicious cycle resulting in persistent hyperglycemia, often leading to various complications 
(Rother, 2007). Maintaining optimum glucose control minimizes the risk of long term 
complications of diabetes.  
In 2008, there were 1.66 million people with diabetes in Canada compared to 1.22 
million in 2003, a staggering increase of 36% in 5 years (Diabetes, by sex, provinces and 
territories). In the year 2009, the American Diabetes Association reported that 23.6 million 
children and adults in the United States, i.e., 7.8% of the population, had diabetes. It is 
estimated that 17.9 million in the US alone have been diagnosed with diabetes, and there are 
another 5.7 million (nearly one in four) diabetics who are not even aware that they have the 
disease (Diabetes facts, Centers for Disease Control, USA). The World Health Organization 
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had predicted that by 2010, there will be more than 230 million people diagnosed with 
diabetes world-wide out of which three million will be in Canada (Diabetes Report, Diabetes 
2000; Diabetes. The Provincial Plan). The risk of heart disease or stroke is six times and the 
risk of high blood pressure is four times higher for people with diabetes aged 35-64 years, 
compared to the general population. In Canada the total costs of health care and services, and 
loss of work resulting from diabetes is estimated to be $ 9 billion annually (Diabetes Report, 
Diabetes 2000; Diabetes. The Provincial Plan). 
 
<5.6 mmol/L
(100 mg/dL) 
5.6-6.9 mmol/L
(100-125 mg/dL) 
≥7.0 mmol/L 
(126 mg/dL) 
<7.8 mmol/L
(140 mg/dL) 
7.8–11.1 mmol/L
(140-199 mg/dL) ≥11.1 mmol/L 
(200 mg/dL) 
Normoglycemia Hyperglycemia
Prediabetes Diabetes
Types of 
diabetes
Type 1
Type 2
Gestational
Other types
Fasting
plasma
glucose
2h 
plasma
glucose
Normal 
glucose 
tolerance
Impaired fasting 
glucose
or impaired 
glucose tolerance
Not insulin 
requiring
Insulin 
required 
for control
Insulin 
required
for survival
Time
(years)
 
Table 1-1. Main types of diabetes mellitus and the associated plasma glucose levels and 
insulin-dependency across the life span (Adapted from Harrisons Principles of Internal 
Medicine, 17th edition, 2008) 
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There are several types of diabetes mellitus (American Diabetes Association, 2007) 
with distinct differences which arise from complicated interactions between genetic and 
environmental factors. An extensive etiologic classification has been formulated (American 
Diabetes Association, 2007). The three main types of diabetes mellitus (Table 1) are described 
below: 
 
1.1.a  Type I diabetes mellitus 
Type I diabetes mellitus (T1DM) also used to be known as insulin dependent diabetes 
mellitus (IDDM) or juvenile onset diabetes mellitus, terms that are no longer used. In T1DM, 
there is pancreatic β cell destruction and patients have to depend on insulin injections for 
survival. The majority of cases of T1DM are due to autoimmunity. In T1DM, the immune 
system mistakenly manufactures antibodies and inflammatory cells which cause damage to the 
patient’s own body (Cooke and Plotnick, 2008). The most commonly observed antibodies in 
T1DM are anti-islet cell antibodies, anti-insulin antibodies and anti-glutamic decarboxylase 
antibodies. These antibodies are used as markers to identify individuals at a risk of developing 
T1DM. However some cases of T1DM are idiopathic, that is no β cell antibodies are found 
(Gillespie, 2006). The abnormal antibodies found in T1DM are in part genetically inherited 
but the details are not yet fully known (Van den Driessche et al., 2009). The number of 
patients having T1DM is ~10% whereas the remaining 90% have type II diabetes mellitus 
(T2DM), which is described later (Gillespie, 2006).  
There are a number of animal models used for T1DM research. The non obese diabetic 
(NOD) mouse develops diabetes spontaneously (Makino et al., 1980) and is often used as a 
T1DM model. Another animal model often used in research laboratories is the streptozotocin 
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(STZ)-induced diabetes. STZ is a chemical which causes destruction of β cells of the pancreas 
and produces symptoms similar to T1DM (Cefalu, 2006). 
.  
1.1.b Type 2 diabetes mellitus 
T2DM also used to be known as non-insulin dependent diabetes mellitus (NIDDM) or 
maturity onset diabetes mellitus as it usually occurs in people above the age of 30 (Lebovitz, 
2001). The latter terms are no longer accepted. T2DM is characterized by insulin resistance, 
impaired β cell function and glucose regulation which ultimately lead to β cell failure. In the 
case of T2DM, there are insulin producing functional β cells in varying numbers, despite 
gradual progressive apoptosis in the advanced stages of the condition. In the early stage of 
T2DM, the insulin resistance, characterized by defects in the insulin signalling pathway 
(Reaven, 1988), elicits a compensatory increase in pancreatic insulin secretion and higher than 
normal plasma insulin levels (Fig. 1). However, as the disease progresses, the release of 
insulin from the pancreas becomes reduced, due to apoptosis and decrease in β cell numbers in 
the later stages of T2DM, resulting in lower than normal plasma insulin levels and 
hyperglycemia. The apoptosis of pancreatic islet β cells in T2DM differentiates it from the 
necrosis of β cells seen in T1DM. Thus, insulin in the circulation can be either high or low 
depending on the stage of diabetes (Fig. 1). Poor eating habits, higher body weight and lack of 
physical exercise make people more susceptible to develop T2DM (Israili, 2009; Barnett, 
2009). T2DM has a strong genetic predisposition, however there are other risk factors 
involved, the most notable of which is obesity. Previous studies have reported that the risk of 
developing T2DM doubles for every 20% increase in the body weight (Inzucchi and Sherwin, 
2005).  
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Figure 1-1. The relationship between pancreatic β cell function, plasma insulin levels and 
the stages of type 2 diabetes mellitus. 
 
Glucose plays a key role in insulin secretion from the pancreatic β cell. Insulin secretion 
starts with glucose transport by the glucose transporter 2 (GLUT2) in pancreas which in turn 
induces an increase in glucokinase. Glucokinase induces phosphorylation of glucose by 
glycolysis leading to the generation of adenosine triphosphate (ATP) which inhibits the ATP 
sensitive potassium (KATP) channels, causing hyperpolarization, and increasing intracellular 
calcium which ultimately leads to exocytosis of the insulin granules. In the case of T2DM, 
glucose transport is greatly reduced (Porte, 1991). As the disease progresses, the release of 
newly synthesized insulin is impaired. This phenomenon is termed as ‘desensitization’ or ‘β 
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cell toxicity’ (Malaisse, 1996). In some families of T2DM patients an absence of glucokinase 
has been reported (Nicholls et al., 1995), however, this has not been seen in other families of 
T2DM. In the majority of cases of T2DM, there is an inherited or acquired defect within the β 
cell. As the disease progresses there is a decrease in insulin secretion due to accumulation of 
glucose metabolites (Mahler and Adler, 1999). 
As described by Neubauer and Kulkarni (2006), there are a number of animal models of 
T2DM like the ob/ob (obese) or db/db (diabetes) mice. The ob/ob mouse model was created 
by inducing mutation in the leptin gene whereas the db/db model was created by inducing 
mutation in the leptin receptor. Leptin is a hormone secreted mainly by the adipocytes in 
response to fatty acid storage in these cells. Leptin plays a negative feedback role in food 
intake, energy production, and weight regulation. Defects in leptin production or leptin 
receptor disrupt this feedback cycle and cause weight gain and obesity (Neubauer and 
Kulkarni, 2006). The Zucker diabetic fatty (ZDF) rat is another T2DM animal model widely 
used in research. ZDF rats also have mutation in their leptin receptor and become obese within 
the first few months of life (Clark et al., 1983; Peterson et al., 1990). The Goto Kakizaki (GK) 
rat is a model of T2DM with the characteristic that it is non obese and has decreased β cell 
mass (Goto and Kakizaki, 1981). As diet contributes to the development of diabetes, a diet 
high in fat or carbohydrate accelerates the development of T2DM (Cefalu, 2006). One such 
model of diet-induced diabetes is the fructose-induced diabetes in Sprague-Dawley (SD) rats 
(Hwang et al., 1987). Our lab has shown that SD rats fed high fructose (60% of total dietary 
calories) develop insulin resistance (Jia and Wu, 2007). The use of an appropriate animal 
model can provide insights into the pathophysiological mechanisms and molecular targets for 
the development of effective and safer drugs and prevention of the disease. T2DM differs 
7 
 
from T1DM in many respects as shown in table 2.   
 
Table 1-2. Differences between type 1 and type 2 diabetes mellitus 
Type 1 Diabetes Type 2 Diabetes 
Prevalence less than 10% Prevalence more than 90% 
Onset: typically in childhood 
Symptoms usually start in childhood or young 
adult 
Onset: typically middle-age and later 
Recently many childhood onset cases  
May not have symptoms before diagnosis 
Genetic predisposition moderate  
Autoimmune disease 
Genetic predisposition is very strong 
 
No or very little insulin Combination of insulin resistance and insulin 
secretary defect 
Episodes of low blood sugar level 
(hypoglycaemia) common with insulin 
treatment  
Hyperglycemia mostly, episodes of low blood sugar 
level relatively few 
Cannot be prevented Can be prevented or delayed with healthy life style 
No glucose intolerance  Glucose intolerance 
Ketonemia and ketoacidosis common with 
uncontrolled hyperglycemia  
Not commonly seen  
  
1.1.c Gestational diabetes mellitus 
Gestational diabetes occurs in pregnant women who have high blood glucose levels 
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during pregnancy. Gestational diabetes may lead to T2DM or sometimes T1DM in 
predisposed people, but is usually resolved once the baby is born. Oral glucose tolerance test 
is done after delivery to determine if the patient is at a future risk of developing diabetes. 4% 
of all pregnant women are affected by gestational diabetes (Diabetes Care, 2004).    
 
1.1.d Insulin signalling pathways 
The hormone insulin is secreted by the β cells of the pancreatic islets in response to 
several stimuli, the main one being an elevation of blood glucose concentration. Insulin has 
anabolic functions. Thus, it helps in growth and development and maintenance of glucose 
homeostasis. Insulin plays a major role in glucose homeostasis, glycogen and protein 
synthesis, the inhibition of lipolysis and the stimulation of fat storage (Saltiel and Kahn, 2001; 
Saltiel and Pessin, 2002).  The insulin receptor is a tyrosine kinase receptor located in the cell 
plasma membrane (Fig. 2).  Stimulation of the insulin receptor phosphorylates and activates 
proteins such as Cb1 (Saltiel and Kahn, 2001), APS [an adaptor protein (Moodie et al., 1999)], 
Shc (an adaptor protein), Gab-1 [Grb-2 associated binding protein 1 (Holgado-Madruga et al., 
1996)] and insulin receptor substrate (IRS) proteins on tyrosine residues (Fig. 2). The 
downstream effectors are components of three major pathways: the more insulin specific 
phosphatidylinositol-3 kinase (PI3K) and the Cb1, and the more common mitogen activated 
protein kinase (MAPK) pathway, through which many growth factors signal. Recruitment of 
PI3K by the activated IRS proteins results in conversion of membrane lipid 
phosphatidylinositol (Jia & Wu, 2007) bisphosphate (PIP2) to phosphatidylinositol (Jia & Wu, 
2007) trisphosphate (PIP3). PIP3 activates phosphoinositide-dependent kinase-1 (PDK1), 
which in turn activates protein kinase (PKB, also known as Akt). Activation of Cb1 causes 
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GLUT4 translocation from the cytosolic vesicles to the cell plasma membrane to facilitate 
glucose transport into the cell (Fig. 1-2). Insulin reduces hepatic glucose production by 
decreasing gluconeogenesis and glycogenolysis, and it promotes glucose uptake into insulin-
sensitive tissues such as skeletal muscle and adipose tissue. 
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Figure 1-2. Insulin’s metabolic and growth promoting signalling pathways. The schematic 
shows the major components in simplified signal transduction pathways stimulated by insulin 
acting on the insulin receptor.  
Abbreviations: Glycogen synthase kinase 3β (GSK3β), protein kinase B (PKB), 
phosphoinositide-dependent kinase-1 (PDK1), mitogen activated protein kinase (MAPK), 
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insulin receptor substrate (IRS), glucose transporter 4 (GLUT4), phosphatidylinositol-3 kinase 
(PI3K). 
 
1.1.e Insulin gene transcription 
The β cells of pancreas contain a large pool of insulin mRNA which accounts for about 
10-15% of total β cell mRNA. At low plasma glucose concentration, the insulin mRNA is due 
to basal gene transcription but as the plasma glucose concentration increases, the insulin 
mRNA increases 3-4 fold and the effect is most pronounced 30 min after glucose stimulation 
and declines thereafter (Leibowitz et al., 2001). The regulation of insulin mRNA production is 
complex and a number of factors are involved in gene expression. There are a number of 
factors involved in insulin gene transcription among which are pancreatic and duodenal 
homeobox-1 (PDX-1), Maf and a heterodimer with a main glucose responsive element on the 
insulin promoter, A3 (Fig. 1-3). PDX-1, also known as insulin promoter factor 1 (IPF-1), is a 
transcription factor involved in β cell maturation and insulin secretion. Previous studies in 
Psammomys obesus, a model of T2DM have shown an apparent lack of PDX-1 in the 
pancreas, which is the main mediator of insulin gene expression and pancreas development 
(Leibowitz et al., 2001). Glucose stimulation of the pancreas shifts PDX-1 from the cytoplasm 
to the nucleus and increases binding of PDX-1 to A3 (Fig. 3). Glucose and PDX-1 also 
regulate insulin gene transcription by influencing histones. Under low glucose conditions, 
PDX-1 interacts with histone deacetylase Hdac-1 and Hdac-2, recruits them to the insulin 
gene promoter, deacetylate histone H4 and thus downregulates insulin gene expression (Ren et 
al., 2007; Leibowitz et al., 2001). 
  Another transcription factor involved in insulin secretion is Maf-A (Fig. 1-3). Maf-A is 
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a basic leucine zipper transcription factor and it regulates gene expression in the pancreas. 
Maf-A is mainly expressed in β cells of the islets of Langerhans and is involved in insulin 
gene transcription, insulin secretion and β cell survival (Vanderford et al., 2007). Maf-A is 
activated by glucose by a distinct mechanism. At low glucose concentration, Maf-A is almost 
undetectable in β cells but as the glucose concentration increases, Maf-A protein is rapidly 
detected. With increasing duration of exposure to high concentration of glucose, Maf-A 
mRNA also increases significantly. Maf-A knockout mice develop glucose intolerance, 
impaired glucose stimulated insulin release, pancreatic islet abnormalities and diabetes 
mellitus (Zhang et al., 2005).   
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Figure 1-3. Schematic representation of the proximal region of the rat insulin promoter 
showing the key cis-acting DNA elements and trans-activating factors involved in glucose 
regulation of insulin gene transcription. 
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 CCAAT-enhancer binding protein (C/EBPβ) is a negative regulator of insulin gene 
expression (Plaisance et al., 2009). It stimulates gluconeogenesis in the liver and adipogenesis 
in the adipose tissue. In db/db mice knockdown of C/EBPβ reduces diabetes, besides reducing 
fatty liver disease and obesity. It was proposed as a novel target for the treatment of fatty liver 
disease and obesity by the authors (Schroeder-Gloeckler et al., 2007). 
 
1.1.f  Insulin resistance 
Insulin resistance can be broadly defined as decreased responsiveness of target tissues 
to normal circulating levels of insulin. Besides playing a role in the development of T2DM, 
insulin resistance is also a feature of the metabolic syndrome, which also involves 
hypertension, dyslipidemia, obesity and glucose intolerance (Sechi & Bartoli, 1997). 
Studies to determine the pathogenesis of insulin resistance have shown that defective 
muscle glycogen synthesis plays a major role because glycogen synthesis in the skeletal 
muscle (Bogardus et al., 1984; Kelly et al., 1996; Damsbo et al., 1991), a main target of 
insulin-mediated glucose uptake, is the major pathway for glucose metabolism in normal and 
T2DM patients (Shulman et al., 1990). The liver also shows reduced glycogen stores in 
insulin-resistant diabetic subjects (Damsbo et al., 1991).  
Insulin-stimulated phosphorylation of the insulin receptor has been shown to be 
impaired in skeletal muscle of T2DM patients (Arner et al., 1987), and obese people 
(Goodyear et al., 1995), in adipose tissue of obese subjects with and without T2DM (Sinha et 
al., 1987), and in liver of T2DM patients (Caro et al., 1986). 
Similarly, decreased phosphorylation of IRS-1 and PI 3-kinase in response to insulin 
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has been observed in skeletal muscle and adipocytes of obese people and T2DM patients 
(Goodyear et al., 1995; Bjornholm et al., 1997; Smith et al., 1999). Insulin-stimulated 
phosphorylation of Akt (protein kinase B, PKB) has been shown to be decreased in skeletal 
muscle in T2DM patients (Brozinick et al., 2003; Krook et al., 1998). 
 
 
1.2 Endothelial dysfunction 
 
Endothelial cells form the inner lining of blood vessels. The endothelial cells have 
been widely studied and it is now recognized that they perform a wide variety of functions. 
Some of the functions of the endothelial cells include regulation of 
vasodilation/vasoconstriction, coagulation/anticoagulation, vascular smooth muscle cell 
proliferation, angiogenesis, capillary permeability, vascular immune responses and 
inflammation. Broadly speaking endothelial dysfunction can be taken to mean a disruption of 
any one or more of these functions. The role of the endothelium in vascular relaxation was 
discovered by the seminal observations of Professor Robert Furchgott (Furchgott and 
Zawadzki, 1980) who elegantly demonstrated that acetylcholine (ACh) induced vascular 
smooth muscle relaxation by stimulating the release of a relaxing substance from the 
endothelium, which he called “endothelium-derived relaxing factor” or EDRF. EDRF was 
later identified as nitric oxide (NO) (Palmer et al., 1987). Since the discovery of EDRF by 
Furchgott, endothelial dysfunction has been typically described as reduced endothelium-
dependent relaxation. More strictly, most studies of endothelial dysfunction refer to reduced 
availability of NO (Fig. 1-4). This notion is being challenged by studies reporting reduced 
availability of other endothelium-derived mediators that cause relaxation such as endothelium-
derived hyperpolarizing factor (EDHF) and prostacyclin in certain vessels (Chen et al., 1988; 
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Taylor and Weston, 1988; Hecker et al., 1994; Chauhan et al., 2003; Bolotina et al., 1994; 
Whittle et al., 1978). The discovery of hydrogen sulphide (Wang, 2009) and carbon monoxide 
(Mustafa et al., 2009) as endothelium derived relaxants will complicate the issue further.  
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NADPH oxidase O2•- Peroxynitrite
VSMC
↑ cGMP
relaxation
↓ bioavailability
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↑ Ca2+
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Figure 1-4. Nitric oxide mediated endothelium-dependent relaxation and endothelial 
dysfunction. 
Schematic figure shows an endothelial cell and the adjacent vascular smooth muscle cell 
(VSMC). Stimuli such as bradykinin (BK), shear stress, insulin and vascular endothelial 
growth factor (VEGF) activate endothelial nitric oxide synthase (eNOS) by causing an 
increase in intracellular calcium (Ca2+) or by causing phosphorylation of eNOS (Phos-eNOS), 
and produce nitric oxide (NO) from the substrate L-arginine (L-arg). NO diffuses to the 
VSMC, where it activates soluble guanylate cyclase (sGC), increases cyclic guanosine 
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monophosphate (cGMP) and causes relaxation (Evora and Nobre, 1999). Under conditions of 
oxidative stress, an increased superoxide anion (O2•-) is produced, mainly from NADPH 
oxidase, which reacts with NO and produces peroxynitrite. This reduces the bioavailability of 
NO and causes endothelial dysfunction. Reduced activity of eNOS can also cause reduced NO 
production (Endemann and Schiffrin, 2004). This figure does not take into account altered 
production of other vasodilators such as EDHF and prostacyclin, or vasoconstrictors such as 
endothelin, that may be responsible for dysfunction.  
Endothelial dysfunction is a hallmark of diabetes (Escandon and Cipolla, 2001; 
Sowers, 2002), atherosclerosis and hypertension (Davignon and Ganz, 2004), and it is 
associated with numerous other conditions. It is characterized by reduced endothelium 
dependent vasorelaxation, a proinflammatory and prothrombic state (Endemann and Schiffrin, 
2004). The pathophysiology of endothelial dysfunction is complex and involves multiple 
mechanisms, however some of these seem to be common to most conditions. The most 
important vasodilating substance released by endothelium is NO, which functions as a 
vasodilator, inhibits growth of vascular smooth muscle, inflammation and has anti-
aggregatory action on platelets. As mentioned earlier, reduced NO has often been reported in 
conditions of endothelial dysfunction. There are a number of reasons for this, such as reduced 
availability of co-factor tetrahydrobiopterin (Consentino et al., 2008), reduced activity of 
endothelial nitric oxide synthase (eNOS) due to endogenous (Boger et al., 2000; Jang et al., 
2000) or exogenous inhibitors (Chiesi and Schwaller, 1995), reduced availability of its 
substrate L-arginine (Lekakis et al., 2002) or rapid destruction of NO by superoxide anion (Ma 
et al., 2001). Reactive oxygen species (ROS), especially superoxide, are often known to 
quench NO, forming peroxynitrite, a reactive cytotoxic oxidant. Peroxynitrite causes nitration 
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of proteins, affects protein function and therefore endothelial function (Koppenol et al., 1992). 
In animal models of hypertension, oxidative stress has been shown to induce endothelial 
dysfunction and the improvement of endothelium-dependent vasorelaxation after 
administration of antioxidants (Chen et al., 2001). The most commonly used parameter for 
assessing endothelial function is endothelium-dependent vasodilation. It is performed 
angiographically in coronary arteries by laser Doppler flow measurement by assessing the 
effect of endothelium-dependent agonists like ACh (Schachinger et al., 2000). Cold pressor 
test is another way of assessing endothelial function. It involves the measurement of coronary 
perfusion by positron emission tomography scanning as a measure of endothelial function 
(Schindler et al., 2003). Endothelial function can also be assessed on forearm resistance 
arteries by forearm blood flow measurement using strain gauge plethysmography (Perticone et 
al., 2001). In animal models endothelial function is measured as changes in endothelium-
dependent relaxation in isolated aortic rings, mesenteric artery or one of the other resistance 
arteries. 
  
1.2.a  Mediators released from endothelium 
Nitric oxide: 
NO is a vasodilator substance with a short half life of about 5-10 seconds. NO can be 
differentiated from prostacyclin, one of the other relaxant mediators released by the 
endothelium, by its ability to be un-affected by cyclooxygenase (COX) inhibitors. EDRF was 
first discovered by Robert Furchgott. Furchgott in his study showed that endothelial lining is 
important for vasorelaxant action of ACh on aortic rings or arterial strips isolated from rabbit. 
Ach acts on muscarinic receptors on the surface of endothelial cells, generates NO, which 
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diffuses to the vascular smooth muscle cells, activates soluble guanylyl cyclase (sGC), which 
converts guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP) and 
causes relaxation. There are also other vasorelaxant substances released by endothelium like 
prostacyclin, carbon monoxide and endothelium derived hyperpolarising factor (EDHF). 
Besides ACh, some of the other substances which generate NO are bradykinin, histamine, 
calcium ionophore, norepinephrine and 5-hydroxytryptamine (Furchgott, 1996; Brandes et al., 
2000).  
 
Endothelium-derived hyperpolarizing factor 
After the discovery of EDRF in and NO in the 1980s it was recognized that ACh 
caused vascular relaxation which was not prevented by inhibitors of NO and prostacyclin 
production, and which was caused by hyperpolarization of the smooth muscle (Chen et al., 
1988). A diffusible mediator released by the endothelium was proposed as endothelium-
derived hyperpolarizing factor by Weston (Taylor and Weston, 1988; Komori and Vanhoutte, 
1990). EDHF typically open potassium channels to cause hyperpolarization and vascular 
smooth muscle relaxation. Subsequently, extensive research has been done to establish the 
chemical identity of the EDHF. Many putative substances have been discovered and proposed 
as EDHF. These include a cytochrome P450 metabolite of arachidonic acid (Hecker et al., 
1994; Fisslthaler et al., 1999), epoxyeicosatrienoic acid (EET) (Campbell et al., 1996); NO 
itself (Bolotina et al., 1994; Chauhan et al., 2003), hydrogen peroxide (Matoba et al., 2000), 
C-type natriuretic peptide (Chauhan et al., 2003; Villar et al., 2007; Ahluwalia an Hobbs, 
2005), heterocellular gap junctions (Chaytor et al., 1998; Yamamoto et al., 1998; Hutcheson et 
al., 1999), K+ ion itself (Edwards, et al., 1998). EDHF plays a compensatory and key role in 
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the absence of NO and prostacyclin (Brandes et al., 2000; Desai et al., 2006; Scotland et al., 
2005). 
 
Prostacyclin 
Prostacyclin is also known as prostaglandin I2 (PGI2) and it is a member of a family of 
molecules known as eicosanoids. PGI2 is produced by the vascular endothelial cells and is a 
vasodilator and inhibits platelet aggregation (Whittle et al., 1978; Coleman et al., 1994; 
Praticò and Dogne, 2009; Gleim et al., 2009). PGI2 has a short half life of about seconds and 
is converted into 6-keto PGF1 which has less vasodilator property than PGI2 (Smyth and 
FitzGerald, 2002). Prostacyclin plays an important role as vasodilator in some vascular beds 
such as the coronary circulation (Duffy et al., 1999) and skeletal muscle arterioles (Sun et al., 
2006). There are a number of synthetic prostacyclin analogues available in the market like 
iloprost, cicaprost. They are mainly used as vasodilators in pulmonary hypertension or 
ischemia (Aronoff et al., 2007; Kermode et al., 1991).  
 
Hydrogen sulphide 
Hydrogen sulphide (H2S) is another gaseous vasorelaxant produced by the endothelial 
cells (Wang, 2009). H2S is produced from L-cysteine by the enzymes cystathionine γ-lyase 
(CSE) and cystathionine β-synthase (CBS) (Wang, 2009). CSE knockout mice have high 
blood pressure and muscarinic stimulation of the endothelial cells produces H2S mediated 
relaxation by activation of KATP channel and hyperpolarization of the vascular smooth muscle 
cells (Yang et al., 2008). 
 
19 
 
Carbon monoxide 
Carbon monoxide (CO) is the third gaseous vasorelaxant produced by the endothelial 
cells (Mustafa et al., 2009). It is produced from the degradation of heme by heme oxygenase 
2. CO activates soluble guanylyl cyclase and increases cGMP levels to produce vascular 
smooth muscle relaxation like NO (Wu and Wang, 2005). However, the function of CO as a 
vasorelaxant is still not clear (Mustafa et al., 2009). 
 
Endothelin 
Endothelin (ET) is produced by endothelial cells and is involved in the regulation of 
vascular function (Yanagisawa et al., 1988; Agapitov and Haynes, 2002). ET is a peptide and 
a very potent vasoconstrictor. Under normal physiological conditions, there is a fine balance 
between NO, which is a vasodilator and ET, however when the balance is disturbed, it leads to 
endothelial dysfunction (ED). Three isoforms ET1, ET2, ET3 and two receptors ETA and ETB 
have been identified (Hynynen and Khalil, 2006). These three isoforms are 21 amino acid 
peptides and have varying tissue distribution. ET acts on ETA receptors on vascular smooth 
muscle and induces vasoconstriction. ET also acts on ETB receptors on the surface of 
endothelial cells and induces vasodilation (Barnes and Turner, 1997). Thus ET induces both 
vasoconstriction and vasodilation. Intravenous injection of ET in animals causes an increase in 
blood pressure. Since ET is a powerful vasoconstrictor and causes increase in blood pressure, 
a number of ET antagonists have been discovered and are used in therapeutics. The first non-
peptide, orally effective ET receptor antagonist discovered was bosentan. Bosentan has been 
widely used both in basic and clinical research (Rubin et al., 2002). The Food and Drug 
Administration (FDA) of USA has approved clinical use of bosentan for the treatment of 
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pulmonary hypertension.  
 
1.2.b  Regulation of endothelial nitric oxide synthase 
NO is produced by the enzyme nitric oxide synthase (NOS) from the substrate L-arginine 
(Palmer et al., 1988). There are three known isoforms of NOS viz. endothelial nitric oxide 
synthase (eNOS), neuronal nitric oxide synthase (nNOS) and inducible nitric oxide synthase 
(iNOS) (Alderton et al., 2001). eNOS and nNOS are constitutive whereas iNOS is induced in 
cells such as macrophages and vascular smooth muscle cells by stimuli as cytokines, bacterial 
lipopolysaccharides (LPS) etc (Alderton et al., 2001). eNOS and nNOS require an elevation of 
intracellular calcium for activation whereas iNOS is calcium-independent for its activity. 
eNOS is primarily expressed in endothelial cells, nNOS in neuronal cells and iNOS in 
macrophages, VSMCs and other cell types (Alderton et al., 2001). eNOS has been extensively 
studied in relation to its regulation. eNOS is membrane associated, primarily with the golgi 
(Sessa et al., 1995) and also with plasma membrane caveoli (Garcia-Cardena et al., 1996; 
Feron et al., 1996; Fulton et al., 2002). Several regulatory proteins have been discovered 
which regulate its expression and activity at translational and posttranslational level. In 
endothelial cells NO is continuously produced by fluid shear stress and pulsatile stretch 
caused by blood flow (Corson et al., 1996; Fleming et al., 1998; Dimmeler et al., 1999), 
which does not depend on intracellular calcium (Fleming et al., 1998) . An increase is 
intracellular calcium in response to agonists such as ACh and bradykinin (Fleming et al., 
2001) is another major mechanism for activation of eNOS. However, the binding of 
calmodulin to the eNOS enzyme is determined by phosphorylation and dephosphorylation of 
eNOS enzyme at specific amino acid residues, which include serine 1177 and threonine 495 
21 
 
(Fleming et al., 2001; Fulton et al., 1999; Dimmeler et al., 1999; Fleming 2010). A number of 
kinases and phosphatases also take part in this process of eNOS regulation and activity 
(Fleimng et al., 2001; Fleming, 2010). Several research papers have been published using 
endothelial cells from different species using different agonists to stimulate eNOS activity and 
NO production and investigate the regulatory pathways (Fulton et al., 1999; Fleming et al., 
1998; Bernier et al., 2000; Fleming et al., 2001; Davda et al., 1994; Drummond et al., 2000; 
Haynes et al., 2000). As a result an integrated regulatory pathway involving key agonists, 
phosphorylation dephosphorylation status, calcium-dependency, phosphatases and kinases is 
difficult to put into place.  
 
1.3 Methylglyoxal 
Methylglyoxal (MG) is an aldehyde compound with two carbonyl groups (Fig. 1-5). 
Chemically it is also known as pyruvaldehyde, pyruvic aldehyde or 2-oxopropanal. It is a 
yellow liquid with a pungent odour. MG has a low molecular weight of 72.06. 
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Figure 1-5. Chemical structure of methylglyoxal 
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1.3.a Synthesis of MG 
Von Penchmann (1887) first developed the method for the synthesis of MG. In his 
study he showed that iso-nitrosoacetone heated in the presence of dilute sulfuric acid forms 
MG. However, along with MG other byproducts such as glycols, formaldehyde and formate 
were also formed. MG can be directly formed from methylglyoxal dimethylacetal by acid 
hydrolysis and also from oxidation of acetone with selenium dioxide followed by distillation 
under nitrogen atmosphere (Kalapos, 1999).  
In living organisms, MG is formed from several metabolic pathways (Fig. 1-6). The 
most common and important source of MG formation is glucose metabolism. During 
glycolysis, MG arises from non-enzymatic elimination of phosphate from glyceraldehyde-3-
phosphate (G-3-P) and dihydroxyacetone phosphate (DHAP) (Thornalley, 1996) (Fig. 1-6). 
Enzymatic formation of MG may involve leakage from active site bound phosphoene-diolate 
on triose phosphate isomerase.  
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Figure 1-6. Metabolic pathways of MG formation from different substrates 
Schematic showing pathways, substrates and enzymes involved in the formation of MG in the 
body. Glucose is the principal substrate.   
Abbreviations: AGEs – advanced glycation endproducts; AMO – acetol/acetone 
monooxygenase; DHAP – dihydroxacetone phosphate; F-1,6-di-P – fructose-1,6-diphosphate; 
G-3-P – glyceraldehyde-3-phosphate; GSH – reduced glutathione; SSAO – semicarbazide-
sensitive amine oxidase; ROS – reactive oxygen species.  
[Adapted from Metabolism. 2008 Sep; 57(9):1211-20.]
 
MG can also be formed by the enzyme semicarbazide-sensitive amine oxidase (SSAO) 
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from aminoacetone, which is an intermediate of threonine catabolism (Fig. 6) (Yu, 2003). 
Another source of MG is fatty acid metabolism. In this case the enzyme acetol 
monooxygenase (AMO) forms MG from the metabolic intermediate acetol (Casazza et al., 
1984; Phillips and Thornalley, 2005) (Fig. 6). The exogenous sources of MG include foods 
rich in carbohydrates like bread, potatoes and sucrose (Hayashi and Shibamoto, 1985). 
Cigarette smoking is other source of MG. Gas chromatographic analysis has shown levels of 
MG up to 59 µg/cigarette (Fujioka and Shibamoto, 2006). 
 
1.3.b Reactivity of MG 
  MG is a highly reactive molecule. This is evident from a reported estimate that 99% of 
MG in the body is bound to proteins and other biomolecules whereas only about 1% is in a 
free form. The high reactivity of MG can be attributed to the electrophilic nature of the methyl 
group and to oxygen atoms (Fig. 1-5), which increase the positive charge on the carbonyl 
carbon of MG. Therefore, it becomes highly reactive in nucleophilic addition reactions than 
other dicarbonyl compounds (Shipar, 2006). Glyoxal and 3-deoxyglucosone (3-DG) are other 
reactive intermediate α-dicarbonyl compounds formed in the body. MG is an alkyl derivative 
of glyoxal and it has been reported that it is more reactive than glyoxal (Shipar, 2006). Due to 
its high reactivity MG can react with and modify certain proteins, DNA, lipids and other 
biomolecules and alter their structure and function. The binding characteristic of MG may also 
be different with different proteins (Dhar et al., 2009). Thus, an excess of MG and other 
dicarbonyl compounds in the body causes carbonyl overload and stress in conditions such as 
diabetes.  
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1.3.c Degradation of MG 
  Since MG is a highly reactive cytotoxic compound, the body has developed several 
detoxification mechanisms to degrade it. One of the major detoxification mechanisms is the 
highly efficient glyoxalase system. The glyoxalase system consists of two enzymes, 
glyoxalase I and glyoxalase II and catalytic amounts of reduced glutathione (GSH). The 
glyoxalase system is found in the cytosol of cells and cellular organelles, particularly 
mitochondria (Thornalley, 1990). MG reacts with GSH forming hemithioacetal. 
Hemithioacetal is converted to S-D-lactoyl-glutathione by glyoxalase I and then further 
metabolised into D-lactate by glyoxalse II and regenerating GSH (Thornalley, 1990).  
MeCOCHO +  GSH
Methylglyoxal
MeCOCHO(OH)-SG 
Hemithioacetal
MeCH(OH)CO-SG 
S-D lactoyl glutathione
MeCH(OH)CO2H  +  GSH 
D-lactic acid
Glyoxalase I
Glyoxalase II + H2O
 
Figure 1-7. Pathway of MG metabolism [Adapted from Biochem J 1990; 269(1): 1-11] 
 
Lactate is formed during anaerobic glycolysis using enzyme lactate dehydrogenase. 
Under conditions of decreased tissue oxygenation, lactic acid is produced as the anaerobic 
26 
 
cycle is utilized for energy production (Robergs et al., 2004). Some studies have reported that 
cells over expressing glyoxalase I show enhanced tolerance to MG and exhibit better 
detoxification (Maclean et al., 1998). Another family of enzymes called aldo-keto reductases 
(AKRs) reduce aldehydes and ketones. AKRs are a large superfamily of related proteins that 
carry out NADPH-dependent reduction of various aldehydes and ketones. The physiological 
function of most putative members of this superfamily is still unclear, partly due to their broad 
substrate specificity and partly because of the difficulty of genetic analysis, as many 
organisms have multiple genes that encode AKRs (Xu et al., 2006). 
Another minor pathway of MG detoxification is via MG dehydrogenase. MG 
dehydrogenase catalyzes the oxidation of MG to pyruvate using NAD or NADP as a cofactor 
(Ray and Ray, 1982).   
 
1.3.d MG levels in pathological conditions 
MG is formed as a byproduct during glycolysis. The plasma MG levels under normal 
conditions are between 0.5-1.5µM (Jia & Wu, 2007; Wang et al., 2007). and the levels 
increase as much as 2 to 4 fold under diabetic conditions (Wang et al., 2007; Beisswenger et 
al., 1999). There is an increased body of evidence suggesting that increased MG formation in 
diabetes mellitus is linked to diabetic complications like retinopathy and nephropathy but the 
exact mechanism is far from clear. Previous studies have shown that MG levels are increased 
in plasma of SHR rats (13.8 µM) at 8 weeks of age and 33 µM at 20 weeks as compared to 
WKY at the same age (9.1 and 14.2µM). MG levels were also elevated in the aorta (2.5 
nmol/mg protein) and kidney (0.3 nmol/mg protein) compared to WKY (1.5 nmol/mg protein) 
(0.2 nmol/mg protein) in an age dependent manner (Wang et al., 2004; Wang et al., 2005). 
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There was a significant increase in MG levels in serum, 3.2 µM as compared to 1.8 µM in 
control rats, and adipose tissue (4.2 µmol/g protein) of SD rats fed with high fructose diet for 
9 weeks as compared to control rats (1.5 µmol/g protein) and the effect was attenuated by MG 
scavenger N-acetyl cysteine (NAC) (Jia and Wu, 2007). We have shown previously that 
incubation of vascular smooth muscle cells (VSMCs, A-10) with high glucose increases MG 
formation in a concentration and time dependent manner along with an increase in oxidative 
stress (Dhar et al.,  2008). The western diet has increasing amounts of carbohydrates and the 
rapidly increasing incidence of childhood obesity and diabetes mellitus have become a major 
health concern (Van dam et al., 2002). In the absence of a genetic predisposition the link 
between high carbohydrate intake and the development of diabetes mellitus is unknown at a 
mechanistic level.   
 
1.3.e Substrates involved in MG formation: 
D-Glucose 
Glucose is a monosaccharide, an important carbohydrate. All living cells use it as a 
main source of energy. There are two stereo-isomers of aldohexose which are D and L-glucose 
and D-glucose is biologically active. D-glucose is often referred to as dextrose monohydrate 
or dextrose. Under normal physiological conditions glucose levels are around 5mM but are 
elevated as much as 25mM under diabetic conditions (www.who.int/diabetes) (Tirosh et al., 
2005). During glycolytic process (breakdown of glucose), MG is formed as intermediate 
product. Elevated levels of MG have been reported in diabetic patients which correlate with 
the degree of hyperglycemia (Wang et al., 2008). MG levels are elevated during 
hyperglycemic (high glucose) conditions. Incubation of vascular smooth muscle cells with 
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high glucose for 3 h increases MG formation (Dhar et al., 2008).  In human umbilical vein 
endothelial cells and rat aortic endothelial cells, incubation of 25mM glucose for 24 h 
increases MG formation and induces endothelial dysfunction (Dhar et al., 2010). Endothelial 
dysfunction is one of the features of diabetes mellitus. Previous studies have shown that 
incubation of human mononuclear cells (HMNCs) with MG and glucose induces apoptosis or 
necrosis. Apoptosis is triggered through multiple biochemical changes including reactive 
oxygen species (ROS) generation, activation of caspase 3 and DNA fragmentation (Hsieh and 
Chan, 2009). Increased glucose levels in diabetic patients have been shown to cause non-
enzymatic glycation (Thomas et al., 2005). 
 
Fructose 
Fructose is also a monosaccharide and a simple reducing sugar. Fructose undergoes 
Maillard reaction (chemical reaction between amino acid and reducing sugars in the presence 
of heat). Because fructose exists to a greater extent in the open-chain form than does glucose, 
the initial stages of the Maillard reaction occurs more rapidly than with glucose. Therefore, 
fructose potentially may contribute to changes in food palatability, as well as other nutritional 
effects, such as excessive browning, volume and tenderness reduction during cake 
preparation, and formation of mutagenic compounds (Gaby, 2005). Feeding of normal SD-rats 
with fructose increased endogenous MG levels, impaired insulin signalling and reduced 
glucose uptake and the effect is mediated through the formation of MG as incubation of 3T3 
adipocytes directly with MG impaired IRS/PI3K pathway, reduced glucose uptake and the 
effect was attenuated by pretreatment with MG scavenger N-acetyl cysteine (NAC) (Jia et al.,  
2006). Normal SD rats fed chronically with fructose for 16 weeks develop hypertension with 
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higher serum MG levels.  The effects were attenuated by metformin possibly by scavenging 
MG (Wang et al., 2008).  Incubation of vascular smooth muscle cells with 25mM fructose for 
3 h increased MG formation significantly as compared to untreated control cells (Dhar et al., 
2008). Increased fructose consumption as seen in Western diets may be a health concern. 
Because currently the main tendency is to focus on glucose in terms of increased MG, AGEs, 
and oxidative stress in conditions such as diabetes, it is important to consider the contribution 
of other substrates such as fructose, acetol, and aminoacetone to MG, AGEs, and oxidative 
stress load. 
 
Aminoactone 
Aminoacetone (AA) is the product of mitochondrial metabolism of threonine and 
glycine. AA is a threonine metabolite accumulated in threonemia, and diabetes. Oxidation of 
AA to MG, NH4+, and H2O2 has been reported to be catalyzed by a copper-dependent 
semicarbazide sensitive amine oxidase (SSAO) as well as by Cu(II) ions. H2O2 generated by 
the auto-oxidation of aminoacetone reacts with Cu(I) to form reactive species capable of 
causing oxidative DNA damage (Hiraku et al., 1999). SSAO catalyzes the conversion of 
aminoacetone to MG.  SSAO is copper containing amine:oxygen reductase. SSAO has a wide 
distribution however is most abundant in vascular smooth muscle cells (Magyar et al., 2001). 
Previous studies have shown that AA can be deaminated to MG by amine oxidase in 
homogenates of various guinea pig tissues and in goat and ox plasma (Lyles and Taneja, 1987; 
Deng and Yu, 1999). We have reported previously increased formation of MG in VSMCs 
treated with different concentrations of AA. The amount of MG formed in VSMCs depends a 
great deal on the nature of the substrate.   The important finding of our study is that 
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aminoacetone has the potential to form significant amounts of MG, carboxyethyl lysine 
(CEL), nitric oxide (NO), and oxidized DCF (peroxynitrite) even at low concentrations (Dhar 
et al., 2008). Because aminoacetone is an intermediate of protein metabolism, the production 
of MG and peroxynitrite under conditions of increased protein catabolism is worthy of further 
investigation.  
 
Acetone 
Acetone is an organic compound with a formula of OC (CH3)2. Acetone is a colorless 
flammable liquid and is a ketone. Small amounts of acetone are produced in the body by the 
decarboxylation of ketone. Once acetone is formed, it can be metabolized in several pathways. 
One of these pathways involves conversion of acetone to MG in two consecutive steps via 
acetol as intermediate. Acetol and MG are intermediates of the intrahepatic metabolism of 
acetone leading to pyruvate formation (Kalapos, 1999). The production of MG from acetone 
was proposed in 1984, based on studies of acetone metabolism in the rat (Casazza et al., 
1984). The possible role of cytochrome P450s in acetone metabolism was recognized in 1980 
(Coleman, 1980), and cytochrome P450 2E1 was identified as both the acetone and acetol 
monooxygenases in liver microsomes from rabbit, rat and mouse (Koop et al., 1985, 
Johansson et al., 1986). This pathway is inducible, and can be induced by several agents 
(acetone, ethanol, pyrazole, imidazole, etc.) or under different physiological and pathological 
circumstances, such as fasting or diabetes mellitus (Gonzalez and Lee, 1996). 
 
1.3.f Methods of MG measurement 
Number of methods have been reported for the measurement of MG in cultured cells, 
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plasma and tissue samples. Numerous studies have reported variable levels of MG in cultured 
cells, tissue and plasma samples of animals. These variabilities can be due to differences in 
protocol and sample preparation method. One of the most common and widely used method 
involves derivatization of MG with 1,2-diaminobenzene derivatives, such as o-PD, and the 
quantification of the resulting quinoxaline with high performance liquid chromatography 
(HPLC) (Chaplen et al., 1998). The high reactivity of MG makes it difficult for reproducible 
quantification from sample to sample. It is believed that less than 1% of MG exists in a free 
form while more than 99% exists in a protein-bound form (Ahmed et al.,, 2002; Chaplen et 
al., 1998). Previous studies have also proposed that the protein bound form can exist as an 
irreversibly bound pool or a reversibly bound pool. In this case the irreversibly-bound form 
remains stable under harsh assay conditions and therefore cannot be detected (Chaplen et al., 
1998). Irreversibly-bound MG, characterized as AGEs, is detected by separate assays for 
AGEs (Ahmed et al., 2002; Nagaraj et al., 1996). The reversibly-bound MG appears to be in 
dynamic equilibrium with free MG and can be measured (Chaplen et al., 1998). However, the 
reversibly bound MG compounds are unstable and are, therefore, possibly a source of error in 
assays (Chaplen et al., 1998). Perchloric acid (PCA) is used in the protocol to stop metabolic 
reactions in the sample and to precipitate proteins which are immediately removed from the 
sample before it is derivatized with o-PD (Chaplen et al., 1996; Chaplen et al., 1998). Chaplen 
et al (1998) theorized that this will also precipitate the reversibly-bound MG adducts and 
remove them from the sample along with the proteins that are removed after centrifugation. 
According to the results obtained by Chaplen et al (1998), a longer incubation of the 
precipitated proteins, which will include the reversible MG adducts, will allow the acidic 
environment to free MG from its reversible binding and make it amenable to detection. 
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Variations in the sample treatment protocol detected up to an amazing 100 to 1000 fold more 
MG from the same sample, when applied to cultured Chinese hamster ovary (CHO) cells 
(Chaplen et al., 1998). However, it is not known if similar variations in protocol would affect 
the amount of MG detected in other sample types such as plasma, body organs or tissues and 
other cultured cells such as vascular smooth muscle cells (VSMCs). 
 
1.3.g Range of doses and concentrations of MG used experimentally 
The physiological concentration of MG in normal rats is between 0.5-10 µM (Wang et 
al., 2005; Wang et al., 2004).  Since MG is formed during glycolysis, the intracellular levels 
of MG are higher than circulating levels. Numbers of studies have used higher concentrations 
and doses of MG. For example, a 1mM concentration of MG in rat pancreatic β cells caused 
rapid depolarization, elevated intracellular Ca2+ concentration and acidification in intact islets 
(Cook et al., 1998). MG concentration of up to 500 µM has been used to study MG induced 
apoptosis of jurkat cells. Sheader et al (2001) used a concentration between 0.1-10mM to 
study the effect of MG on insulin secreting cells (Sheader et al., 2001). In one in vivo study by 
Jerzykowski et al., a dose of up to 500 mg/kg MG has been used to see its effect on plasma 
glucose levels in cats (Jerzykowski et al., 1975). MG concentration between 2.5-5mM have 
been used to study the effect of MG on insulin signalling pathway in L6 muscle cells in vitro 
in cell culture studies (Chavey et al., 2006). Similar high concentrations of exogenous MG 
have been employed in most in vivo and in vitro studies, which were not grossly aimed at 
studying the toxic effects of MG (Cook et al., 1998). This raises an important concern of 
whether these studies bear physiological or pathological relevance. However in normal 
healthy people, MG is not a concern because the highly efficient glyoxalase system degrades 
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it and coverts it into D-lactate (Desai & Wu, 2007).  
 
1.3.h Advanced glycation endproducts 
MG, 3-deoxy glucosone and glyoxal are major precursors of advanced glycation 
endproducts (AGEs). AGEs are formed when MG reacts with certain proteins and alters their 
structure and function. AGEs play a significant role in causing the pathologic changes in many 
conditions like aging and diabetic complications such as micro vascular complications, 
retinopathy, neuropathy and nephropathy (Desai and Wu, 2007). AGE formation is a non-
enzymatic glycation reaction between reducing sugars and amino groups of proteins. These 
phenomena lead to browning, fluorescence and cross-linking of proteins (Desai & Wu, 2007). 
The glycation reaction is initiated with the reversible formation of a Schiff base which 
undergoes further rearrangement to form a stable Amadori product (Desai & Wu, 2007). The 
Amadori product undergoes further reactions with dicarbonyl intermediates to form AGEs 
(Tomoko et al., 1999). Since the product formed is brown in colour, it is also known as 
“browning reaction” (Maillard, 1916). MG is one of the intermediates in Maillard reaction 
both in vitro and in vivo. 
A number of AGEs are formed under various in vitro or in vivo conditions. Some of 
the most common non-cross-linking AGEs are N- carboxymethyl-lysine (CML) (Ahmed et al., 
1986; Reddy et al., 1995), carboxymethylvaline (CMV) (Cai and Hurst, 1999), N-
carboxyethyl-lysine (CEL) (Ahmed et al., 1997) and pyralline (Miyata and Monnier, 1992). 
The fluorescent cross-linking AGEs are pentosidine (Sell and Monnier, 1989) and crossline 
(Obayashi et al., 1996) and non-fluorescent cross-linking AGEs are argpyrimidine (Shipanova 
et al., 1997) (Glomb et al., 2001), methylglyoxal-lysine dimer (Chellan and Nagaraj, 1999) 
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and imidazolones (Konishi et al., 1994). One of the non specific AGEs found routinely in 
disease conditions is CML and these can be detected immuno-histochemically in tissues and 
cultured cells.  
AGEs are markers of oxidative stress. A number of AGE inhibitors or AGE breakers 
have been developed over the years and they act by targeting multiple steps of AGE 
formation. Some of the examples of AGE inhibitors are aminoguanidine, N-acetyl cysteine 
(NAC) and aspirin. AGE breakers act by breaking α-dicarbonyl crosslinks. One of the most 
promising AGE breaking compounds developed by Alteon is ALT-711 (Alagebrium) (Desai 
and Wu, 2007).  
 
1.3.i MG and insulin signalling 
Insulin, a peptide hormone plays a major role in regulating pathways leading to 
cellular proliferation and differentiation. When insulin binds to its receptor (IR), the receptor 
tyrosine kinase is activated, leading to phosphorylation of several intracellular proteins. These 
rapid events generate multiple signalling cascades that eventuate in the final cellular responses 
to insulin. Insulin activated signalling molecules are Ras/Raf, PI3K/AKT and PKC pathway 
(Taniguchi et al., 2006; Kruger et al., 2008). Insulin resistance is a common abnormality in 
disease situations like diabetes and obesity. Chronic hyperglycemia leading to insulin 
resistance is the primary etiological factor in the pathogenesis of diabetic microvascular and 
macrovascular complications (Vuorinen-Markkola et al., 1992). One of the mechanisms of 
hyperglycemia induced damage in diabetes is AGEs. Large number of substantial data 
indicates that glucose toxicity may be the consequence of increased formation of MG. 
Increased formation of MG may occur due to increased availability of its precursors like 
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increased glucose during diabetes, increased acetone and acetol during diabetic ketoacidosis 
and more of threonine in gout and hyperuricemia. Exposure of cultured L6 muscle cells with 
MG induces inhibition of insulin stimulated phosphorylation of PKB and ERK1/2 (Chavey et 
al., 2006). MG modifies the B-chain of human insulin in vitro, and that modification occurs 
predominantly at the N terminus and arginine residue via Schiff base formation. The extent of 
modification increases with the relative concentration of MG. The formation of MG-insulin 
adducts leads to the reduction of insulin-mediated glucose uptake by its target cells or tissues, 
impairs autocrine control of insulin release from pancreatic ß-cells, and decreased hepatic 
clearance of insulin from liver cells (Jia et al., 2006). Increased formation of MG has been 
observed in vivo in serum and adipose tissue of fructose fed rats. A significant reduction in 
IRS-1 tyrosine phosphorylation and PI3K activity was observed in cultured 3T3 adipocytes 
treated with MG. The effects of MG were reversed by N-acetyl cysteine (NAC), an MG 
scavenger, which supports the role of MG in the impaired insulin stimulated glucose uptake 
(Jia and Wu, 2007).  Moreover, MG levels in the body are dependent on the balance between 
its synthesis and degradation. When the formation of MG exceeds its degradation, 
accumulation of MG occurs even with normal concentration of its precursors. Also 
accumulation of MG occurs when the degradative capacity of the glyoxalase system is 
compromised. Increased MG formation has been observed after application of glyoxalase-I 
inhibitors (Creighton et al., 2003). Clarification of the role of MG in the development of 
insulin resistance may lead to a discovery of new mechanisms and methods for the 
management and prevention of insulin-resistance syndrome, including diabetes and 
hypertension. 
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1.3.j  MG and Oxidative stress 
Numerous in vitro and in vivo studies have reported MG induces oxidative stress. The 
markers used to measure oxidative stress are superoxide, hydrogen peroxide and peroxynitrite 
levels (Desai and Wu, 2008). Increased superoxide production has been observed in aorta of 
SHR which was associated with elevated plasma MG as compared to age matched WKY rats 
(Wang et al., 2005). Incubation of VSMCs with exogenous MG induces superoxide formation 
in a concentration and time dependent manner (Chang et al., 2005). These effects of MG were 
reversed by superoxide scavenger SOD or NADPH-oxidase inhibitor diphenylene iodonium 
(DPI) (Wang et al., 2006). Previous studies have shown that incubation of VSMCs with MG 
increased the generation of H2O2. The effects of MG were prevented by NAC and GSH, both 
act as scavengers of MG. In 4-13 week old SHR rats, increased blood pressure was associated 
with increased NO production, increased iNOS expression and reduced eNOS expression in 
aorta along with elevated aortic and plasma MG levels as compared to age matched WKY rats 
(Wang et al., 2006). Increased Reactive Oxygen Species (ROS) generation has been observed 
in various insulin resistant and cardiovascular disease conditions. Excess superoxide (O2•-) 
can react with NO to form peroxynitrite (ONOO-) (Fig. 8). Peroxynitrite is a reactive 
oxidising and nitrating agent and it can damage wide range of molecules including DNA and 
proteins (Pacher et al., 2007). 
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Figure 1-8: Schematic showing mechanisms of MG induced oxidative stress. 
MG induces oxidative stress through multiple mechanisms and pathways as shown in the 
figure. Free radicals and reactive oxygen species such as superoxide, peroxynitrite and 
hydrogen peroxide, and advanced glycation endproducts (AGEs) cause cellular injury, 
pathological conditions and diseases.  
Abbreviations: AGEs, advanced glycation end products; GSH, reduced glutathione; GSH-Px, 
glutathione peroxidase; GSH-Red, glutathione reductase; GSSG, oxidized glutathione; H2O2, 
hydrogen peroxide; ICAM 1, intracellular adhesion molecule 1; IFNγ, interferon γ; IL1, 
interleukin 1; JNK, JUN N-terminal kinase; MG, methylglyoxal; NF-κB, nuclear factor-
kappaB; NO, nitric oxide; O2•-, superoxide anion;  ONOO−, peroxynitrite; p38 MAPK, p38 
mitogen activated protein kinase; RAGE, receptor for advanced glycation endproduct; SOD, 
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superoxide dismutase; VCAM 1, vascular cell adhesion molecule 1. 
[Adapted from Drug Metabol Drug Interact. 2008;23(1-2):151-73.] 
 
MG also induces oxidative stress by inducing cytokine IL-1 beta in cultured rat 
hippocampal neuronal cells.  The activity of antioxidant enzymes superoxide dismutase 
(SOD), catalase and glyoxalase has been shown to be affected by MG in vitro. MG is mainly 
detoxified by glyoxalase system which requires catalytic amount of reduced glutathione for its 
activity. High glucose and oxidative stress have been shown to reduce GSH levels (Kikuchi et 
al., 1999). MG has also been shown to reduce the activity of glutathione peroxidase and 
glutathione reductase (Blakytny and Harding, 1992; Paget, 1998) which in turn recycle the 
oxidized glutathione (GSSG) back to GSH. This phenomenon impairs the detoxification of 
MG, increases its half-life and adds to further oxidant damage. Morphological changes have 
been observed in human umbilical vein endothelial cells (HUVECs) with MG in a 
concentration dependent manner (Chan and Wu, 2008).  
High concentrations of MG upto 5mM induce apoptosis in bovine aortic endothelial 
cells (BAECs) by impairing mitochondrial membrane potential, elevation of caspase-3, thus 
inducing oxidative stress and ultimately apoptosis (Takahashi et al., 2010).  MG levels are 
high in the cerebrospinal fluid (CSF) of neurodegenerative patients and hippocampus is found 
to be vulnerable to oxidative damage. MG treatment caused an inhibition of antioxidant 
defence mechanism and detoxification processes, shifting the cellular environment towards a 
more oxidized state and causing the damage (Desai et al., 2010). However most of the studies 
done so far have studied in vitro effects of MG in cultured cells.  Whether MG directly 
induces similar changes in vivo are not known.  
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1.3.k  Agents that inhibit MG formation 
A number of agents have been tested in the past for scavenging MG directly or by 
inhibiting AGE formation. Here we will discuss some of the agents which have been used in 
the past and which might be used in the near future. 
Aminoguanidine (AG) 
Aminoguanidine is the best known and most widely used AGEs inhibitor. 
Aminoguanidine was first known to prevent diabetes induced arterial wall protein cross 
linking. Aminoguanidine inhibits the ‘cross-linking’ (or glycosylation) of proteins. It acts by 
inhibiting the formation of amadori products by reacting with dicarbonyl compounds like MG 
(Thornalley, 2003). Aminoguanidine is an irreversible inhibitor of SSAO, an enzyme which 
catalyses the conversion of aminoacetone to MG (Casazza et al., 1984). Aminoguanidine also 
reduces oxidative stress by inhibiting peroxynitrite and inducible nitric oxide synthase 
formation (Szabo et al., 1997) (Misko et al., 1993). Aminoguanidine prevents AGEs formation 
in vitro as well as in vivo. The doses used in vivo range from 25 mg/kg/day to 50 mg/kg/day 
and up to 100 mg/kg/day. Aminoguanidine has also been shown to prevent oxidative 
modification of low density lipoproteins by binding reactive aldehydes formed during lipid 
peroxidation and preventing their subsequent conjugation to apo B. Previous studies have also 
shown that aminoaguanidine treatment decreases age related cardiovascular damage in rats. 
There was a decrease AGE formation in cardiac, renal and aortic tissue of rats treated with 
aminoguanidine. Age related cardiac hypertrophy and aortic stiffening was also prevented by 
aminoaguanidine administration in comparison to untreated rats (Li et al., 1996). Recent 
studies have also shown that aminoaguanidine treatment reduces the age dependent 
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development of hypertension in spontaneously hypertensive (SHR) rats by scavenging MG 
(Wang et al., 2007). However further studies are required to investigate the causative role of 
MG and MG related AGEs in hypertension.  
 
Metformin 
Metformin is an oral antihyperglycemic agent for the treatment of type II diabetes. It is 
a biguanide with structure similar to aminoguanidine. In a study done in type II diabetic 
patients, metformin lowered MG levels in these patients (Tanaka et al., 1999). Metformin is 
also shown to be a potent inhibitor of glycation. Chronic treatment with metformin reduces 
AGE formation in lens, kidney and nerves in diabetic rats. It has also been reported that 
metformin reduces MG formation in dose dependent manner (Beisswenger et al., 1999). There 
are several mechanisms by which metformin inhibit glycation processes. One mechanism is 
that metformin acts by binding its guanidine group to the α-dicarbonyl group of MG. In one in 
vitro study metformin directly reacts with MG to form stable triazepinone derivatives (Lopez 
et al., 1999). Another study has shown that metformin reduces MG levels by increasing MG 
detoxification via increased glyoxalase pathway (Rahbar et al., 2000).  
 
Alagebrium (ALT-711) 
Alagebrium (4,5-dimethylthiazolium, ALA) (formerly known as ALT-711) (Fig. 1) is a 
novel advanced glycation endproducts (AGEs) cross-link breaking compound which has been 
studied mainly for its chronic effects on AGEs (Coughlan et al., 2007; Guo et al., 2009; Little 
et al., 2005; Peppa et al., 2006; Susic et al., 2004; Thallas-Bonke et al., 2004; Wolffenbuttel et 
al., 1998; Ulrich and Zhang, 1997; Zieman et al., 2007). The first AGEs cross-link breaking 
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compound discovered was phenacylthiazolium bromide (PTB) in 1996. PTB reacts with and 
cleaves covalent cross-links of AGEs-derived proteins. PTB degrades rapidly and hence a 
more stable derivative alagebrium was developed. ALA (210 mg/kg twice a day for 8 weeks) 
given to patients with systolic hypertension reduced vascular fibrosis and markers of 
inflammation (Zieman et al., 2007). Intraperitoneal injection of ALA (1 mg/kg) daily for 1 or 
3 weeks reversed diabetes-induced increase of arterial stiffness measured by in vivo and in 
vitro parameters in STZ-induced diabetic rats, and improved impaired cardiovascular function 
in older rhesus monkeys (Wolffenbuttel et al., 1998; Ulrich, 1997). ALA (10 mg/kg for 16 
weeks) also increased glutathione peroxidase and superoxide dismutase activities in aging rats 
and reduced oxidative stress (Guo et al., 2009). The Alteon Corporation in USA is developing 
alagebrium (ALT-711, thiazolium salt) as an antiaging drug. ALT-711 is currently being tested 
in human clinical trials. However, it has not been shown yet if ALA has acute effects against 
precursors of AGEs such as methylglyoxal (MG) and glyoxal. 
 
N-acetyl cysteine 
NAC is another agent that can scavenge MG (Jia and Wu, 2007; Vasdev et al., 1998). 
NAC a cysteine containing thiol compound and MG binds with high affinity to cysteine. NAC 
has other beneficial properties, e.g. it can increase GSH levels, which itself is the prime MG 
scavenger in the body (McLellan et al., 1994; Desai and Wu, 2007), and it can also directly 
react with free radicals and thus acts as an antioxidant (Aruoma et al., 1989; Dekhuijzen, 
2004). NAC is already used clinically for other conditions such as acetaminophen overdose 
(Millea, 2009).  
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CHAPTER 2  
2.1 Hypothesis 
Rationale for hypothesis 
Studies have reported elevated levels of MG in hyperglycemic and hypertensive rats 
(Wang et al., 2005; Jia and Wu, 2007). The plasma levels of MG have been reported to be 
increased 2-4 fold in diabetic patients (Wang et al., 2007a; McLellan et al., 1994). In vitro 
studies have shown that MG impairs the functioning of the insulin molecule and second 
messengers of the insulin signalling pathway in cultured cells (Jia et al., 2006, Jia and Wu, 
2007; Ribolet-Chavey et al., 2006).  However, elevated plasma levels in diabetic patients and 
fructose-fed rats are associative findings and do not establish a cause-effect relationship. 
Moreover, the effects of MG, especially high concentrations of MG employed, on insulin 
signalling in cultured cells cannot be extrapolated to in vivo situations. In vivo studies on the 
effects of exogenously administered MG to animals have not been performed to evaluate its 
role in the pathogenesis of insulin resistance. Thus, it is not known if the elevated MG levels 
in diabetic patients are the cause of diabetes or an effect of diabetes or both?   
Based on the above rationale the following hypothesis was formed: 
 
Hypothesis: A pathological elevation of methylglyoxal in the body is one of 
the causative factors in the development of insulin resistance, endothelial 
dysfunction and type 2 diabetes mellitus. 
 
I designed protocols to perform a comprehensive study on the effects of exogenously 
administered MG to normal male Sprague-Dawley rats, on glucose tolerance and adipose 
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tissue glucose uptake, and pancreatic islet insulin secretory machinery.  
My project evolved by following the objectives and experimental approaches described 
below: 
 
2.2 Objectives and experimental approach 
2.2.a  Comparison of methylglyoxal production in vascular smooth muscle cells from 
different metabolic precursors 
Although MG production from glucose has been well documented, the relative 
contribution of other intermediates of different metabolic pathways to MG formation is far 
less known. My aim was to determine and compare the formation of MG, MG-induced AGE, 
Nε-carboxyethyl-lysine (CEL), inducible nitric oxide synthase (iNOS), nitric oxide and 
peroxynitrite from different metabolic precursors in cultured rat aortic VSMCs. The 
experimental approach was to incubate cultured A10 VSMCs with different concentrations of 
the known substrate d-glucose (Thornalley, 1996; Desai and Wu, 2007) for different times to 
determine the optimum concentration and incubation time. This concentration and incubation 
time was used for incubation of A10 cells with other putative substrates (Figure 1-6) to 
determine their relative potencies in generating MG and oxidative stress compared to d-
glucose.   
 
2.2.b  Optimization of sample preparation protocol for the measurement of MG by 
HPLC 
Variable plasma MG values have been reported in the literature. In the body MG is 
free, reversibly bound or irreversibly bound with cellular constituents (mostly with proteins) 
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(Mugo and Bottaro, 2008; Chaplen et al., 1998). The most widely used method, viz. high 
performance liquid chromatography (HPLC), detects the free MG levels in a given sample 
(Chaplen et al., 1998). It has been proposed that incubation of the sample with an acid frees 
up the reversibly bound MG, which is detected, and that the longer the incubation time with 
the acid, the greater is the amount of reversibly-bound MG released (Chaplen et al., 1998). To 
test this proposal, several different protocols were tested on different biological samples. The 
aim was to define a protocol/s that provided reproducible and consistent values of MG in a 
biological sample.   
 
2.2.c  To investigate whether exogenously administered MG has acute effects on glucose 
homeostasis in Sprague-Dawley rats, and whether alagebrium, an AGE-breaker, can 
prevent these acute effects of MG  
MG was administered by three routes: oral gavage, intraperitoneal (i.p.) injection and 
intravenous (i.v.) injection to determine a dose and route that would give plasma MG levels 
within the range of 1-10 µM reported in the literature (Jia and Wu, 2007; Wang et al., 2008).  
Subsequently, a single dose of MG was administered to 12 week old male SD rats and after 2 
h a  glucose tolerance test (GTT) was performed to evaluate glucose tolerance. The adipose 
tissue and pancreatic islets were isolated to determine glucose uptake and insulin release, 
respectively. Alagebrium (ALA, formerly known as ALT-711) has been developed as an 
AGEs-breaker (Coughlan et al., 2007; Guo, Y et al., 2009; Wolffenbuttel et al., 1998). The 
acute effects of ALA on major precursors of AGEs such as methylglyoxal (MG) have not been 
reported. The preventive effects of ALA were examined by preadministration of ALA 
followed by MG in groups of rats. Distribution of exogenously administered MG to different 
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organs/tissues was measured.   
 
2.2.d To investigate whether high glucose induced endothelial dysfunction is mediated by 
methylglyoxal 
  Hyperglycemia induces endothelial dysfunction by increasing oxidative stress 
(Potenza et al., 2009, Triggle, 2008, Nishikawa et al., 2000). The aim was to investigate 
whether MG induces endothelial dysfunction, and compare it with high glucose (25 mM)-
induced endothelial dysfunction. Two models were used: isolated rat aortic rings from 12 
week old male SD rats, and cultured endothelial cells from two species, viz. rat aorta and 
human umbilical vein. The parameters chosen as indicators of endothelial dysfunction were 
endothelium-dependent relaxation of isolated aortic rings, eNOS activity, protein expression, 
NO production, cyclic guanosine monophosphate (cGMP) levels, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase activity and superoxide production in cultured rat 
aortic endothelial cells (RAECs) and human umbilical vein endothelial cells (HUVECs). Two 
types of compounds were used in an attempt to differentiate the direct effects of MG on eNOS 
and the indirect effects of oxidative stress induced by MG and high glucose on eNOS. These 
compounds were aminoguanidine, an MG scavenger, apocynin, an NADPH oxidase inhibitor 
and antioxidant, and NAC, which is an MG scavenger as well as an antioxidant.   
  
2.2.e To investigate whether MG is a causative factor in the development of insulin 
resistance in vivo in SD rats 
The chronic effects of MG on glucose homeostasis and pancreatic insulin secretory 
machinery were studied in 12 week old male SD rats. A comprehensive protocol was 
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developed that incorporated in vivo, in vitro and molecular techniques. GSH plays a vital role 
in the degradation of MG and keeps MG levels in the body within a physiological range. In 
one group of rats buthionine l-sulfoximine (BSO), a glutathione synthesis inhibitor, was co-
administered with MG with a view to examine whether higher MG levels were achieved and 
whether the effects of administered MG, under study were compounded in this group. ALA co-
treatment with MG was used to try and prevent any observed effects of MG. One novel feature 
of this study was administration of MG by continuous infusion via an osmotic minipump 
implanted subcutaneously on the back (Wang et al., 2006b). The purpose was to mimic the 
supposedly continuous generation of MG in the body and avoid the excessive plasma peaks of 
MG that inevitable arise from i.p. or i.v. administration.  
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Cell culture 
Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American 
Type Culture Collection and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS), 1% penicillin-streptomycin at 37° C in a 
humidified atmosphere of 95% air and 5% CO2, as described previously (Chang et al., 2005). 
A-10 cells were seeded either in 100 mm dishes for MG measurement or in 96-well plates for 
other assays, with an equal amount of cells (106/ml) in each well, and cultured to confluence. 
For immunocytochemistry staining, cells were seeded on cover glass slides (2×106/ml). Cells 
were starved in FBS-free DMEM for 24 h before exposure to different metabolic precursors.  
Rat aortic endothelial cells (RAECs) were isolated from male SD rats according to the 
method of McGuire, et al (Mcguire et al., 1987). The cells were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 0.15 
mg/mL endothelial cell growth supplement (Biomedical Technologies Inc., MA, USA) at 37° 
C in a 95% air / 5% CO2 incubator. For the initial culture matrigel (Sigma-Aldrich, Oakville, 
ON, Canada) coated 100-mm culture dishes were used. RAECs were identified by their 
typical cobblestone morphology and positive staining for von Willebrand factor. Cells 
between passage 3 and 6 were used for the experiments. Human umbilical vein endothelial 
cell (HUVEC) line was obtained from American Type Culture Collection and cultured in 
Kaighns F12K medium containing 10% fetal bovine serum (FBS), 0.1 mg/mL heparin and 
0.03-0.05 mg/mL endothelial cell growth supplement at 37°C in a humidified atmosphere of 
95% air and 5% CO2.  HUVECs were seeded either in 100-mm dishes or in 96-well plates for 
different assays, with an equal amount of cells (106/mL) in each well, and cultured to 
confluence.  
50 
 
 A B
200 μm 200 μm
 
Fig. 1-9 Rat aortic endothelial cells were freshly isolated and cultured. The identity of 
endothelial cells was confirmed at the beginning of the culture by (A)) the typical cobblestone 
morphology of confluent cells and also by (B) positive staining for von Willebrand factor.  
 
Animals 
Male 11-week old Sprague-Dawley (SD) rats from Charles River Laboratories 
(Quebec, Canada) were used according to guidelines of the Canadian Council on Animal Care. 
After one week of acclimatization the rats were fasted overnight before the experiments. 
Carotid artery and jugular vein cannulation was done under halothane anaesthesia for blood 
collection and drug injection. At the end of each experiment, rats were euthanized with 
thiopental sodium (100mg/kg, i.p.). Blood samples were collected in EDTA containing tubes. 
Heart, liver, kidney, aorta, brain, spleen, adipose tissue and skeletal muscle were collected and 
snap frozen in liquid nitrogen and stored at -80 c for further processing.  
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MG measurement 
MG was measured by a specific and sensitive high-performance liquid 
chromatography (HPLC) method (Dhar et al., 2009). MG was derivatized with o-
phenylenediamine (o-PD) to form the quinoxaline product, 2-methylquinoxaline, which is 
very specific for MG (Chaplan et al., 1998). After the specified incubation time of the cultured 
cells with MG, the culture medium was aspirated completely and the cells were washed twice 
with phosphate buffered saline (PBS). The cells were scraped, centrifuged and cell pellets 
were resuspended in ice-cold PBS, and lysed over ice by sonication (5 s, three times). The 
sample was then incubated on ice for 24 h with 1 N perchloric acid (PCA) and 10mM o-PD. 
The sample was centrifuged (12,000 rpm, 15 min) to remove the PCA-precipitated material. 
The 2-methylquinoxaline and underived 5-methylquinoxaline, which was added to the 
samples as the internal standard, were quantified on a Hitachi D-7000 HPLC system (Hitachi, 
Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle 
diameter, MA, USA). 
 
Measurement of peroxynitrite 
The formation of peroxynitrite was determined by a sensitive dicholorofluorescin 
(DCFH) assay. Briefly, cells were loaded with a membrane-permeable, nonfluorescent probe 
2’,7’-dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37°C in FBS-free 
DMEM in the dark. After washing with PBS 3 times, cells were treated with or without 
different substrates or MG for different incubation times, and finally subjected to detection. 
Once inside the cells, CM-H2DCFDA becomes membrane-impermeable DCFH2 in the 
presence of cytosolic esterases, and is further oxidized by peroxynitrite to form the fluorescent 
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oxidized dichlorofluorescein (DCF). The probe has high reactivity with peroxynitrite and its 
products CO3·- and NO2· but is not entirely specific for it. It also has low reactivity for 
hydrogen peroxide and even lower for superoxide (Wardman, 2007).The fluorescence 
intensity was measured with excitation at 485 nm and emission at 527 nm utilizing a 
Fluoroskan Ascent plate reader (Thermo Labsystem) and Ascent software, and expressed in 
arbitrary units. 
 
Measurement of nitrite and nitrate 
Cells were incubated with different substrates or MG and then washed with PBS. The 
supernatant was used for the measurement of nitrite and nitrate with a fluorimetric assay kit 
(Calbiochem) based on the Greiss reaction.  The assay is based on the enzymatic conversion 
of nitrate to nitrite by nitrate reductase followed by the addition of 2,3-diaminonaphthalene, 
which converts nitrite to a fluorescent compound. Fluorescence intensity measurements of this 
compound accurately determine the nitrite (NO2) concentration (excitation max.: 365 nm; 
emission max.: 450 nm) (Nussler et al., 2006). 
 
Immunocytochemistry /Immunohistochemistry 
A-10 cells were seeded on glass cover slips followed by incubation with different 
substrates for 3 h, and subjected to iNOS and CEL staining. As described previously (Wang et 
al., 2007), the treated cells were fixed in 4% paraformaldehyde for 30 min at room 
temperature and washed twice with 0.01 N phosphate buffered saline (PBS). After permeation 
with 0.1% Triton X-100 for 5 min and two washes with PBS, the cells were incubated with 
normal goat serum (diluted 1:30 in 0.1 N PBS) for 1 h to block non-specific binding sites. 
53 
 
After shaking off the goat serum the slides were incubated with iNOS antibody (1:500; BD 
Transduction Laboratories) and CEL antibody (1:100; a generous gift from Novo Nordisk, 
A/S, Denmark) overnight at room temperature. Cells were washed twice in PBS (0.01 N) for 5 
min and incubated with secondary fluorescein isothiocynate (FITC) conjugated anti-CEL and 
Texas red conjugated anti-iNOS antibodies (Molecular Probes) for 2 h. After washing thrice 
with PBS the slides were mounted in glycerol:PBS (3:7), coverslipped and observed under a 
fluorescence microscope. Staining intensity was quantified using the Metamorph image 
analysis software (v. 7, Molecular Devices). Slides from four different experiments were 
analyzed with 5 fields per slide observed and averaged. 
 
Intravenous Glucose Tolerance Test (IVGTT)  
After overnight fasting, an intravenous glucose tolerance test (IVGTT) was performed 
as described previously (Laight et al., 1999).  Briefly, the trachea, left jugular vein, and right 
carotid artery were cannulated in anesthetised rats. After collecting a basal blood sample rats 
were treated with saline, MG or MG+ALA. After 2 h a 0 min blood sample was taken and a 
bolus dose of glucose (0.5 g/kg) was given i.v. and further blood samples were collected at 1, 
3, 6, 12 and 24 min from the carotid artery. Plasma glucose levels were determined using a 
glucose assay kit (BioAssay Systems, Hayward, CA, USA) and insulin levels were measured 
with a rat insulin assay kit (Mercodia Rat Insulin ELISA). The IVGTT result was calculated as 
the area under the curve (AUC) for both plasma glucose and insulin levels between time 0 min 
and 24 min and expressed as arbitrary units.  
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Glucose uptake  
Insulin sensitivity of adipose tissue was evaluated by measuring insulin-induced 2-
Deoxy-[3H] glucose (2-DOG) uptake as described previously (Jia et al., 2006). Briefly, 
abdominal visceral adipose tissue was chopped and digested in DMEM base (no glucose, no 
serum) with collagenase (1.5mg/ml) at 37° for 20 min. The mixture was filtered, centrifuged, 
supernatant discarded and the pellet was re-suspended in the same DMEM. Thereafter, the 
cells were exposed to 100 nM insulin for 30 min and continuously incubated for another 20 
min after the addition of [3H]-2-DOG (0.1 μCi/500µl) with glucose (50 µM) to the medium. 
The incubation was stopped by washing cells three times with ice-cold glucose-free phosphate 
buffer. The cells were lysed in 0.1% sodium dodecyl sulphate (SDS) and 1 N NaOH and 
transferred into scintillation vials for counting (Beckman LS 3801 scintillation counter). 
 
Preparation of total membrane fraction from adipose tissue for GLUT4 
 
Abdominal visceral adipose tissue isolated from rats was homogenized in buffer B [10 
mmol/l Tris–HCl, 1 mmol/l EDTA, 250 mmol/l sucrose and 0.1 mmol/l phenylmethylsulfonyl 
fluoride (PMSF, pH 7.4)] using a polytron homogenizer. The homogenate was centrifuged at 
1700×g for 10 min at 4° C and the resulting supernatant was centrifuged at 8600 x g for 10 
min at 4° C. The supernatant was then centrifuged at 185000 x g for 60 min at 4 °C, and 
stored at −70° C before use. The protein concentration of the supernatant was determined by 
the bicinchoninic acid (BCA) protein assay reagent.  
 
Immunoprecipitation and western blotting 
For immunoprecipitation abdominal visceral adipose tissue was lysed in an ice-cold 
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radioimmunoprecipitation assay buffer (RIPA) buffer containing 30 mM HEPES (pH 7.4), 5 
mM EDTA; 1% Nonidet P-40, 1% Triton X-100, 0.5% sodium deoxycholate, 8 mM Na3VO4, 
1 mM NaF and 2 mM protease inhibitor (Jia and Wu, 2007). Tissue homogenates were 
incubated with IRS-1 antibody for two hours at 4º C, followed by incubation with Protein 
A/G-Agarose for further two hours at 4º C. Immunoprecipitates were separated using spin-
collection filters and washed once with RIPA buffer and three times with PBS. For western 
blotting, cell lysates or membrane fractions (50 µg) were boiled with sample buffer for 5 min, 
resolved by 10–12% SDS-PAGE, and transferred onto polyvinylidene fluoride (PVDF) 
membranes (Millipore, MA, USA). The membranes were blocked and incubated with the anti-
IR (1:500) (Santa Cruz, CA, USA), anti-GLUT4 (1:500) (Santa Cruz, CA, USA), and anti-β-
actin antibodies (1:2000) (Santa Cruz, CA, USA),  respectively, followed by incubation with 
horse radish peroxidase conjugated secondary antibodies (1:3000) (Upstate, MA, USA). The 
proteins were then visualized with chemiluminescence reagents (Amersham Biosciences, NJ, 
USA) and exposed to X-ray film (Kodak Scientific Imaging film, X-Omat Blue XB-1). 
 
Isometric tension studies on aortic rings 
Isometric tension studies were carried out on rat aortic rings as described (Wu et al., 
1998). Briefly, the thoracic aorta was rapidly removed from different groups of SD rats and 
placed in Krebs solution. The aorta was cleaned gently off extra tissue and cut into rings 3-4 
mm in length and mounted in 10 mL organ baths containing Krebs solution maintained at 37° 
C and bubbled with 95% O2 + 5% CO2. Aortic rings were equilibrated for 90 min at a resting 
tension of 2 g, the bathing solution being renewed every 15 min. To obtain relaxant responses 
the rings were pre-contracted with phenylephrine (1 µM) and concentration-dependent 
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relaxation in response to acetylcholine (ACh) was obtained. Sets of rings were incubated with 
Krebs alone (control, 5 mM glucose) or Krebs containing glucose (15 or 25 mM) or MG (30 
or 100 μM) for 2 h before obtaining dose-related responses with ACh. One set of rings was 
co-incubated with the MG scavenger aminoguanidine (AG, 100 μM) for 2 h. Isometric tension 
was measured with isometric force transducers with the ‘Chart’ software and Powerlab 
equipment (AD Instruments Inc., Colorado Springs, CO, USA).  
 
eNOS activity assay 
The NOS activity assay is based on the biochemical conversion of [3H] L-arginine to 
[3H] L-citrulline by NOS. Briefly control and test compounds treated cells were washed in 
PBS, harvested and centrifuged for 2 min to pellet the cells. The cells were resuspended in 1x 
homogenization buffer and sonicated briefly. Cells were centrifuged, the supernatant was 
separated and the resulting protein concentration was adjusted to 5-10 mg/mL. The eNOS 
activity was measured using the Cayman Chemicals NOS activity assay kit (Cayman 
Chemical Company, MI, USA). 
 
Measurement of reduced glutathione (GSH) 
Briefly, monochlorobimane stock (100 µM) was added to endothelial cells treated with 
test compounds. After 30 min, the medium was collected for medium GSH measurement. 
Cells were washed with PBS and harvested in 1000 µL of 1% sodium dodecylsulfate (SDS) in 
50 mM Tris buffer (pH 7.5), sonicated and the aliquots (100 µL) of supernatants were read in 
triplicate with an excitation wavelength of 380 nm and an emission wavelength of 470 nm 
(Wu et al., 2002). 
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 Implantation of subcutaneous MG pump 
 Subcutaneous pumps (Alzet® 2ML4) were implanted in all rats (Fig. 1-9) delivering either 
saline (2.5 μl/h) or MG (1.2 mg/h) by continuous infusion for 28 days. BSO, a GSH synthesis 
inhibitor and ALA, a MG scavenger were administered in drinking water (30 mg/kg) for 28 
days. The site for s.c. implantation of ALZET pumps in rats will be on the back, slightly 
posterior to the scapulae.  The rats were anesthetized with isoflurane, the skin over the 
implantation site was shaved and washedand sterilized with povidone iodine solution.   A 
suitable mid-scapular incision was made adjacent to the site chosen for pump placement. A 
hemostat was inserted into the incision by opening and closing the jaws of the hemostat, the 
subcutaneous tissue was spread to create a pocket for the pump. Care was taken to make sure 
that the pump was not rest immediately beneath the incision, which could interfere with the 
healing of the incision. A filled pump was inserted into the pocket. The wound was closed 
with wound clips or sutures. Post-operative recovery was observed closely for the first 1-2 h. 
The wound site was observed everyday post-op for signs of infection and inflammation. Any 
infection wase treated with locally applied antibiotics.  
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Figure 1-10 Surgical implantation of an osmotically driven infusion minipump filled with 
methylglyoxal. An incision was made on the back under aseptic conditions, just behind the 
ears in an anesthetised rat under isoflurane anaesthesia. A subcutaneous pocket was created in 
the fascia and the pump was inserted, followed by closure of the incision with surgical sutures. 
The rat was under buprenorphine (0.05mg/kg) analgesia pre- and post-surgically. 
Oral Glucose Tolerance Test (OGTT) 
After an overnight fast, basal blood sample was drawn through the tail vein in ice cold EDTA 
containing Eppendorf tubes. A bolus dose of glucose (1g/kg) was given through oral 
administration and blood samples were collected at 0, 15, 30, 60, 90 and 120 min from the tail 
vein and analyzed for glucose using glucose assay kit (BioAssay Systems, Hayward, CA, 
59 
 
USA) and insulin using rat insulin ELISA kit (Mercodia Rat Insulin ELISA, Uppsala, 
Sweden). 
 
Insulin tolerance test (ITT) 
After an overnight fast, the rats received an insulin injection (1U/Kg, i.v.). Blood samples 
were collected in EDTA containing tubes. Plasma was separated by centrifugation and plasma 
glucose levels were measured before and after 5, 10, 15, 30, 60 and 90 min using glucose 
assay kit. 
 
Insulin release from freshly isolated pancreatic islets 
The pancreatic islets were freshly isolated from SD rats as described by others (Shewade et 
al., 1999). Briefly, rats were anesthetised with isoflurane, the pancreatic duct was cannulated 
and injected with ~ 7 ml of ice-cold collagenase (Type IV, Worthington, 5 mg/ml) solution in 
Krebs buffer. The pancreas was cut out, washed in Krebs buffer and finely chopped into small 
pieces. The tissue was digested with 20 ml collagenase (Type IV) for 20 min at 37 °C in a 
shaker bath. The digestion was stopped by addition of 20 ml of calcium-free ice-cold Krebs 
buffer. The digested tissue was then centrifuged at 1000 rpm for 10 min and washed twice 
with Krebs buffer. The cell suspension was transferred into a Petri dish. Islets were separated 
under a dissection microscope. The identity of islets was confirmed under a high power 
microscope. For each treatment 10-20 islets were used in Eppendorf tubes. The islets were 
incubated for 30 min at 37°C in Krebs buffer containing either 5mM or 20mM glucose.  The 
incubation medium was collected and analyzed for released insulin with insulin assay kit. 
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Terminal deoxynucleotidyl transferasedUTP nick end labelling (TUNEL) assay 
The TUNEL assay was done using TUNEL assay kit (Roche Diagnostics, Indianapolis, 
USA). In brief, paraformaldehyde- fixed and optimal cutting temperature (OCT) compound-
embedded sections of pancreas were cut into 4µM on glass slides. The sections were washed 
twice with PBS. After permeation with 0.1% Triton X-100 for 5 min and two washes with 
PBS, the tissue sections were incubated with blocking solution (3% H2O2 in methanol) for 10 
min. After washing with PBS the slides were incubated with TUNEL reagent for 1h in dark 
and then converter POD (horse-radish peroxidise) for 30 min. After rinsing with PBS, the 
3,3’-diaminobenzidine (DAB) reagent was added; the sections were mounted under glass 
cover slips and analyzed under light microscope. 
 
DNA fragmentation assay 
DNA was isolated from pancreas using DNA extraction kit (R & D Systems, MN, 
USA). Equal amount and concentration (1µg) of DNA was loaded on 1% agarose gel and run 
at 100V for 2h. The gel was visualized on Syngene bio-imaging system.   
 
Real time Quantitative PCR (RT-PCR) 
RNA was isolated from the pancreas using RNA isolation kit (Qiagen sciences, 
Germantown, MD, USA). The total RNA was reverse-transcribed in triplicate using 
RevertAidTM H Minus M-MuLV reverse transcriptase (MBI, Fermentas, Burlington, ON, 
Canada) in the presence of 5x RT buffer (MBI, Fermentas), Random primer (Invitrogen), 
dNTP mixture (Amersham Pittsburgh, PA, USA) at 42°C for 50 min, followed by 72°C for 10 
min. The pre-designed primers for Pdx-1 and Maf-A were from Qiagen sciences, 
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Germantown, MD. The real-time PCR was carried out in an iCycler iQ apparatus (Bio-Rad 
Hercules, CA, USA) associated with the ICYCLER OPTICAL SYSTEM software (version 
3.1) using SYBR Green PCR Master Mix (Bio-Rad). All PCRs were triplicated and performed 
in 96-well optical-grade PCR plates and run for 45 cycles at 95°C for 20 s, 62°C for 1 min, 
and 72°C for 30s. After cycling, melting curves of the PCR products were acquired by 
stepwise increase of the temperature from 62° to 95°C. 
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Abstract 
Methylglyoxal (MG), a metabolic byproduct, reacts with certain proteins to yield 
irreversible advanced glycation endproducts (AGEs) and increases oxidative stress that causes 
the pathophysiological changes in diabetes, hypertension and aging. Although MG production 
from glucose has been well documented, the contribution of other intermediates of different 
metabolic pathways to MG formation is far less known.  Our aim was to determine and 
compare the formation of MG, MG-induced AGE, Nε-carboxyethyl-lysine (CEL), inducible 
nitric oxide synthase (iNOS), nitric oxide and peroxynitrite from different metabolic 
precursors in cultured rat aortic vascular smooth muscle cells (VSMCs). High-performance 
liquid chromatography was used to determine MG levels whereas nitrite plus nitrate, 
indicators of nitric oxide production, and peroxynitrite levels were measured with specific 
assay kits. CEL and iNOS were detected using immunocytochemistry. There was a 
concentration-dependent increase in MG levels in VSMCs after 3 h incubation with 5, 15 and 
25 mM of D-glucose, fructose or aminoacetone.  Aminoacetone produced a 7 fold increase in 
MG levels above the basal value followed by fructose (3.9 fold), D-glucose (3.5 fold), acetol 
(2.8 fold) and sucrose (2.3 fold) after a 3h incubation with 25 mM of each precursor. L-
glucose, 3-O-methylglucose, and mannitol had no effect on MG production.  All precursors, 
except L-glucose, 3-O-methylglucose and mannitol, increased CEL. Aminoacetone, D-glucose 
and fructose significantly increased iNOS, nitrite/nitrate and peroxynitrite levels. In 
conclusion, aminoacetone is the most potent precursor of MG production in VSMCs, followed 
by fructose and D-glucose. This could have important implications in relation to high dietary 
fructose and protein intake. 
Keywords: methylglyoxal, advanced glycation end products, fructose, inducible nitric oxide 
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synthase, peroxynitrite 
 
1. Introduction 
A number of highly reactive metabolic intermediates of glucose, fatty acids, and amino 
acids react with proteins, lipids, DNA and other molecules and alter their normal structure 
and/or function (Desai and Wu, 2007). Methylglyoxal (MG) is one such highly reactive 
dicarbonyl compound formed mainly in the glycolytic pathway non-enzymatically 
(Thornalley, 1996; Kalapos, 1999) (Fig. 4-1A, B). Other sources of MG include intermediates 
of protein metabolism, such as aminoacetone (Deng et al., 1998), and fatty acid metabolism, 
such as acetone and acetol (Casazza et al., 1984) (Fig. 4-1A, B). The enzymes catalyzing 
conversion of aminoacetone and acetone/acetol to MG are semicarbazide-sensitive amine 
oxidase (SSAO) (Yu et al., 2003) and acetone mono-oxygenase/acetol monooxygenase 
(Casazza et al., 1984), respectively. SSAO is found in vascular smooth muscle cells (VSMCs) 
and the plasma (Yu et al., 2003). 
MG reacts oxidatively with arginine or lysine residues of proteins and forms 
irreversible advanced glycation endproducts (AGEs) such as argpyrimidine (Shipanova et al., 
1997), Nε-carboxymethyl-lysine (CML) (Reddy et al., 1995), and Nε-carboxyethyl-lysine 
(CEL) (Ahmed et al, 1997). Along with 3-deoxyglucosone and glyoxal, MG is a major source 
of intracellular and plasma AGEs (Vlassara et al., 1994). Elevated MG levels and AGEs such 
as CEL and CML are markers of carbonyl overload, oxidative stress and the resultant damage 
in aging and diabetes (Vlassara et al., 1994).  An increase in glucose leads to increased 
formation of MG as occurs in diabetes (Thornalley, 1996; Vlassara et al., 1994). The serum 
concentration of MG increases in patients with type 1 or type 2 diabetes (Wang et al., 2007; 
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McLellan et al., 1994). We have recently shown that MG attaches to the internal arginine in 
the β-chain of insulin (Jia et al., 2006) and significantly reduces its capacity to stimulate [3H]-
2-deoxyglucose uptake by 3T3-L1 adipocytes and L8 skeletal muscle cells, compared with 
native insulin. These structural and functional abnormalities of insulin may contribute to the 
pathogenesis of insulin resistance (Jia et al., 2006). Our studies have also shown that as 
spontaneously hypertensive rats (SHR) developed hypertension there was an increase in MG 
levels in the plasma and aorta in an age-dependent fashion. No difference was observed in 
blood glucose levels between SHR and normotensive Wistar-Kyoto (WKY) rats (Wang et al., 
2005; Wang et al., 2007).   
We have shown earlier that MG activated nuclear factor kappaB p65 (NF-κB p65) and 
increased oxidative stress in rat VSMCs rats (Wu and Juurlink, 2002). MG induced inducible 
nitric oxide synthase (iNOS) and increased formation of peroxynitrite (ONOO-), a highly 
reactive oxidant, that was inhibited by the NOS inhibitor, Nω-nitro-L-arginine methyl ester (L-
NAME) (Chang et al., 2005; Wang et al., 2006).  Increased peroxynitrite has been found in 
type 1 diabetes (Pacher et al., 2007).  Superoxide, hydrogen peroxide, and peroxynitrite 
activate NF-κB which triggers inflammation and proliferative responses in VSMCs (Hoare et 
al., 1999).    
Glucose, the principal carbohydrate nutrient in the body, is also the most important 
contributor to the formation of glycated proteins (Desai and Wu, 2007; Thornalley, 1996) 
(Vlassara et al., 1994).  Fructose, another monosaccharide consumed in our diet, is also a 
precursor of MG (Wang et al., 1996).  Sucrose from the diet is converted into glucose and 
fructose. Metabolic intermediates such as glucose-6-phosphate form AGEs at a faster rate than 
glucose (Bucala et al., 1984).  
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Given the importance of endogenous MG level and the potential for MG production 
from various metabolic intermediates of carbohydrates, proteins, and fatty acids (Fig. 4-1B), it 
is imperative to characterize the transformation capability of different metabolic precursors to 
MG in the cells. The production of MG from glucose has been well documented and 
quantitated (Thornalley, 1996; Kalapos, 1999; Vlassara et al., 1994). Unfortunately, 
production of MG from other metabolic precursors, such as aminoacetone, acetol, or sucrose 
has not been systematically and directly examined or quantitatively compared with that from 
glucose. Our main aim was to determine and compare the formation of MG from different 
precursors (Fig. 4-1A, B) in VSMCs to provide fundamental information for cellular MG 
production.  MG-induced CEL, iNOS, NO and peroxynitrite in the presence of different 
metabolic precursors were further investigated in VSMCs. 
 
2. Methods 
2.1 Vascular smooth muscle cell culture 
Rat thoracic aortic smooth muscle cell line (A-10 cells) was obtained from American 
Type Culture Collection and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% fetal bovine serum (FBS) at 37° C in a humidified atmosphere of 95% air and 
5% CO2, as described in our previous studies (Chang et al., 2005; Wang et al., 2006) . A-10 
cells were seeded either in 100 mm dishes for MG measurement or in 96-well plates for other 
assays, with an equal amount of cells (106/ml) in each well, and cultured to confluence. For 
immunocytochemistry staining, cells were seeded on cover glass slides (2×106/ml). Cells were 
starved in FBS-free DMEM for 24 h before exposure to different metabolic precursors.  
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2.2 MG measurement 
MG was measured by a specific and sensitive high-performance liquid 
chromatography (HPLC) method (Wang et al., 2005; Wang et al., 2006). MG was derivatized 
with o-phenylenediamine (o-PD) to form the quinoxaline product, 2-methylquinoxaline, 
which is very specific for MG (Wang et al., 2005; Wang et al., 2007). After the specified 
incubation time of the cultured cells with precursors such as glucose and fructose, the culture 
medium was aspirated completely and the cells were washed twice with phosphate buffered 
saline (PBS). The cells were scrapped and cell pellets were resuspended in ice-cold PBS, and 
lysed over ice by sonication (5 s, three times). The sample was then incubated on ice for 10 
min with ¼ volume of 1 N perchloric acid (PCA) and centrifuged (12,000 rpm, 15 min) to 
remove the PCA-precipitated material. The supernatant was supplemented with 10 mM o-PD 
and incubated for 3 h at room temperature. The 2-methylquinoxaline and underived 5-
methylquinoxaline, which was added to the samples as the internal standard, were quantified 
on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® 
C18 column (3.9×150 mm, and 4 μm particle diameter, MA, USA). 
 
2.3 Measurement of peroxynitrite 
The formation of peroxynitrite was determined by a sensitive dicholorofluorescin 
(DCFH) assay as described previously (Wang et al., 2006). Briefly, cells were loaded with a 
membrane-permeable, nonfluorescent probe 2’,7’-dichlorofluorescin diacetate (CM-
H2DCFDA, 5 μM) for 2 h at 37°C in FBS-free DMEM in the dark. After washing with PBS 3 
times, cells were treated with or without different substrates for 3 h, and finally subjected to 
detection. Once inside the cells, CM-H2DCFDA becomes membrane-impermeable DCFH2 in 
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the presence of cytosolic esterases, and is further oxidized by peroxynitrite to form the 
fluorescent oxidized dichlorofluorescein (DCF). The probe has high reactivity with 
peroxynitrite and its products CO3·- and NO2· but is not entirely specific for it. It also has low 
reactivity for hydrogen peroxide and even lower for superoxide (Wardman, 2007). The 
fluorescence intensity was measured with excitation at 485 nm and emission at 527 nm 
utilizing a Fluoroskan Ascent plate reader (Thermo Labsystem) and Ascent software, and 
expressed in arbitrary units. 
 
2.4 Measurement of nitrite and nitrate 
Cells were incubated with different substrates for 3 h and then washed with PBS. The 
supernatant was used for the measurement of nitrite and nitrate with a fluorimetric assay kit 
(Calbiochem) based on the Greiss reaction.  The assay is based on the enzymatic conversion 
of nitrate to nitrite by nitrate reductase followed by the addition of 2,3-diaminonaphthalene, 
which converts nitrite to a fluorescent compound. Fluorescence intensity measurements of this 
compound accurately determine the nitrite (NO2) concentration (excitation max.: 365 nm; 
emission max.: 450 nm). 
 
2.5 Immunocytochemistry  
A-10 cells were seeded on glass cover slips followed by incubation with different 
substrates for 3 h, and subjected to iNOS and CEL staining. As described previously [18], the 
treated cells were fixed in 4% paraformaldehyde for 30 min at room temperature and washed 
twice with 0.01 N phosphate buffered saline (PBS). After permeation with 0.1% Triton X-100 
for 5 min and two washes with PBS, the cells were incubated with normal goat serum (diluted 
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1:30 in 0.1 N PBS) for 1 h to block non-specific binding sites. After shaking off the goat 
serum the slides were incubated with iNOS antibody (1:500; BD Transduction Laboratories) 
and CEL antibody (1:100; a generous gift from Novo Nordisk, A/S, Denmark) overnight at 
room temperature. Cells were washed twice in PBS (0.01 N) for 5 min and incubated with 
secondary fluorescein isothiocynate (FITC) conjugated anti-CEL and texas red conjugated 
anti-iNOS antibodies (Molecular Probes) for 2 h. After washing thrice with PBS the slides 
were mounted in glycerol:PBS (3:7), coverslipped and observed under a fluorescence 
microscope. Staining intensity was quantified using the Metapmorph image analysis software 
(v. 7, Molecular Devices). Slides from four different experiments were analyzed with 5 fields 
per slide observed and averaged. 
 
2.6 Materials 
 The substrates used in this study (Fig. 1A), D- and L-glucose, mannitol, fructose, 
sucrose, 3-O-methylglucose (3-OMG) and acetol were purchased from BDH. Aminoacetone 
was synthesized and characterized in our laboratory as described previously (Kazachkov et 
al., 2005). All cell culture reagents were purchased from GIBCO. 
 
2.7 Data analysis 
 Data are expressed as mean ± SEM and analyzed using one way ANOVA and post-hoc 
Dunnett’s test where applicable. P<0.05 was considered statistically significant when group 
difference was compared. 
 
3. Results 
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 3.1 Generation of MG from different metabolic precursors 
Cultured VSMCs were incubated with D-glucose, fructose, and aminoacetone at 
different concentrations for 3 h.  The 3 h incubation time was based on our previous 
observation of a time-dependent production of MG after incubation of VSMCs with fructose 
that reached a peak at 3 h (Wang et al., 2006). All three precursors induced a concentration-
dependent increase in MG levels (Fig. 4-2A). The greatest increase was observed with 
aminoacetone whereas fructose and D-glucose exhibited similar potency in generating MG 
(Fig. 4-2A, B).  Even at 5 mM the amount of MG produced by aminoacetone is 3.6 fold more 
than that produced by an equimolar concentration of D-glucose and 3.9 fold above the 
baseline levels of MG (Fig. 4-2A).  
In subsequent comparative experiments, in addition to D-glucose, fructose, and 
aminoacetone, acetol and sucrose also produced significant amount of MG in cultured VSMCs 
when 25 mM of each substrate was incubated for 3 h (Fig. 4-2B). However, L-glucose, 3-
OMG and mannitol at the same concentration of 25 mM did not induce significant production 
of MG after 3 h incubation of VSMC (Fig. 4-2B).   
 
3.2 Effect of different MG precursors on CEL formation 
The levels of the MG-induced AGE, CEL, were increased in VSMCs after incubation 
with aminoacetone, fructose, D-glucose, acetol and sucrose, each at 25 mM for 24 h (Fig. 4-
3A). CEL staining was located mainly in the cytosol of the cell with all precursors except 
aminoacetone, which showed CEL over the nuclear area also. The greatest increase was 
induced by aminoacetone, followed by fructose and D-glucose (Fig. 4-3B). Acetol and sucrose 
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caused less increase in CEL formation at a 25 mM concentration incubated for 24 h (Fig. 4-
3B). L-glucose, 3-OMG and mannitol at a concentration of 25 mM did not cause CEL 
formation after 24 h incubation of VSMCs (data not shown). 
 
3.3 Effect of different MG precursors on the generation of nitric oxide and peroxynitrite   
Aminoacetone, fructose, and D-glucose all increased NO production, measured as the 
stable products nitrite+nitrate (Fig. 4-4A), and peroxynitrite levels (Fig. 4-4B) in VSMCs 
when 25 mM of each substrate was incubated for 3 h. Aminoacetone was the most potent 
inducer of NO and peroxynitrite production. No significant increases in nitrite+nitrate levels 
and peroxynitrite level were observed when VSMCs were treated for 3 h with 25 mM each of 
sucrose, acetol, L-glucose, 3-OMG, or mannitol (Fig. 4-4A & 4-4B). 
 
3.4 Effect of MG precursors on inducible nitric oxide synthase expression 
The staining intensity for iNOS was increased in VSMCs after incubation with 
aminoacetone, fructose, and D-glucose, each at 25 mM for 3 h (Fig. 4-5A). The greatest 
increase was induced by aminoacetone, followed by fructose and D-glucose (Fig. 4-5B). 
Acetol, sucrose, L-glucose, 3-OMG and mannitol at a concentration of 25 mM did not cause 
iNOS induction after 3 h incubation of VSMCs (data not shown). 
The fold increase in MG, NO and peroxynitrite production has been shown in Fig. 4-6. 
This representation shows correlation of the magnitude of increase in nitrite+nitrate levels 
with the increase in MG levels after incubation with aminoacetone, fructose and D-glucose. In 
case of peroxynitrite, the ratio of peroxynitrite/MG showed correlation with the increase in 
MG levels obtained with aminoacetone, fructose and D-glucose (Fig. 4-6).   
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Fig. 4-1 A. Structures of methylgyoxal and various metabolic precursors used for the study. B. 
Pathways of methylglyoxal formation from different substrates. 
AGEs – advanced glycation endproducts; AMO - acetone monooxygenase and acetol 
monooxygenase; DHAP – dihydroxyacetone phosphate; FA – fatty acid; F-1-P – fructose -1-
phosphate; F-1,6-di-P – fructose -1,6-bisphosphate; F-6-P – fructose -6-phosphate; G-6-P – 
glucose -6-phosphate; G-3-P – glyceraldehyde -3-phosphate; GSH – reduced glutathione; 
ROS – reactive oxygen species; SSAO – semicarbazide-sensitive amine oxidase 
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Fig. 4-2  A. Concentration-dependent production of methylglyoxal (MG) from different 
metabolic precursors in cultured rat aortic smooth muscle cells (A-10). The production of MG 
was determined after A-10 cells were incubated for 3 h with 5, 15 or 25 mM of precursors. 
n=3-4 for each group. *P<0.05, **P<0.01, ***P<0.001 vs. basal value. P<0.01, P<0.001 
vs. fructose and D-glucose at same concentration. 
†† †††
B. Different amounts of methylglyoxal 
(MG) are produced from different substrates in cultured rat aortic smooth muscle cells (A-10). 
The production of MG was determined after A-10 cells were incubated for 3 h with different 
substrates (25 mM each). n=6 for each group. *P<0.05, **P<0.01, ***P<0.001 vs. control 
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Fig. 4-3  Detection of methylglyoxal-induced advanced glycation endproduct, Nε-
carboxyethyl-lysine (CEL), in cultured rat aortic smooth muscle cells (A-10) after incubation 
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with different substrates (25 mM each) for 24 h. A. Immunocytochemistry was performed on 
fixed cells with specific CEL antibody and fluorescein isothiocynate (FITC) conjugated 
secondary antibody. Scale bar 10 µm. B. Staining intensity was quantified using the 
Metamorph imaging program (Molecular Devices). **P<0.01 vs. control. 
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Fig. 4-4  Effect of different substrates on the production of nitrite plus nitrate (nitric 
oxide) (A) and peroxynitrite (B) in cultured rat aortic smooth muscle cells (A-10). The 
production of nitrite plus nitrate and peroxynitrite was determined after A-10 cells were 
incubated for 3 h with different substrates (25 mM each). n=3-6 for each group. *P<0.05, 
**P<0.01, ***P<0.001 vs. control. 
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Fig. 4-5  Detection of inducible nitric oxide synthase (iNOS)  in cultured rat aortic 
smooth muscle cells (A-10) after incubation with different substrates (25 mM each) for 3 h. A. 
Immunocytochemistry was performed on fixed cells with specific iNOS antibody and texas 
red conjugated secondary antibody. Scale bar 10 µm. B. Staining intensity was quantified 
using the Metamorph imaging program (Molecular Devices). *P<0.05, **P<0.01 vs. control. 
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Fig. 4-6 Fold increase in methylglyoxal (MG), nitric oxide (nitrite plus nitrate) and 
peroxynitrite levels above basal values after incubation of cultured rat aortic smooth muscle 
cells for 3 h with different substrates (25 mM each). *P<0.05, **P<0.01, ***P<0.001 vs. 
control. 
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4. Discussion 
We report major differences in MG produced in rat aortic smooth muscle cells 
incubated with different metabolic precursors derived from carbohydrates, proteins, and fatty 
acids. D-glucose, fructose, and aminoacetone induced concentration-dependent increase of 
MG. Aminoacetone, an intermediary product of L-threonine metabolism, produced the greatest 
amount of MG with a 7 fold increase above the baseline value (Fig. 4-6). Fructose and D-
glucose at an equimolar concentration of 25 mM produced 3.9 and 3.5 fold increase in MG 
levels, respectively. Acetol and sucrose also produced significant MG whereas L-Glucose, 3-
OMG and mannitol did not (Fig. 4-2B, 4-6). Importantly, aminoacetone, even at 5 mM, 
produced a significant increase in MG above the baseline levels whereas 5 mM D-glucose and 
fructose did not (Fig. 4-2A).    
Aminoacetone, fructose, D-glucose, acetol and sucrose also caused MG-induced AGE, 
CEL, formation after 24 h incubation with VSMCs. MG reacts with cysteine, arginine and 
lysine residues of different proteins in a reversible or irreversible manner to form different 
endproducts. CEL, which is formed when MG reacts with lysine residues of proteins (Ahmed 
et al, 1997)  has been detected in human lens proteins at a concentration similar to that of 
CML  (Ahmed et al, 1997), which is one of the most frequently found MG-derived AGEs 
(Reddy et al, 1995). CEL increased with age in parallel with the concentration of CML and 
was formed in highest yields during the reaction of MG with lysine and protein and the 
authors suggested that CEL levels can provide an index of glyoxal and MG concentrations in 
tissues (Ahmed et al., 1997).  In a recent study, the levels of MG-derived hydroimidazolone 
correlated with those of CML (Kilhovd et al., 2003), which in turn correlated with CEL 
formation (Ahmed et al., 1997). These AGEs can be detected immunohistochemically in 
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tissues (Reddy et al., 1995; Ahmed et al., 1997; Wang et al., 2005). 
Aminoacetone, fructose and D-glucose also caused significant increase in NO and 
peroxynitrite formation and induced iNOS after 3 h incubation with VSMCs, whereas acetol, 
sucrose, L-glucose, 3-OMG and mannitol had no effect on NO and peroxynitrite formation 
and iNOS expression. It should be noted that that even though the probe 2’,7’-
dichlorofluorescin diacetate has high reactivity with peroxynitrite and its products CO3·- and 
NO2· (Warman 2007)  it is not entirely specific for peroxynitrite. As mentioned in the methods 
this probe also has low reactivity for hydrogen peroxide and even lower for superoxide 
(Warman 2007). Previously we have shown that exogenous MG can induce iNOS and increase 
superoxide and peroxynitrite in VSMCs (Chang et al., 2005; Wang et al., 2006). In this study, 
the levels of MG correlate with nitrite+nitrate formed from different substrates (Fig. 4-6) and 
suggest a direct link between the amount of MG formed endogenously, and the magnitude of 
NO formation. One possible source of NO could be the increased levels of iNOS induced by 
aminoacetone, fructose and D-glucose as shown here (Fig. 4-5A, B) (Wang et al., 2006; 
Pacher et al., 2007; Hoare et al., 1999). Increased levels of iNOS are known to be associated 
with states of inflammation and immune reactions (Kaneki et al., 2007). Thus, MG can trigger 
an inflammatory reaction partly through induction of iNOS. Increased NO in turn can lead to 
increased formation of peroxynitrite, which can nitrosylate proteins and cause cellular damage 
(Pacher et al., 2007).  
MG is detoxified via the glyoxalase system to form the inert D-lactate (Kalapos, 
1999). Activity of the glyoxalase system is dependent on adequate levels of reduced 
glutathione (GSH) (Kalapos, 1999). Oxidative stress and hyperglycemia both lead to depletion 
of GSH (Wang et al., 2005; Chang et al., 2005; Park et al., 2003). Moreover, MG has been 
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shown to inactivate glutathione peroxidase and glutathione reductase (Chang et al., 2005; Park 
et al., 2003), which is required to recycle the oxidized glutathione (GSSG) back to GSH. This 
will impair the detoxification of MG and increase its half-life.   
The high levels of MG, NO and peroxynitrite produced by aminoacetone may assume 
importance in conditions of increased amino acid metabolism, in particular increased L-
threonine metabolism in people who are taking high amounts of protein such as athletes and 
body builders (Brandle et al., 1996) or in conditions of increased SSAO level such as 
hypertension and diabetes (Deng et al., 1998; Yu et al., 2003). L-threonine is metabolized to 
aminoacetone which can be deaminated to MG by SSAO, especially if the level of the 
antioxidant GSH is compromised as in cases of increased oxidative stress (Deng et al., 1998) 
(Vlassara et al., 1994; McLellan et al., 1994; Wu, 2002). Aminoacetone can be detected in the 
urine of normal people as well as patients with acute intermittent porphyria (Tschudy et al., 
1964). However, it must be admitted that plasma levels of aminoacetone in the range of 25 
mM that have been used in our in vitro study, have not been reported in the literature. We 
could not find any literature reports on the intracellular levels of aminoacetone thus limiting 
the significance of our findings regarding aminoacetone. Even so the potential of 
aminoacetone to form more MG and oxidative stress on a molar basis is a significant finding 
of our study.  
Fructose produced equivalent amounts of MG, nitrite+nitrate and peroxynitrite as D-glucose 
(Fig. 4-6). In healthy people the plasma concentrations of fructose are low, around 0.13 
mmol/L, compared to that of D-glucose, around 5 mmol/L, and it may not contribute to 
extracellular glycation as much as glucose (Kohlmeier et al., 2006). However, intracellular 
fructose is elevated in a number of tissues of diabetic patients in which the polyol pathway is 
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active and the concentrations of intracellular fructose and glucose are similar (Tomlinson et 
al., 1992). Plasma levels of fructose also increase in response to high fructose intake 
(Kohlmeier et al., 2006). No dietary fructose is needed since required amounts are modest and 
can be easily produced endogenously from glucose through the aldose reductase pathway 
(Tomlinson et al., 1992). Most fructose is consumed as refined sugar, such as sucrose, and 
through fruits and vegetables. In most Western societies the main source of fructose is high 
fructose corn syrup which is added to many industrial food products including ketchup and 
bread (Kohlmeier et al., 2006)  and the daily intake of fructose maybe as high as 100 g 
(Ruxton et al., 1999). The glycemic index (GI) reflects the magnitude of increase in blood 
glucose levels after consuming a given carbohydrate. A GI of 55 or less is classed as low, 
between 56 and 69 as medium and more than 70 as high (http://www.glycemicindex.com/). 
The GI for a 50 g dose of fructose varies between 12 and 24 depending on the manufacturer 
(http://www.glycemicindex.com/). This is much lower than a GI between 85 and 111 for a 50 
g dose of glucose. The GI for 50 g sucrose is between 58 and 65 
(http://www.glycemicindex.com/). Due to the low GI of fructose diabetic patients are advised 
to eat lots of fresh fruits and vegetables (http://www.diabetes.co.uk/nutrition.html)  
(http://www.diabetes.org/nutrition-and-recipes/nutrition/healthyfoodchoices.jsp). This advice 
needs to be carefully re-evaluated in light of the equipotency of fructose, compared to D-
glucose, in producing increased amounts of MG, NO and peroxynitrite (Fig. 4-6). 
Interestingly, in one study it was reported that in a population of vegetarians and omnivores 
plasma AGEs were higher (Krajcovicova et al, 2002). This was linked to a higher intake of 
fructose derived from a higher consumption of vegetables and fruit. Thus, it is likely that the 
increased formation of MG from fructose, as shown here, may substantially contribute to the 
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formation of intracellular AGEs, damage to cellular proteins and vascular complications 
(Mikulikova et al, 2008; Tokita et al, 2005). 
As mentioned earlier, acetol is a precursor for MG formation. An equimolar 
concentration of acetol produced a 2.8 fold increase in MG levels compared to the 3.5 fold 
produced by D-glucose (Fig. 4-6). Acetone, which is converted to acetol, is one of the ketone 
bodies and increased plasma levels of acetone are encountered in situations of abnormally 
high lipolysis as in diabetic ketoacidosis (Owen et al., 1982), as well as during extended 
periods of fasting where there is increased fatty acid metabolism and with the ketogenic diet in 
children with epilepsy (Gasior et al., 2007). The ketogenic diet, composed of 80-90% fat and 
10-20% carbohydrates and protein, is used for the treatment of drug-resistant seizures in 
children (Gasior et al., 2007). Mean serum acetone levels were 4 mM in children on the 
ketogenic diet and up to 8 mM in some of them (Musa et al., 2006). Acetone levels up to 8.9 
mM were found in patients with diabetic ketoacidosis (Owen et al., 1982). Intracellular 
acetone/acetol levels are likely to be much higher than these values. Thus, there is a potential 
for increase in MG levels in these situations and indeed increased acetone (6.12 fold) and MG 
levels (1.67 fold) have been reported in subjects taking the Atkins diet which has a higher 
percentage of fat (Beisswenger et al., 2005).  
Sucrose is the common sugar from sugar beets or sugar cane (Kohlmeier et al., 2006). 
Significant amounts are consumed with many sweet fruits. The sucrose in peaches may 
constitute as much as half of their dry weight. Sucrose is converted by the intestinal 
epithelium into glucose and fructose for absorption (Kohlmeier et al., 2006). Sucrose 
produced a relatively smaller increase in MG and CEL compared to D-glucose, and no 
significant increase in nitrite+nitrate or peroxynitrite. The result seems to indicate that sucrose 
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is not quickly converted to glucose and fructose in short period of time in the VSMCs. 
L-glucose is the metabolically inert isomer of D-glucose (Kohlmeier et al., 2006)   
whereas 3-OMG is a non-metabolizable glucose analogue that is not phosphorylated by 
hexokinase. 3-OMG is used as a marker to assess glucose transport by evaluating its uptake 
within various cells and organ systems (Dringen et al., 1993). Mannitol is commonly used for 
its osmotic effect (Paczynski et al., 1997) and is not likely to be metabolized. As anticipated, 
L-glucose, 3-OMG and mannitol did not increase MG, CEL, nitrite+nitrate and peroxynitrite 
above the basal levels (Fig. 4-6). Thus, MG production is restricted to specific substrates.   
The choice of 25 mM concentration is based on the observation that plasma glucose 
level in diabetic patients or STZ-induced diabetic rats (Cheng et al., 2001) can reach this high 
level and as such this concentration level can be used as a bench mark to compare the 
capabilities of other metabolic precursors on MG production. 
In conclusion, the amount of MG formed in VSMCs depends a great deal on the nature 
of the substrate. The important finding of our study is that aminoacetone has the potential to 
form significant amounts of MG, CEL, NO and peroxynitrite even at low concentrations. 
Since aminoacetone is an intermediate of protein metabolism, the production of MG and 
peroxynitrite under conditions of increased protein catabolism is worthy of further 
investigation. Another key finding is that fructose, despite its low GI value compared to D-
glucose, can form equal amounts of MG, CEL and induce oxidative stress as D-glucose.  
Increased fructose consumption, as seen in Western diets may be a health concern. The advice 
given to diabetic patients to eat lots of fruits, that contain fructose, needs to be carefully re-
evaluated. Since currently the main tendency is to focus on glucose in terms of increased MG, 
AGEs and oxidative stress in conditions such as diabetes, it is important to consider the 
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contribution of other substrates such as fructose, acetol and AA to MG, AGEs and oxidative 
stress load. This is despite their lower concentrations and apparently no correlation to high 
glucose levels. Our findings also bear relevance to situations where the metabolic pathways 
are altered and the intracellular concentrations of metabolites such as fructose, aminoacetone 
and acetone/acetol may reach high levels.  
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Abstract 
Methylglyoxal (MG), a reactive metabolic byproduct and a precursor of advanced glycation 
endproducts (AGEs), is elevated in diabetes. In the body MG is free or reversibly or 
irreversibly bound (mostly with proteins). Variable plasma MG values have been reported. 
MG is commonly measured using high performance liquid chromatography. We tested several 
protocols on different biological samples, which resulted in significant differences in MG 
values measured in a given sample. The different values do not appear to be due to release and 
detection of bound MG under assay conditions. Protocols that provide consistent values of 
MG in biological samples are recommended.  
 
Key words: Methylglyoxal, Perchloric acid, o-Phenylenediamine, HPLC 
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1. Introduction 
Methylglyoxal (MG), an alpha-oxoaldehyde, is mainly formed from intermediates of 
glycolysis such as dihydroxyacetone phosphate (DHAP) and glyceraldehyde-3-phosphate 
(G3P) (Desai and Wu, 2007; Thornalley, 1996). It is also formed in lesser quantities from 
acetone during fatty acid metabolism and from threonine during protein metabolism (Desai 
and Wu, 2007; Thornalley, 1996). As a highly reactive electrophilic compound, MG is a major 
precursor of advanced glycation endproducts (AGEs). Glycation is a reaction between a free 
amino group of a protein and a carbonyl group of a reducing sugar, ultimately leading to the 
formation of advanced glycation endproducts (AGEs). MG reacts reversibly with cysteine 
residues to form hemithioacetal adducts, and with lysine and arginine residues to form 
glycosylamine residues (Lo et al., 1994). MG reacts irreversibly with lysine residues to form 
N -(1-carboxyethyl)lysine (CEL) (Desai and Wu, 2007; Ahmed et al., 1997) and 1,3-di(N -
lysino)-4-methyl-imidazolium (MOLD) (Brinkmann et al., 1998) and with arginine to form 
Nδ-(4-carboxy-4,6-dimethyl-5,6-di-hydroxy-1,4,5,6-tetra-hydropyrimidine-2-yl)ornithine 
(THP) (Oya et al., 2000)  and argpyrimidine (Shipanova et al., 1997). However, it has been 
reported that the major adduct formed in vivo, is MG-derived hydroimidazolone (MG-H) 
(Kilhovd et al., 2003) , which occurs as three structural isomers: Nδ-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine (MG-H1), 2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-
yl)pentanoic acid (MG-H2), and 2-amino-5-(2-amino-4-hydro-4-methyl-5-imidazolon-1-
yl)pentanoic acid (MG-H3). AGEs are implicated in the pathological changes of diabetes 
mellitus and aging (Vlassara et al., 1994). Under normal physiological conditions, MG is kept 
at low levels by catabolism with glyoxalase I and glyoxalase II enzymes of the glyoxalase 
pathway that utilizes reduced glutathione (GSH) as a cofactor [2] but under hyperglycemic 
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condition, the levels of MG are high in plasma (McLellan et al., 1994; Thornalley et al., 1989; 
Beisswenger et al., 1999; Odani et al., 1999). To study the role of MG in various conditions it 
is critical to have a consistent protocol and a method of estimation that can give reproducible 
results when applied to different biological samples to measure MG levels.  
In the literature, variable plasma levels of MG have been reported in humans plasma 
(McLellan et al., 1994; Thornalley et al., 1989; Beisswenger et al., 1999; Odani et al., 1999; 
Han et al., 2007) and rats (Nagaraj et al., 2002; Wang et al., 2007) and the different values of 
MG might be due to differences in protocol used for the preparation of samples. A number of 
methods have been developed for the measurement of MG in plasma and animal tissues 
(Bednarski et al., 1989; McLellan et al., 1992; Chaplen, et al., 1996; Hoffman et al., 1991; 
Sawicki et al., 1975; Ohmori, et al., 1989). At the center of each is a derivatization step to 
stabilize MG. The compounds which have been used to derivatize include 1,2-diamino-4,5-
dimethoxybenzene (McLellan et al., 1992), ortho-phenylene diamine (o-PD) (Chaplen et al., 
1996), o-(2,3,4,5,6-pentafluorobenzyl) hydroxylamine hydrochloride (PFBOA) (Hoffman et 
al., 1991), dinitrophenylhydrazine (Sawicki et al., 1975; Ohmori et al., 1989)  and 9-(3,4-
diaminophenyl)acridine (DAA) (Mugo-Voloso et al., 2008). Dinitrophenylhydrazine may not 
be entirely specific for MG since it also reacts with intermediates from the glycolytic pathway 
to form the same osazones as MG (Ohmori et al., 1989). The most widely used and more 
specific method involves the derivatization of MG with 1,2-diaminobenzene derivatives, such 
as o-PD (Chaplen et al., 1996; Hoffman et al., 1991; Sawicki et al., 1975; Ohmori et al., 1989; 
Mugo-Veloso et al., 2008; Chaplen et al., 1998)  and the quantification of the resulting 
quinoxaline with high performance liquid chromatography (HPLC). The high reactivity of 
MG might be a factor that makes it difficult for reliable and reproducible quantification from 
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sample to sample (Chaplen et al., 1998). It is believed that less than 1% of MG exists in a free 
form while more than 99% exists in a protein-bound form (Mugo-Veloso et al, 2008; Chaplen 
et al., 1998). To complicate matters, it has been proposed that the protein bound form can exist 
as an irreversibly bound pool or a reversibly bound pool (Chaplen t al., 1998; Ahmed et al., 
2002). In this case the irreversibly-bound form remains stable under harsh assay conditions 
and therefore cannot be detected (Chaplen et al., 1998). Irreversibly-bound MG, characterized 
as AGEs, is detected by separate assays for AGEs (Ahmed et al., 2002; Nagaraj et al., 1996). 
The reversibly-bound MG is believed to be in dynamic equilibrium with free MG and can be 
measured (Fig.1). However, the reversibly bound MG compounds are unstable and are, 
therefore, possibly a source of error in assays (Chaplen et al., 1998). Perchloric acid (PCA) is 
used in the protocol to stop metabolic reactions in the sample and to precipitate proteins which 
are immediately removed from the sample before it is derivatized with o-PD (Chaplen et al., 
1996; Hoffman et al., 1991; Sawicki et al., 1975; Ohmori et al., 1989; Mugo-Veloso et al., 
2008; Chaplen et al., 1998). Chaplen et al (Chaplen et al., 1998) theorized that this will also 
precipitate the reversibly-bound MG adducts and remove them from the sample along with the 
proteins that are removed after centrifugation. According to the results obtained by Chaplen et 
al. (Chaplen et al., 1998), a longer incubation of the precipitated proteins, which will include 
the reversible MG adducts, will allow the acidic environment to free MG from its reversible 
binding and make it amenable to detection. Variations in the sample treatment protocol 
detected up to an amazing 100 to 1000 fold more MG from the same sample, when applied to 
cultured Chinese hamster ovary (CHO) cells (Chaplen et al., 1998). However, it is not known 
if similar variations in protocol would affect the amount of MG detected in other sample types 
such as plasma, body organs or tissues and other cultured cells such as vascular smooth 
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muscle cells (VSMCs). We tested the protocol variables on plasma and liver samples from 
Sprague-Dawley rats and on rat cultured aortic VSMCs. Our aim was to determine what 
impact the protocol variability had on the amounts of MG measured and establish optimum 
protocols for different sample types. Since 99% of MG is reported to exist in a protein bound 
form, we also prepared a MG (120 μM) - 1% bovine serum albumin (BSA, in phosphate 
buffered saline, PBS) and a MG (120 μM) – 1% liver homogenate in PBS solution to 
determine time-related reactivity, the degree of protein binding (reversible or irreversible) and 
the detectable amount of MG with different protocols.  
  
2. Experimental 
2.1 Preparation of samples  
 
2.1.1 Preparation of plasma and liver samples. Six male SD rats, 12-13 weeks old, were 
obtained from, Charles Rivers, Quebec, Canada and treated in accordance with guidelines of 
the Canadian Council on Animal Care. The protocol was approved by the Animal Care 
Committee of the University of Saskatchewan. Animals were fed normal chow diet ad libidum 
and acclimatized for one week before the experiment. Blood was collected in EDTA tubes 
from anesthetized (thiopental sodium 100 mg/kg, intraperitoneal) normal SD rats. Plasma was 
separated by centrifugation (3000 g for 5 min). Liver was removed from normal SD rats and 
was frozen in liquid nitrogen. The liver sample was homogenized under liquid nitrogen in a 
Mikro-Dismembrator (B. Braun Biotech. Int., Bethlehem, PA, USA). The homogenized 
sample was reconstituted in PBS or sodium phosphate buffer (pH 4.5) and sonicated (30 s, 
three times). The same sample of plasma or liver was treated with designed protocols to study 
the impact of different protocols on the amount of MG measured. The experiment was 
98 
 
repeated a minimum of four times on plasma and liver samples from different rats. 
 
2.1.2 Vascular smooth muscle cells: Rat thoracic aortic smooth muscle cell line (A-10 cells) 
was obtained from American Type Culture Collection and cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) at 37° C in a humidified 
atmosphere of 95% air and 5% CO2, as described previously (Dhar et al., 2008; Chang et al., 
2005; Wang et al., 2006). A-10 cells were seeded in 100 mm dishes and were starved in FBS-
free medium for 24 h prior to scrapping and collection. The cell pellet was reconstituted in 
PBS and sonicated (5 s, three times). The homogenate was used for MG level analysis and 
protein determination.  
 
2.1.3 MG-BSA, MG-liver, MG-liver/EDTA and MG-PBS samples: MG (120 μM) was 
incubated for varying times ranging from 1 min to 24 h in an incubator (37º C) with 1% BSA 
in 1 N PBS (pH 7.4) solution (MG-BSA), 1% liver homogenate in 1 N PBS (pH 7.4) solution 
(MG-liver), 1% liver homogenate in sodium phosphate (pH 4.5) containing 50 μM EDTA 
(MG-liver/EDTA) or PBS alone (MG-PBS). The same sample was treated with different 
protocols. The experiment was repeated a minimum of four times on different samples.  
 
2.2 Protocol variables:  
2.2.1  Different samples were incubated with perchloric acid (PCA, 0.2 N or 0.45 N final 
concentration) for 10 min, 3 h or 24 h at room temperature, which has been described in 
results as PCA 10 min, 3 h or 24 h. The concentrations of PCA were chosen based on their use 
in previously published reports (McLellan et al., 1992; Hoffman et al., 1991; Chaplen et al., 
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1998; Ahmed et al., 2002; Dhar et al., 2008; Wang et al., 2006; Randell et al., 2005). PCA 
was used to precipitate proteins from the sample and to inhibit metabolic reactions. The 
precipitated protein was removed from the samples by centrifugation (12,000 rpm for 10 min 
at 4º C). 
 
2.2.2  o-PD (0.2 mM, 1 mM or 10 mM final concentration) was used as a thermodynamic 
trap to derivatize MG to form the stable 2-methylquinoxaline (Fig. 5-1). In case of PCA 
10min, o-PD was added to the supernatant after removal of precipitated protein (McLellan et 
al., 1992; Chaplen et al., 1996; Chaplen et al., 1998; Ahmed et al., 2002; Dhar et al., 2008; 
Wang et al., 2006; Randell et al., 2005), while in case of PCA 3 h or 24 h it was added to the 
sample along with PCA and incubated at room temperature for 3 or 24 h (Chaplen et al., 
1998). The sample was further centrifuged at 12,000 rpm for 10 min before adding the 
supernatant to the HPLC sample tubes. The concentrations of o-PD were chosen based on 
their use in previously published reports (McLellan et al., 1992; Hoffman et al., 1991; 
Chaplen et al., 1998; Ahmed et al., 2002; Dhar et al., 2008; Wang et al., 2006; Randell et al., 
2005). 
 
2.2.3  The incubation time was varied as described above.  
  
2.3 Quantification of MG by high performance liquid chromatography (HPLC) 
2.3.1 Method validation: Methylglyoxal was quantified on Hitachi D-7000 HPLC system 
(Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 
column (3.9×150 mm, and 4 μm particle diameter, MA, USA) using the external standard 2-
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methylquinaxaline (2-MQ) method, by plotting the concentration of standard quinoxaline 
derivative (µM) as a function of peak area detected at 315 nm, corresponding to their UV 
absorption maxima. Regression equation and correlation coefficient, reported in Table 5-1, 
was calculated by least square method. The limit of detection (LOD), calculated as the amount 
of analyte required to obtain a signal to noise ratio of 2:1, was 3 µvolts The limit of 
quantification (LOQ), that is the lowest concentration required to yield a signal to noise ratio 
of 12, was 0.05 µM. 
Method repeatability (inter and intra-assay) was evaluated by analyzing the derivatized 
samples 3 times in 3 days. The inter and intra-assay standard deviation of the methylglyoxal 
was consistently <3 (Table 5-2). 
The recovery of the HPLC method was determined by recovery tests performed by adding 
four different concentrations of standard quinoxaline (2-MQ) derivative to samples before 
derivatization. The results (Table 5-3) showed recovery rates between 98-100%. 
 
Table 5-1. Calibration data and LOQ and LOD of 2-methylquinoxaline 
 
Compound Linear 
range (µM) 
Regression 
equation 
Correlation 
coefficient 
LOQ 
(µM) 
LOD 
(µvolts) 
2-
methylquinoxaline 
20% y = 0.5634x-
0.5464 
0.9958 0.05 3 
 
 
Table 5-2. Method of precision of 2-MQ in samples after derivatization with o-PD 
Values of 2-MQ (μM) are Mean ± SEM. 
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Compound Day 1 Day 2 Day 3 RSD (%) 
intra- assay  
(day 1) 
RSD (%)  
(intra-assay) 
2-methylquinoxaline 2.4  ± 0.03 2.3 ± 0.05 2.35 ± 0.02 1.7 1.41 
 
 
Table 5-3. Recovery rates of the HPLC method for 2-MQ determination  
 
Compound Amount added (µM) Amount found (µM) %  recovery (n=3) 
2-methylquinoxaline 10 9.915 
 
99.15 
 
To determine recovery, two sets of samples (n=3 each) of rat plasma were prepared. One set of 
samples was analyzed as is and the second set was spiked with 10 μM of MG. The MG in both 
sets of samples was determined by HPLC. Calculation of recovery involved subtraction of the 
MG in the unadulterated plasma sample from that in the spiked sample. The recovery 
experiment was done using the internal standard 5-MQ. Recovery is shown in Table 5-4. 
 
Table 5-4. Recovery rate of standard quinoxaline (2-MQ) after derivatization 
Compound Concentration (µM) Peak area Peak ratio (2-MQ/5-MQ) 
2-methylquinoxaline 10 134252 
 
5-methylquinoxaline 100 115254 
 
1.164836 
 
 
 
Solvent B (100% methanol) was used for washing the column and lines. Solvent A 
(acetonitrile 20%) was kept at 100% for running the samples. Each sample run was for 30 min 
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with a flow rate of 1 ml/min. The whole series of samples in a single experiment was run in 
duplicate.  
 
2.4 Chemicals  
All chemicals were of analytical grade. Methylglyoxal, o-phenylenediamine (o-PD), ethylene 
diamine tetraacetic acid (EDTA), sodium dihydrogen phosphate monohydrate (NaH2PO4 · 
H2O), sodium phosphate dibasic (Na2HPO4), 2-methylquinoxaline (2-MQ), 5-
methylquinoxaline (5-MQ) and perchloric acid (PCA) (ACS reagent grade) were purchased 
from Sigma Aldrich, Ontario, Canada. HPLC grade acetonitrile and methanol were purchased 
from EMD Chemicals Inc., Gibbstown, NJ, USA. Sodium metabisulfite (Na2S2O5) was 
purchased from Alfa Aesar, A Johnson Matthey Company, MA, USA.  
 
2.5 Statistical analysis  
Data are expressed as Mean ± SEM and analyzed using one way ANOVA to compare 
differences between three or more values from the same sample subjected to different 
protocols. Student’s unpaired t-test was used to compare differences between two values 
forming a pair. The P value was considered significant when it was less than 0.05 (P<0.05) 
 
3. Results  
3.1 Method validation: Regression equation and correlation coefficient, reported in Table 5-
1, was calculated by least square method. The limit of detection (LOD), calculated as the 
amount of analyte required to obtain a signal to noise ratio of 2:1, was 0.01 µM. The limit of 
quantification (LOQ), that is the lowest concentration required to yield a signal to noise ratio 
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of 12, was 0.05 µM. 
Method repeatability (inter- and intra-assay) was evaluated by analyzing the derivatized 
samples 3 times in 3 days. The inter- and intra-assay standard deviation of MG was 
consistently <3 (Table 5-2). 
The recovery of the HPLC method was determined in two separate ways: 1) Plasma sample 
was divided into two. One was analyzed as the unadulterated sample after derivatization with 
o-PD. The other parallel plasma sample was spiked with a known amount of MG (10 μM) and 
was derivatized with o-PD. To calculate recovery the MG in the unadulterated plasma sample 
(without any externally added MG) was subtracted from the spiked sample (with 10 μM MG 
added). % recovery = (amount detected / amount added) x 100 (n = 3 each). As shown in 
Table 5-3 recovery was 99%. 
2) Recovery of the external standard: Plasma sample was spiked with a known amount of 
external standard (2-MQ, 5 μM) and subjected to the entire HPLC protocol. 2-MQ detected in 
the spiked sample was then compared against the external standard (5 μM, used for calibration 
of standard curve) using the following equation.  % recovery = [(2-MQ in spiked sample – 2-
MQ in unspiked sample) / 2-MQ in external standard] x 100 (n = 3 each). As shown in Table 
5-4 recovery was 102%. 
 
3.2 Fig. 5-1 shows representative chromatograms of plasma, liver and VSMC samples. 
 
3.3 Plasma samples: The same plasma sample treated with different protocols resulted in 
significant differences in the amount of MG measured (Fig. 5-2). The sample incubated with 
0.45 N PCA consistently produced greater levels of MG than 0.2 N PCA (Fig. 5-2A). This 
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difference was remarkable when the sample was incubated with PCA (0.45 N) and o-PD (10 
mM) for 24 h (Fig. 5-2A). When the PCA (0.2 or 0.45 N)-precipitated protein was incubated 
for 3 h or 24 h instead of 10 min, before removal by centrifugation, there was no significant 
difference in MG levels except in two instances (Fig. 5-2B). Incubation with 10 mM o-PD, as 
compared to 0.2 or 1 mM, also did not result in significantly different values of MG except in 
one instance where incubation of 10 mM o-PD and PCA (0.45 N) for 24 h produced almost 
double the value of MG in the same sample as compared with 0.2 and 1 mM o-PD (Fig. 5-
2C).  
 
3.4 Liver samples: The same liver sample treated with different protocols produced 
significant differences in the amount of MG detected (Fig. 5-3). Treatment with 0.45 N PCA 
consistently produced significantly higher values of MG than 0.2 N PCA (Fig. 5-3A). When 
the PCA (0.2 or 0.45 N)-precipitated-protein was incubated for 3 h or 24 h instead of 10 min, 
before removal by centrifugation, it gave a greater measure of MG in all instances (Fig. 5-3B). 
Incubation with 10 mM o-PD, as compared to 1 mM, produced significantly higher values of 
MG in most instances (Fig. 5-3C). 0.2 mM was not tried with liver samples.  
 
3.5 Cultured VSMCs: The MG levels were also measured in A-10 cells with different 
protocols (Fig. 5-4). As with plasma and liver samples, 0.45 N PCA yielded significantly 
higher values of MG than 0.2 N PCA (Fig. 5-4A). Incubation of samples for 10 min or 3 h 
with 0.45 N PCA did not produce any difference in MG values. However, incubation of 
samples for 24 h with 0.45 N PCA resulted in higher values of MG, compared to 10 min or 3 h 
incubation (Fig. 5-4B). Incubation of samples with 1 or 10 mM o-PD did not produce 
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significant differences in values of MG detected in VSMCs (Fig. 5-4C). 
 
3.6 Methylglyoxal-bovine serum albumin (MG-BSA) samples: In one group of 
experiments, MG (120 μM) was incubated with or without 1% BSA in 1 N PBS (pH 7.4) for 
different times (1 min to 24 h) and then MG levels were determined in these MG-BSA or MG-
PBS (protein-free control) samples with different protocols. As shown in Fig. 5-5 the different 
protocols failed to produce significant differences in the amount of MG detected in MG-BSA 
samples. Incubation of PCA for 10 min, 3 h or 24 h resulted in equivalent values of MG (Figs. 
5-5A, 5-5C). Similarly, incubation of the same MG-BSA sample with 1 or 10 mM o-PD did 
not result in any significant differences in MG values (Fig. 5-5B). Fig. 5C shows a time-
dependent decrease in MG levels in the MG-BSA group. For example, after incubation of MG 
(120 μM) with 1% of BSA for 3 h and 24 h, the detectable MG was decreased to 66% and 
22% of the value detected in MG-PBS, respectively (Fig. 5-5C). This indicates decreased free 
MG or increasing binding of MG to BSA with increasing time. In addition, incubation of MG-
BSA with 0.45 N PCA for 10 min or 24 h did not produce significant differences in MG 
values. Based on previous results 0.2 N PCA and 1 mM o-PD were not tested with MG-BSA 
samples. 
 
3.7 Methylglyoxal-liver homogenate (MG-liver) samples: Fig. 5-6A shows the amount of 
MG detected when 120 μM of MG was incubated for 3 or 24 h with 1% liver homogenate in 1 
N PBS (pH 7.4) (MG-liver), 1% liver homogenate in sodium phosphate (pH 4.5) containing 
50 μM EDTA (MG-liver/EDTA) or 1 N PBS (MG-PBS). The same sample treated with 0.45 N 
PCA for 10 min or 24 h did not produce any differences in the amount of MG detected (Fig. 5-
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6A). o-PD (10 mM) was incubated for 24 h with all samples. Based on previous results 0.2 N 
PCA and 1 mM o-PD were not tried with MG-liver homogenate samples.  
Fig. 5-6B shows that an incubation of the sample with 120 μM of MG for 3 or 24 h 
resulted in different levels of MG detected in the MG-PBS (control), MG-BSA, MG-liver and 
MG-liver/EDTA samples. In comparison with MG-PBS control, only 49% and 2% of MG can 
be detected in MG-liver samples after 3 h and 24 h incubation, respectively, while 65% and 
19% of MG can be detected in MG-liver/EDTA samples and 66% and 24%, respectively, in 
the MG-BSA samples. This further suggests that decreased MG values reflect decreased free 
MG level with increased binding of MG to BSA or proteins in liver homogenate suspension 
with increasing incubation times. It also indicates possible degradation of added MG by liver 
enzymes in the MG-liver sample. 
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Liver
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Smooth muscle cells
 
Fig. 5-1 Original chromatograms showing 2-methylquinoxaline (2-MQ) and 5-
methylquinoxaline (5-MQ) peaks in samples of (A) liver, (B) plasma and (C) cultured rat 
aortic vascular smooth muscle (A10) cells. 2-MQ is a specific stable product formed by 
derivatization of methylglyoxal in the sample when the sample is incubated with o-phenylene 
diamine (o-PD). 5-MQ is the internal standard (10 μM). 
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Fig. 5-2 Methylglyoxal (MG) levels in the plasma measured with different protocols. A. The 
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sample was acidified and deproteinized with 0.2 or 0.45 N perchloric acid (PCA). B. The 
PCA-precipitated protein was incubated in the sample for 10 min, 3 h or 24 h before removal 
by centrifugation. C. MG was derivatized by incubation with o-phenylenediamine (o-PD, 0.2, 
1 or 10 mM) for 3 h or 24 h. n = 5-6 for each group. *P<0.05, **P<0.01, ***P<0.001 vs. 
corresponding paired value, δδδP<0.001 vs. corresponding 0.2 mM value. 
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Fig. 5-3 Methylglyoxal (MG) levels in liver sample treated with different protocols. A. The 
sample was acidified and deproteinized with 0.2 or 0.45 N perchloric acid (PCA). B. The 
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PCA-precipitated protein was incubated in the sample for 10 min, 3 h or 24 h before removal 
by centrifugation. C. MG was derivatized by incubation with o-phenylenediamine (o-PD, 1 or 
10 mM) for 3 h or 24 h. n = 4-5 for each group *P<0.05, **P<0.01, ***P<0.001 vs. 
corresponding paired value. 
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Fig. 5-4 Methylglyoxal (MG) levels in cultured vascular smooth muscle cells (VSMCs). A. 
The sample was acidified and deproteinized with 0.2 or 0.45 N perchloric acid (PCA). B. The 
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PCA-precipitated protein was incubated in the sample for 10 min, 3 h or 24 h before removal 
by centrifugation. C. MG was derivatized by incubation with o-phenylenediamine (o-PD, 1 or 
10 mM) for 3 h or 24 h. n = 3-4 for each group. *P<0.05, **P<0.01, ***P<0.001 vs. 
corresponding paired value. 
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Fig. 5-5 Methylglyoxal (MG) levels in bovine serum albumin (BSA) samples measured with 
different protocols. MG (120 μM) was incubated with 1% BSA in 1 N PBS (MG-BSA) or 1 N 
PBS (MG-PBS) solution at 37° C for different times. The samples were then treated with 
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different protocols and subjected to HPLC for quantification of MG. A. The PCA (0.45 N)-
precipitated protein was incubated in the sample (MG-BSA) for 10 min, 3 h or 24 h before 
removal by centrifugation. B. MG was derivatized by incubation with o-phenylenediamine (o-
PD, 1 or 10 mM) for 3h or 24h. C. Decreasing MG levels after increasing incubation times 
with BSA. The PCA (0.45 N)-precipitated protein was incubated in the sample for 10 min, 3 h 
or 24 h. o-phenylenediamine (o-PD, 10 mM) was incubated for 24 h in all samples to 
derivatize MG. n = 3-4 for each group. *P<0.05, ***P<0.001 vs. corresponding PBS control. 
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Fig. 5-6 Methylglyoxal (MG) levels in liver homogenate and bovine serum albumin (BSA) 
samples. Liver homogenate (see Methods) was dissolved in sodium phosphate (pH 4.5) to 
make a 1% solution and immediately assayed for MG (Basal). For other samples MG (120 
μM) was incubated at 37° C for 3 or 24 h with 1% liver homogenate in 1 N PBS (pH 7.4) 
(MG-liver), 1% liver homogenate in sodium phosphate (pH 4.5) solution containing 50 μM 
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EDTA (MG-liver/EDTA), 1% BSA in 1 N PBS (pH 7.4) (MG-BSA) or 1 N PBS (MG-PBS). 
A. The 0.45 N PCA-precipitated protein was incubated in the sample for 10 min or 24 h 
before removal by centrifugation. MG was derivatized by incubation with o-
phenylenediamine (10 mM) for 24 h. **P<0.01 vs. corresponding PCA-protein 10 min value; 
δδP<0.01, δδδP<0.001 vs. corresponding MG-liver value. B. The 0.45 N PCA-precipitated 
protein along with o-PD (10 mM) was incubated in the sample for 24 h before removal by 
centrifugation. **P<0.01, ***P<0.001 vs. corresponding MG-PBS value, δP<0.05, δδP<0.01 
vs. corresponding MG-liver value. 
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4. Discussion 
The consumption of excess carbohydrates, high blood glucose levels and the incidence 
of diabetes are increasing at an alarming rate in North America. High glucose is associated 
with elevated plasma MG levels. The high reactivity of MG with proteins and its implications 
are coming under increased scrutiny. Variations in the amount of MG reported are a source of 
confusion in the literature review involving MG. Chaplen et al. (Chaplen et al., 1998) reported 
that variations in the protocol for sample treatment and preparation for HPLC can yield 
significantly different values of MG from the same sample when tested on cultured Chinese 
hamster ovary cells. The effect of variations in protocol on the amount of MG detected in 
different biological samples has not been reported. Our results with variations in protocol 
when applied to commonly used biological samples are unexpected and very interesting.  
Plasma samples are the ones most commonly analyzed and varying plasma 
concentrations have been reported in human (McLellan et al., 1992; Thornalley et al., 1989; 
McLellan et al., 1992; Beisswenger et al., 1999; Odani et al., 1999)  as well as rat (Nagaraj et 
al., 2002; Wang et al., 2007). Plasma typically contains a mixture of numerous proteins 
without any cells. The bulk of the protein is albumin and globulin with lesser amounts of other 
proteins. Our results revealed significantly different values from the same plasma sample 
treated with different protocols in some instances. Use of 0.45 N PCA, as compared to 0.2 N, 
yielded higher values of MG in many instances (Fig. 5-2A). It is likely that a stronger acidic 
environment releases more MG from its reversible binding to proteins and other cellular 
components (Chaplen et al., 1998). Incubation of the PCA-precipitated protein for 24 h or 
even for 3 h did not yield significantly different values of MG as compared to 10 min of 
incubation except in a couple of instances (Fig. 5-2B). For example, there was a marked 
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difference in values when 10 mM of o-PD was used along with 0.45 N PCA incubated for 24 
h as compared to PCA-protein for 10 min or 1 mM o-PD (Fig. 5-2B, 5-2C). A 10 mM 
concentration of o-PD did not give any interfering peak (Chaplen et al., 1998) on the HPLC 
when ran alone as a control. It should be noted that the difference was not as striking as with 
Chinese hamster ovary cells, which had more than 100 to 1000 fold difference in MG values 
(Chaplen et al., 1998). Also, we found that the plasma sample did not require passage through 
C18 solid-phase extraction (SPE) cartridge after precipitation with PCA (Randell et al., 2005). 
Our chromatograms were very clean within the regions of 2MQ and 5-MQ peaks (Fig. 5-1). 
Moreover, sample concentration was not necessary since the values detected were way above 
the detection limits. Moreover, passage through a column is likely to result in loss of sample 
and possibly some MG adducts. To begin with, plasma samples have limited volumes (200 – 
400 μl) and loss in a column cannot be afforded.  Thus, incubation of plasma samples with 
0.45 N PCA-precipitated proteins and 10 mM o-PD for 24 h yielded very consistent values of 
MG in the plasma and is recommended. 
Treatment of liver samples with 0.45 N PCA instead of 0.2 N gave consistently higher 
values of MG (Fig. 5-3A). Also, incubation of PCA-precipitated protein for 3 h or 24 h, as 
opposed to 10 min, resulted in higher values of MG in all instances (Fig. 5-3B). Our 
homogenized liver samples were reconstituted in an appropriate amount of sodium phosphate 
buffer (pH 4.5) and did not require sample concentration by passage through a C18 SPE 
column, as is necessary with cultured cells, especially when the dilute supernatant is analyzed 
for MG levels (Chaplen et al., 1998). We recommend incubation of liver and other organ 
samples with 0.45 N PCA-precipitated proteins and 10 mM o-PD for 24 h. 
Analysis of cultured VSMCs showed significant differences in MG values when 0.45 
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N PCA was used instead of 0.2 N (Fig. 5-4A). A 24 h incubation with the 0.45 N PCA-
precipitated protein gave consistently higher values of MG. Use of 10 mM o-PD as against 1 
mM did not give impressive differences in MG values (Fig. 5-4C). We analyzed intracellular 
MG instead of MG in the culture medium. Accordingly the sample did not require 
concentration by passage through a SPE column. Since the culture medium was washed out 
there was no question of contamination with phenol red that is reported to give an interfering 
peak and requires removal by a SPE column (Chaplen et al., 1998). For cultured cells we 
recommend incubation of samples with 0.45 N PCA-precipitated proteins and 1-10 mM o-PD 
for 24 h. 
In order to determine more accurately the binding of MG to protein and the impact of 
different protocols on the amount measured we incubated a known amount of MG with 1% 
BSA for different times and subjected the same sample to different protocols (Fig. 5-5). 
Surprisingly incubation of the 0.45 N PCA-precipitated protein for 10 min, 3 h or 24 h did not 
affect the amount of MG detected. This implies that a longer incubation of the protein in acid 
either did not release more MG from its reversible binding or that the MG was not reversibly 
bound to BSA. However, Lo et al (Lo et al., 1994) have shown that when BSA was incubated 
with MG for up to 6 days almost half of it was irreversibly bound within 24 h to the arginine 
residues in BSA. About another quarter of the added MG was reversibly bound which 
remained reversibly bound over 6 days of incubation (Lo et al., 1994). Use of 1 or 10 mM o-
PD also did not affect the amount of MG detected. Our results (Fig. 5-5C) also indicate that 
measurement of MG production in cultured cells is maximum in a time window of 1 min to 3 
h after the cells start producing increased MG in response to a stimulus such as incubation 
with high glucose or fructose (25 mM or more) (Dhar et al., 2008). After 3 h a greater 
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proportion of MG binds to cellular components and becomes undetectable. 
It is likely that the binding characteristics of MG are different with different proteins. 
Hence, we incubated MG with liver homogenate which contains an array of different proteins, 
lipids and other cellular components. Surprisingly, incubation of MG-liver samples with PCA 
for 10 min or 24 h did not affect the amount of MG detected (Fig. 5-6A). This implies that a 
longer incubation of the PCA-precipitated protein in acid either did not release more MG from 
its reversible binding or that the binding of MG to liver homogenate components is not 
reversible, the latter being highly unlikely. Moreover, after 24 h of incubation of MG with 
liver homogenate in PBS, in contrast to liver/EDTA, the amount of MG detected was not 
different from the basal (without any added MG) values in the same sample (Fig. 5-6A).  
In contrast to detection of 66% and 24% MG after incubation of MG with 1% BSA for 
3 h and 24 h respectively, we detected 49% and 2% MG after incubation of MG with 1% liver 
homogenate for 3 h and 24 h in 1 N PBS, respectively (Fig. 5-6B). The greatly reduced 
detection of MG from liver homogenate could be either due to metabolism by liver enzymes 
or due to increased irreversible binding of MG to liver proteins and other cellular components. 
To characterize this further, we prepared liver samples in sodium phosphate (pH 4.5) 
containing 50 μM EDTA with a view to minimize enzyme activity in the sample. Incubation 
of MG with this sample resulted in amounts of MG that were similar to MG-BSA sample 
indicating equivalent detectable fractions and similar protein binding characteristics of MG in 
both samples (Fig. 5-6B). It also indicated the possibility that the reduced MG in MG-liver 
sample was due to degradation of added MG by metabolic activity in the homogenate. Thus, 
addition of 50 μM EDTA to organ samples, though not necessary, is recommended. 
Results with MG-BSA and MG-liver homogenate raise the question why more MG is 
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detected by different protocols from the same sample when applied to plasma, VSMC and 
especially liver samples. Plasma is mostly constituted of different proteins with hardly any 
cells hence, formation of MG from glycolytic intermediates such as dihydroxyacetone 
phosphate and DNA (Chaplen et al., 1998) can be safely ruled out. In the case of liver and 
VSMC samples formation of MG from glycolytic intermediates and DNA is possible. 
However, the strongly acidic environment created by 0.45 N PCA can be assumed to prevent 
formation of MG from glycolytic intermediates.  
The detection of 100 to 1000 fold more MG from Chinese hamster ovary cells 
(Chaplen et al., 1998)  after incubation  of the sample with 0.45 N PCA-precipitated material 
for 24 h as opposed to 10 min is truly surprising as the authors describe it. One reason for this 
could be the excessively high glucose (100 mM) which they used for preincubation for 24 h. 
This can lead to very high amounts of MG formation that can possibly overwhelm the 
catalytic glyoxalase enzymes that efficiently remove MG. The glucose concentration in normal 
culture media is 5 mM (Chaplen et al., 1996). In one of our studies incubation of VSMCs with 
25 mM glucose or fructose for 3 h resulted in between 3.5 and 4 fold increase in MG 
production along with a significant increase in oxidative stress when compared to untreated 
control cells (Dhar et al., 2008). It should be noted that plasma glucose levels are in the range 
of 20-25 mM in the severe diabetes seen in STZ-induced diabetic rats (Cheng et al., 2001). 
MG values in lens tissue are also analyzed and perhaps routine analysis of adipose 
tissue or muscle tissue may become possible. Routine analysis of plasma MG in other groups 
of patients such as hypertensives or those on a ketogenic diet or Atkins diet which has high fat 
content, and in obese people, may soon become a reality (Dhar et al., 2008). Our results make 
a significant observation that the differences in MG levels in plasma, liver and VSMC samples 
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obtained with different protocols were most probably not due to protein binding 
characteristics of MG as indicated by the MG values in samples prepared by reacting MG with 
BSA and liver homogenate. In the latter samples no differences were observed in the amount 
of MG detected by varying the protocol, including a longer incubation of the PCA-
precipitated protein in the sample with o-PD.  
5. Conclusions  
Variations in sample treatment protocol result in significant differences in the amount 
of MG detected in plasma, cultured VSMC and especially liver samples. Incubation of the 
sample with 0.45 N PCA and 10 mM o-PD for 24 h gave consistent values and is 
recommended for plasma, liver and other organ samples. Addition of 50 μM EDTA to organ 
samples reconstituted in sodium phosphate buffer (pH 4.5), though not necessary, is 
recommended. For cultured cells we recommend incubation of samples with 0.45 N PCA-
precipitated proteins and 1-10 mM o-PD for 24 h. Our results may help in choosing a protocol 
that yields consistent values of MG in a given biological sample.  
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Abstract 
Background and purpose: Alagebrium (ALA) is a novel advanced glycation endproducts 
(AGEs)-cross-link breaking compound. However, acute effects of ALA on major precursors of 
AGEs such as methylglyoxal (MG) have not been reported. MG is a highly reactive 
endogenous metabolite and its levels are elevated in diabetic patients. We investigated 
whether ALA attenuates the acute effects of exogenously administered MG on plasma MG 
levels, glucose tolerance and distribution of administered MG in different organs in vivo in 
Sprague-Dawley rats.  
Experimental approach: We measured MG levels by HPLC, performed glucose tolerance test, 
adipose tissue glucose uptake, GLUT4, insulin receptor (IR) and insulin receptor substrate 1 
(IRS-1) protein expression, and phosporylated IRS-1 in rats treated with MG at doses of either 
17.25 mg/kg i.p. (MG-17 i.p.) or 50 mg/kg i.v. (MG-50 i.v.) with or without ALA, 100 mg/kg 
i.p.  
Key results: ALA significantly attenuated the significant increases in MG levels in the plasma, 
aorta, heart, kidney, liver, lung, and urine after exogenous MG administration. In MG treated 
rats glucose tolerance was impaired, plasma insulin levels were higher and insulin-stimulated 
glucose uptake by adipose tissue was reduced than the respective control groups. In MG-50 
i.v. treated rats GLUT4 protein expression and IRS-1 tyrosine phosphorylation were 
significantly reduced. ALA pretreatment attenuated these effects of MG. In an in vitro assay 
ALA significantly reduced the amount of detectable MG.  
Conclusions and implications: Our results show for the first time that ALA acutely attenuates 
MG-induced glucose intolerance suggesting a possible preventive role for ALA against 
harmful MG effects.  
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 Introduction 
Alagebrium (4,5-dimethylthiazolium, ALA) (formerly known as ALT-711) (Fig. 1) is a 
novel advanced glycation endproducts (AGEs) cross-link breaking compound which has been 
studied mainly for its chronic effects on AGEs (Coughlan et al., 2007; Guo, Y et al., 2009; 
Little et al., 2005; Peppa et al., 2006; Susic et al., 2004; Thallas-Bonke et al., 2004; 
Wolffenbuttel et al., 1998; Ulrich and Zhang, 1997; Zieman et al., 2007). The first AGEs 
cross-link breaking compound discovered was phenacylthiazolium bromide (PTB) in 1996. 
PTB reacts with and cleaves covalent cross-links of AGEs-derived proteins. PTB degrades 
rapidly and hence a more stable derivative alagebrium was developed. ALA (210 mg/kg twice 
a day for 8 weeks) given to patients with systolic hypertension reduced vascular fibrosis and 
markers of inflammation (Zieman et al., 2007). Intraperitoneal injection of ALA (1 mg/kg) 
daily for 1 or 3 weeks reversed diabetes-induced increase of arterial stiffness measured by in 
vivo and in vitro parameters in STZ-induced diabetic rats, and improved impaired 
cardiovascular function in older rhesus monkeys (Wolffenbuttel et al., 1998; Ulrich and 
Zhang, 1997). ALA (10 mg/kg for 16 weeks) also increased glutathione peroxidase and 
superoxide dismutase activities in aging rats and reduced oxidative stress (Guo et al., 2009). 
However, it has not been shown if ALA has acute effects against precursors of AGEs such as 
methylglyoxal (MG) and glyoxal. 
MG, a highly reactive dicarbonyl compound, is a metabolite of glucose, fatty acid, and 
protein metabolism (Desai and Wu, 2007; Thornalley, 1996). The clinical significance of MG 
lies in the fact that it reacts with and modifies certain proteins to form advanced glycation end 
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products (AGEs) (Desai and Wu, 2007; Thornalley, 1996; Vlassara, 2002). Among other 
things AGEs are implicated in the pathogenesis of vascular complications of diabetes 
(Vlassara, 2002). Plasma MG levels in healthy humans are 1 μM or less and are elevated to 2-
6 μM in diabetic patients with a positive correlation to the degree of hyperglycemia (Wang et 
al., 2007; McLellan et al., 1994). Sprague-Dawley (SD) rats fed chronically with fructose 
develop insulin resistance (Hwang et al., 1987; Jia and Wu, 2007). We have shown that 
incubation of vascular smooth muscle cells with 25 mM glucose or fructose for 3 h increases 
MG production 3.5 or 3.9 fold, respectively, and increases oxidative stress (Dhar et al., 2008). 
MG modifies the structure of the insulin molecule in vitro, in a way that impairs insulin-
mediated glucose uptake in adipocytes (Jia et al., 2006). In cultured 3T3-L1 adipocytes MG 
(20 μM) decreased insulin-induced insulin-receptor substrate-1 (IRS-1) tyrosine 
phosphorylation and phosphatidylinositol (PI) 3-kinase (PI3K) activity (Jia and Wu, 2007). 
Incubation of cultured L6 muscle cells with high concentrations of MG (2.5 mM) for 30 min 
impaired insulin signaling (Riboulet-Chavey et al., 2006) and a very high dose of MG (500 
mg/kg i.p.) elevated plasma glucose level in cats, by releasing glucose from the liver via an 
adrenergic mechanism (Jerzykowski et al., 1975). Despite all of these cellular and molecular 
studies on MG and insulin signaling the in vivo effect of exogenous MG administration on 
glucose tolerance, especially in pathologically relevant plasma MG concentrations, is not 
known. 
Numerous studies have been carried out to study the toxicity of high concentrations of 
MG in vitro (up to 20 mM) (Sheader et al., 2001) and in vivo (100 mg/kg to 1 g/kg, i.p. or i.v.) 
. Similar high concentrations of exogenous MG have been employed in most in vivo and in 
vitro studies, which raises concern of whether these studies bear physiological or pathological 
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relevance (Riboulet-Chavey et al., 2006; Ghosh et al., 2006; Kalapos, 1999; Cantero et al., 
2007; Golej et al., 1998; Berlanga et al., 2005). Under physiological conditions the highly 
efficient glyoxalase system degrades MG into D-lactate (Thornalley, 1996) and keeps plasma 
MG levels at around 1 μM or less (Wang et al., 2007; McLellan et al., 1994). The glyoxalase 
system consists of two enzymes, glyoxalase I and glyoxalase II that require catalytic amounts 
of reduced glutathione (GSH) for its activity (Thornalley, 1996).  
In the present study we have we determined an appropriate dose and route for 
administration of exogenous MG that would result in pathologically relevant plasma 
concentrations of MG in experimental animals. We used this dose to investigate the 
tissue/organ distribution of exogenously administered MG in these animals and the effects of 
acute elevation of plasma MG levels on glucose tolerance and plasma insulin levels. In 
adipose tissue from MG treated rats glucose uptake, GLUT4, insulin receptor (IR), insulin 
receptor substrate-1(IRS-1) protein expression and IRS-1 tyrosine phosphorylation was 
studied. More importantly, we examined whether ALA can prevent or attenuate these effects 
of exogenously administered MG. 
 
Methods 
Animals 
Male 11-week old Sprague-Dawley (SD) rats from Charles River Laboratories 
(Quebec, Canada) were used according to guidelines of the Canadian Council on Animal Care. 
After one week of acclimatization the rats were fasted overnight before the experiments.  
 
In vitro incubation of alagebrium with methylglyoxal 
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MG (10 μM) was incubated with or without ALA (100 μM) for different times at 37° 
C. After the given incubation time, the sample was analyzed for MG by HPLC as described 
below. 
 
Determination of an appropriate dose and route of administration of MG: Effects of 
pretreatment with ALA  
In view of the inherent bioavailability barriers associated with the oral route, 
administering MG in drinking water or by gavage was not considered suitable for acute 
administration of a single dose to achieve consistent plasma levels. We chose the 
intraperitoneal (i.p.) and intravenous (i.v.) routes to get consistent plasma levels of MG. In 
order to achieve a pathologically relevant plasma concentration of 2-5 μM MG (Wang et al., 
2007; McLellan et al., 1994; Wang et al., 2008; Baynes and Thorpe, 1999), we calculated a 
dose based on an average blood volume of 6 ml per 100 g body weight (Lee and Blaufox, 
1985) for a 300 g rat and assumed complete absorption from the i.p. injection site into the 
circulation. We administered 17.25 mg/kg (240 μmol/kg) by a single i.p. injection (described 
hereafter as MG-17 i.p.) or 6.48 mg/kg/h (90 μmol/kg/h) by i.v. infusion for 2 h (12.96 or 
about 13 mg/kg, MG-13 i.v.) with or without ALA (ALA -100 mg/kg i.p.). ALA was 
administered 15 min before the administration of MG (described hereafter as pretreatment).  
The continuous i.v. infusion was chosen to deliver a constant low dose of MG in the 
circulation and compare its plasma levels with those resulting from the i.p. injection. In 
another group of rats, MG (50 mg/kg i.v., described hereafter as MG-50 i.v.) was given as a 
bolus injection in order to achieve higher plasma MG level. The rats were anesthetized with 
thiopental sodium (100 mg/kg i.p.). The trachea was cannulated to allow spontaneous 
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respiration and the left jugular vein and right carotid artery were also cannulated. Blood 
samples were collected at 5, 15, 30, 60 and 120 min into ethylene diamine tetra acetic acid 
(EDTA) containing tubes. Plasma MG levels were determined by HPLC.  
 
In vivo distribution of MG after exogenous administration 
 In rats treated with saline (control), MG-17 i.p., or MG-17 i.p. + ALA, selected organs, 
tissues, and urine were collected 3 h after administration of tested compounds and frozen in 
liquid nitrogen. The organs and tissues were finely ground and homogenized in liquid nitrogen 
and reconstituted in sodium phosphate buffer (pH 4.5) and sonicated (30 s, three times). The 
samples were assayed for MG by HPLC, as described below, and for protein measurement. 
 
Intravenous Glucose Tolerance Test (IVGTT)  
After overnight fasting, an intravenous glucose tolerance test (IVGTT) was performed 
as described previously (Laight et al., 1999).  Briefly, the trachea, left jugular vein, and right 
carotid artery were cannulated in anesthetized rats. After collecting a basal blood sample rats 
were treated with saline, MG or MG+ALA. After 2 h a 0 min blood sample was taken and a 
bolus dose of glucose (0.5 g/kg) was given i.v. and further blood samples were collected at 1, 
3, 6, 12 and 24 min from the carotid artery. Plasma glucose levels were determined using a 
glucose assay kit (BioAssay Systems, Hayward, CA, USA) and insulin levels were measured 
with a rat insulin assay kit (Mercodia Rat Insulin ELISA). The IVGTT result was calculated as 
the area under the curve (AUC) for both plasma glucose and insulin levels between time 0 min 
and 24 min and expressed as arbitrary units.  
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Glucose uptake  
Insulin sensitivity of adipose tissue was evaluated by measuring insulin-induced 2-
Deoxy-[3H] glucose (2-DOG) uptake as described previously (Jia and Wu, 2007). Briefly, 
abdominal visceral adipose tissue was chopped and digested in DMEM base (no glucose, no 
serum) with collagenase (1.5mg/ml) at 37° for 20 min. The mixture was filtered, centrifuged, 
supernatant discarded and the pellet was re-suspended in the same DMEM. Thereafter, the 
cells were exposed to 100 nM insulin for 30 min and continuously incubated for another 20 
min after the addition of [3H]-2-DOG (0.1 μCi/500µl) with glucose (50 µM) to the medium. 
The incubation was stopped by washing cells three times with ice-cold glucose-free phosphate 
buffer. The cells were lysed in 0.1% sodium dodecyl sulfate (SDS) and 1 N NaOH and 
transferred into scintillation vials for counting (Beckman LS 3801 scintillation counter). 
 
Preparation of total membrane fraction from adipose tissue for GLUT4 
 
Abdominal visceral adipose tissue isolated from rats was homogenized in buffer B [10 
mmol/l Tris–HCl, 1 mmol/l EDTA, 250 mmol/l sucrose and 0.1 mmol/l phenylmethylsulfonyl 
fluoride (PMSF, pH 7.4)] using a polytron homogenizer. The homogenate was centrifuged at 
1700×g for 10 min at 4° C and the resulting supernatant was centrifuged at 8600 x g for 10 
min at 4° C. The supernatant was then centrifuged at 185000 x g for 60 min at 4 °C, and 
stored at −70° C before use (Furuta et al., 2002). The protein concentration of the supernatant 
was determined by the bicinchoninic acid (BCA) protein assay reagent.  
 
Immunoprecipitation and western blotting 
For immunoprecipitation abdominal visceral adipose tissue was lysed in an ice-cold 
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radioimmunoprecipitation assay buffer (RIPA) buffer containing 30 mM Hepes (pH 7.4), 5 
mM EDTA; 1% Nonidet P-40, 1% Triton X-100, 0.5% sodium deoxycholate, 8 mM Na3VO4, 
1 mM NaF and 2 mM protease inhibitor (Jia and Wu, 2007). Tissue homogenates were 
incubated with IRS-1 antibody for two hours at 4º C, followed by incubation with Protein 
A/G-Agarose for further two hours at 4º C. Immunoprecipitates were separated using spin-
collection filters and washed once with RIPA buffer and three times with PBS. For western 
blotting, cell lysates or membrane fractions (50 µg) were boiled with sample buffer for 5 min, 
resolved by 10–12% SDS-PAGE, and transferred onto polyvinylidene fluoride (PVDF) 
membranes (Millipore, MA, USA). The membranes were blocked and incubated with the anti-
IR (Santa Cruz, CA, USA), anti-GLUT4 (Santa Cruz, CA, USA), and anti-β-actin antibodies 
(Santa Cruz, CA, USA), respectively, followed by incubation with horse radish peroxidase 
conjugated secondary antibodies (Upstate, MA, USA). The proteins were then visualized with 
chemiluminescence reagents (Amersham Biosciences, NJ, USA) and exposed to X-ray film 
(Kodak Scientific Imaging film, X-Omat Blue XB-1). 
 
Methlyglyoxal assay 
MG was measured by a specific and sensitive HPLC method as described previously 
(Dhar et al., 2008) with some modifications to the original protocol (Chaplen et al., 1998). 
MG was derivatized with o-phenylenediamine (o-PD) to specifically form 2-
methylquinoxaline. The samples were incubated in the dark for 24 h with 0.45 N perchloric 
acid (PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 12000 rpm 
for 10 min. 2-methylquinoxaline and quinoxaline internal standard (5-methylquinoxaline) 
were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., Mississauga, ON, Canada) 
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via Nova-Pak® C18 column (3.9×150 mm, and 4 μm particle diameter, MA, USA). 
 
Glutathione and D-lactate assays 
GSH was measured by HPLC whereas D-lactate was measured by an assay kit (  ).  
 
Chemicals and Statistical analysis   
All chemicals were of analytical grade. Methylglyoxal and o-phenylenediamine (o-
PD) were purchased from Sigma Aldrich, Oakville, ON, Canada. Alagebrium (formerly 
known as ALT-711) was a generous gift from Synvista Therapeutics, Inc. (Montvale, NJ, 
USA). Data are expressed as mean ± SEM and analyzed using one way ANOVA and post hoc 
Dunnett’s test. P value less than 0.05 was considered significant. Data on tissue distribution of 
MG (Fig. 3) were analyzed with two-way ANOVA with treatment and tissue as two variables. 
 
Results 
Incubation of ALA with MG in vitro. 
Incubation of MG (10 μM) with ALA (100 μM) for different times resulted in a 
significant reduction in the amount of MG detected by HPLC with increasing time of 
incubation. Even after 15 min of incubation the amount of MG detected was significantly 
reduced suggesting an acute effect of ALA (Table 6-1).  
 
ALA attenuates increase in plasma MG levels following exogenous MG administration  
After acute administration of MG-17 i.p. the plasma level of MG peaked at 15 min to 
reach 2.5 µM, 2.6 fold higher than the basal value (Fig. 6-2A). The MG level declined to a 
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plateau after 1 h but was still higher (2.1 fold) than the basal value even after 2 h.  In another 
group of rats, after i.v. infusion of MG (6.48 mg/kg/h or 90 μmol/kg/h for 2 h) the plasma MG 
level peaked at 5 min to reach 2.7 µM, 2.7 fold higher than the basal value (Fig. 6-2B). 
Similarly, the plasma level of MG in this group declined gradually and was still significantly 
(2.2 fold) higher than the basal value after 2 h. Pretreatment with ALA (100 mg/kg) 
significantly prevented the increase in plasma MG after both i.p. and i.v. administration of 
MG (Fig. 6-2A and B), which most probably could be due to scavenging of MG by ALA. 
Thus, both routes of administration (i.p. & i.v.) can increase plasma MG levels in similar 
pattern to a level comparable to that under various pathological conditions reported in the 
literature (Wang et al., 2007; McLellan et al., 1994; Wang et al., 2008; Baynes and Thorpe, 
1999). Therefore, MG-17 i.p. was chosen for most of the following studies. Administration of 
a higher dose of MG-50 i.v. resulted in significantly higher plasma MG levels than with MG-
17 i.p. or MG-13 i.v. and ALA attenuated the increase in plasma MG (Fig. 6-2C). MG-50 i.v. 
was administered to some groups of rats to assess dose-related severity of effects of MG on 
glucose tolerance and plasma insulin levels. 
 
ALA attenuates distribution of MG in rats after exogenous administration 
Following administration of MG-17 i.p. MG levels increased significantly in the aorta 
(1.6 fold), heart (1.4 fold), liver (1.3 fold), lungs (1.3 fold), and kidney (1.2 fold) compared to 
the basal levels in the control group (Fig. 6-3). The aorta had the greatest increase in the level 
of MG (11.2 ± 0.7 nmol/mg protein) compared to control (7.2 ± 0.3 nmol/mg protein) and had 
the highest levels amongst the organs or tissues tested (Fig. 6-3). Urinary MG level was also 
significantly higher (2.5 fold) in the MG-17 i.p. group compared to the control group (Fig. 6-
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3). The increased MG levels in rats treated with MG-17 i.p. were significantly attenuated by 
pretreatment with ALA (Fig. 6-3). The urinary MG levels (Mean ± SEM, μM) in the MG-50 
i.v. group were as follows: Control (saline), 25 ± 4 (n = 9); MG-50 i.v., 232 ± 45*** (n = 6); 
MG-50 i.v. + ALA, 134 ± 41** (n = 4); **P<0.01, ***P<0.001 vs. control group. There was 
no significant increase in MG levels in spleen and brain of rats after MG-17 i.p. 
administration.  Inter-tissue variation in MG levels before and after MG or MG+ALA 
administration was significantly different as analyzed by two-way ANOVA (Fig. 6-3). 
 
Impairment of glucose tolerance and glucose uptake in MG-treated rats is prevented by ALA 
After acute MG-17 i.p. and MG-50 i.v. administration plasma glucose and AUC were 
determined in these rats (Fig. 6-4).  MG-17 i.p. significantly impaired glucose tolerance with 
increased AUC, which was attenuated by pretreatment with ALA (Fig. 6-4A, B). The 
impairment of glucose tolerance was significantly greater in the MG-50 i.v. treated group than 
its control group (Figs. 6-4C, D). Pretreatment with ALA significantly attenuated impairment 
of glucose tolerance by MG and reduced the AUC (Fig. 6-4D). 
Insulin-stimulated glucose uptake was evaluated in abdominal visceral adipose tissue 
freshly isolated from rats 2 h after administration of MG-17 i.p. or MG-50 i.v. or saline 
(control) in separate groups of rats. There was a significant decrease in insulin-stimulated 
glucose uptake in MG-17 i.p. treated rats and it was more severe in MG-50 i.v. treated rats 
compared to control. The reduced glucose uptake by both doses was prevented by 
pretreatment with ALA (Fig. 6-5). 
 
Increased plasma insulin levels in MG-treated rats are attenuated by ALA 
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The basal plasma insulin levels were not different among the control, MG-treated and 
MG+ALA groups. Following an IVGTT, the plasma insulin levels were higher in rats treated 
with MG-17 i.p. and MG-50 i.v. (Fig. 6-6A, C). The AUC for plasma insulin levels after the 
IVGTT was significantly greater in MG-17 i.p. and MG-50 i.v. treated rats compared to 
respective control (Fig. 6-6B, D). Pretreatment with ALA significantly attenuated the increase 
in plasma insulin levels and AUC values induced by MG-17 i.p. (Fig. 6-6A, B).  
 
ALA prevents decreased plasma GSH levels in MG-treated rats. 
Rats treated with MG-17 i.p. had significantly reduced plasma GSH levels compared 
to the control rats (Table 6-2). Co-administration of ALA (100 mg/kg i.p.) with MG-17 i.p. 
significantly reversed the decrease in plasma GSH induced by MG-17 i.p. (Table 6-2).  
 
Effects of MG and ALA on plasma and aortic D-lactate levels 
 D-lactate is a metabolite of MG (Desai and Wu, 2007). Plasma D-lactate levels were 
significantly elevated after MG-50 i.v. and even further elevated after MG-17 i.p.+ALA and 
MG-50 i.v.+ALA (Table 6-3).  Aortic D-lactate levels (μmol/mg protein, n=3 each group) 
were also significantly elevated after MG-17 i.p. (7.7 ± 0.8*) and further elevated after MG-
17 i.p.+ALA (9.6 ± 1.0**) compared to the control group (4.0±0.6) (*P<0.05, **P<0.01 vs. 
control group). 
 
Effects of MG on insulin signaling pathway in adipose tissue are attenuated by ALA  
In order to confirm the possible mechanism of MG induced glucose intolerance and reduced 
glucose uptake, the protein expression of GLUT4 (Fig. 6-7), IR, IRS-1 (Fig. 6-8) and tyrosine 
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phophorylation of IRS-1 (Fig. 6-9) was examined in MG-50 i.v. treated rats. There was 
significant decrease in GLUT4 protein expression in abdominal visceral adipose tissue from 
MG-50 i.v. treated rats compared to that from control rats (Fig. 6-7). There was no change in 
the protein expression of IR and IRS-1 (Fig. 6-8). However, insulin-induced tyrosine 
phosphorylation of IRS-1 was significantly reduced in MG-50 i.v. treated rats that was 
attenuated by pretreatment with ALA (100 mg/kg i.p.) (Fig. 6-9).  
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Table 6-1 
ALA reduces detectable methylglyoxal. MG was incubated with ALA at 37° C for different 
times. The solution was analyzed for MG by HPLC after the given incubation period. The 
values are mean ± SEM (n = 4 each). *P<0.05, **P<0.01 vs. MG alone. 
 
 
Time of in vitro 
incubation 
MG (10μM) 
alone 
MG (10μM) + 
ALA (100 μM) 
ALA (100 μM) 
alone 
 Amount of MG detected by HPLC 
15 min 9.5 ± 0.7 6.9 ± 0.1* 0 
30 min 9.4 ± 0.7 6.8 ± 0.3* 0 
1 h 9.3 ± 0.7 5.8 ± 0.1** 0 
2h 9.4 ± 0.7 5.2 ± 0.9* 0 
24 h 9.4 ± 0.7 5.0 ± 0.1** 0 
 
Table 6-2 
Effect of saline (control), MG-17 i.p. (MG, 17.28 mg/kg intraperitoneally) and MG+ALA 
(alagebrium 100 mg/kg, i.p.) on plasma reduced glutathione (GSH) in Sprague-Dawley rats. 
The values are mean ± SEM (n = 6 each). ***P<0.01 vs. control group, δP<0.05 vs. MG 
group. 
 Control MG MG+ALA 
Plasma GSH (μM) 111 ± 5 35 ± 1*** 61 ± 5*** δ 
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Table 6-3  
Effect of saline (control), MG-17 i.p. (MG, 17.28 mg/kg intraperitoneally), MG-50 i.v. (MG, 
50 mg/kg intravenous) and MG+ALA (alagebrium 100 mg/kg, i.p.) on plasma D-lactate levels 
in Sprague-Dawley rats. The values are mean ± SEM (n = 4 each). *P<0.05, ***P<0.01 vs. 
control group. 
 
 Treatment group 
 Control MG-17 i.p. MG-17 i.p. + 
ALA 
MG-50 i.v. MG-50 i.v. + 
ALA 
Plasma 
D-lactate (mM) 
4.6 ± 0.3 6.0 ± 0.9 7.8 ± 1.0* 7.5 ± 1.0* 8.9 ± 0.5*** 
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Fig. 6-1 Chemical Structure of alagebrium (4,5-dimethylthiazolium) 
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Figure 6-2 Plasma methylglyoxal (MG) levels after (A) intraperitoneal (i.p.) or (B, C) 
intravenous (i.v.) administration of MG in SD rats. n = 6 for each group.  Control: saline 
injection; MG-17 i.p.: MG 17.25 mg/kg i.p.; MG-13 i.v.: MG 6.48 mg/kg/h i.v. infusion for 2 
h; MG-50 i.v.: MG 50 mg/kg i.v. slow bolus injection; ALA: algebrium 100 mg/kg i.p. was 
given 15 min before the administration of MG in A, B and C. **P<0.01, ***P<0.001 
compared to control at same time point, †P<0.05, ††P<0.01, †††P<0.001 compared to 
respective MG-17 i.p., MG-13 i.v. or MG-50 i.v. treated group at the same time point. 
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Figure 6-3 Distribution of methylglyoxal (MG) in different organs/tissues/urine in 
Sprague-Dawley rats after intraperitoneal administration. Saline (control), MG (17.25 mg/kg 
i.p., MG-17 i.p.) or MG-17 i.p. + ALA (alagebrium 100 mg/kg i.p.) were administered to three 
groups of rats (n = 6 each). The organs, tissues and urine were collected 3 h after 
administration of treatment. Data were analyzed with two-way ANOVA with treatment and 
tissue as variables. *P<0.05, **P<0.01, ***P<0.001 vs. corresponding control group, 
†P<0.05, ††P<0.01 vs. MG-17 i.p. group. 
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Figure 6-4 Intravenous glucose tolerance test (IVGTT) in MG-treated Sprague-Dawley 
rats, effect of ALA.  Basal plasma glucose levels were determined before any treatment. The 
plasma glucose levels (A) and area under curve (B) were evaluated in rats for 24 min during 
an IVGTT which was performed 2 h after treatment with saline (control), MG-17 i.p. or MG-
17 i.p. + ALA (alagebrium 100 mg/kg i.p.). The plasma glucose levels (C), area under curve 
(D) were evaluated in rats for 24 min during an IVGTT which was performed 2 h after 
treatment with saline (control), MG-50 i.v. or MG-50 i.v + ALA (alagebrium 100 mg/kg i.p.). 
2 h after saline or drugs a time 0 plasma sample was obtained before giving a glucose load 
(0.5 g/kg i.v.) to perform the IVGTT. (C) *P<0.05, **P<0.01 compared to control group at the 
same time point, (B, D) *P<0.05, **P<0.01 compared to respective control group, †P<0.05 
compared to respective MG treated group.  n = 9 in each group.  
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Figure 6-5 Adipose tissue glucose uptake in MG-treated Sprague-Dawley rats. Glucose 
uptake by adipose tissue was evaluated in five groups of rats 2 h after treatment with saline 
(control); MG 17.25 mg/kg i.p. (MG-17 i.p.); MG-17 i.p.+ALA (alagebrium 100 mg/kg i.p. 
given 15 min before the administration of MG); MG 50 mg/kg i.v. slow bolus injection (MG-
50 i.v.) and MG-50 i.v.+ALA (alagebrium 100 mg/kg i.p.). Visceral adipose tissue was 
removed from the abdomen and tested for insulin-stimulated glucose uptake in vitro. *P<0.05, 
**P<0.01 compared to control, †P<0.05 compared to MG-50 i.v. treated group. n = 4 for each 
group. 
150 
 
  
Basal 01 3 6 12 24
0
1
2
3
4
5
6
Control
MG-17 i.p.
MG-17 i.p.+ ALA
A
Pl
as
m
a 
in
su
lin
 (n
g/
m
l)
Time (min)
**
*
0
15
30
45
60
75
85
*
B
†
Ar
ea
 u
nd
er
 c
ur
ve
Control MG-17 i.p. MG-17 i.p.
+ ALA
01 3 6 12 24
0
1
2
3
4
5
6
Control
MG-50 i.v.
MG-50 i.v. + ALA
Basal
**
C
Time (min)
Pl
as
m
a 
in
su
lin
 (n
g/
m
l)
0
15
30
45
60
75
85
D
Ar
ea
 u
nd
er
 c
ur
ve
Control MG-50 i.v. MG-50 i.v.
+ ALA
*
Figure 6-6 Plasma insulin levels in MG-treated Sprague-Dawley rats, effect of ALA. Basal 
plasma insulin levels were determined before any treatment. The plasma insulin levels (A) and 
area under curve (B) were evaluated in the rats for 24 min during an IVGTT which was 
performed 2 h after treatment with saline (control), MG-17 i.p., or MG-17 i.p. + ALA 
(alagebrium 100 mg/kg i.p.). The plasma insulin levels (C) and area under curve (D) were 
evaluated in the rats for 24 min during an IVGTT which was performed 2 h after treatment 
with saline  (control),  MG-50 i.v., or MG-50 i.v. + ALA (alagebrium 100 mg/kg i.p.). 2 h after 
saline or drugs a time 0 plasma sample was obtained before giving a glucose load (0.5 g/kg 
i.v.) to perform the IVGTT. *P<0.05, **P<0.01 compared to respective control group, 
†P<0.05 compared to MG-17 i.p. group. n = 9 for each group. 
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Figure 6-7 GLUT4 protein expression in MG treated rats. Groups of rats were treated with 
saline (Control), MG-50 i.v. or MG-50 i.v. + ALA (alagebrium 100 mg/kg i.p.). After 2 h the 
abdominal adipose tissue was removed and processed for determination of GLUT4 protein 
expression by western blotting. *P<0.05 compared to control. n = 4 for each group. 
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Figure 6-8 Insulin receptor (IR) and insulin receptor substrate 1 (IRS-1) protein expression 
in MG treated rats. Groups of rats were treated with saline (Control), MG-50 i.v. or MG-50 
i.v. + ALA (alagebrium 100 mg/kg i.p.). After 2 h the abdominal adipose tissue was removed 
and processed for determination of IR and IRS-1 protein expression by western blotting. n = 4 
for each group.  
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Figure 6-9  Insulin receptor substrate 1 (IRS-1) tyrosine phosphorylation in MG treated 
rats. Groups of rats were treated with saline (Control), MG-50 i.v. or MG-50 i.v. + ALA 
(alagebrium 100 mg/kg i.p.). After 2 h the abdominal adipose tissue was removed and tissue 
lysates were subjected to immunoprecipitation (IP) with IRS-1 antibody. The 
immunoprecipitates were then subjected to Western blotting (WB) using anti-pTyr. The 
immunoreactivity level was compared to the control level of IRS-1 phosphorylation. 
*P < 0.05 vs. control rats, n = 4 for each group. 
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Discussion 
In the present study we report for the first time that ALA has acute preventive effects 
against the harmful of effects of the AGEs precursor MG in vivo. ALA is a well documented 
AGEs cross-link breaking compound in chronic studies (Coughlan et al., 2007; Guo, Y et al., 
2009; Little et al., 2005; Peppa et al., 2006; Susic et al., 2004; Thallas-Bonke et al., 2004; 
Wolffenbuttel et al., 1998; Ulrich and Zhang, 1997; Zieman et al., 2007). We also show for 
the first time that acute administration of a single dose of MG adversely affects glucose 
tolerance in SD rats. When MG was administered in a lower dose (17.25 mg/kg, i.p.: MG-17 
i.p.) the plasma MG levels were elevated to the pathologically relevant concentrations 
observed in diabetic patients (Wang et al., 2007; McLellan et al., 1994), for more than 2 
hours. With this acute elevation of circulating MG, glucose tolerance of the rats was impaired; 
glucose-stimulated plasma insulin level increased, insulin-stimulated glucose uptake in the 
adipose tissue was reduced and urinary MG levels and aortic tissue content of MG increased. 
To achieve a higher plasma MG level it was administered at a higher dose (50 mg/kg i.v.: 
MG-50 i.v.) in separate groups of rats. Indeed with MG-50 i.v., an even higher plasma MG 
level (Fig. 6-2B) was obtained that also significantly impaired glucose tolerance, increased 
plasma insulin levels, reduced insulin-stimulated glucose uptake in adipose tissue along with a 
significant reduction in GLUT4 protein expression and tyrosine phosphorylation of IRS-1. 
ALA, administered i.p. 15 min prior to MG, attenuated all of these acute effects of MG and 
the increase in plasma levels following MG administration. In vitro incubation of ALA with 
MG for different times, starting with 15 min, significantly reduced the amount of MG detected 
in the sample (Table 6-1) possibly suggesting binding (scavenging) of MG by ALA. The 
attenuation by ALA of increased plasma MG levels following exogenous MG administration 
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also suggests a scavenging or binding effect of ALA on MG. To the best of our knowledge an 
acute scavenging or binding effect of ALA on MG has not been reported before. 
Phenacylthiazolium bromide (PTB) was the first AGEs cross-link breaking compound 
reported in 1996 but it degrades rapidly (Vasan et al., 1996).  ALA is a more stable thiazolium 
derivative (Fig. 6-1) (Desai & Wu, 2007) and was developed based on an earlier observation 
that the carbon-carbon bond of α-diketones can be selectively cleaved with some thiazolium 
salts (Vasan et al., 1996). Thus, our results show that ALA has additional acute upstream 
effects that can prevent AGEs formation from MG, which can be useful for preventive 
treatment of AGEs related disorders. 
The in vivo fate of exogenously administered MG is unknown. Our results show for 
the first time that the majority of administered MG-17 i.p. is excreted in the urine, an effect 
attenuated by ALA (Fig. 6-3). Since proteins are not filtered from the glomerular capillaries, 
the presence of MG in the urine indicates that most of the administered MG is likely in free 
form in the plasma, at least initially, and gets filtered into the urine. When ALA is present the 
free MG likely binds to ALA and urinary excretion of MG is reduced. We have observed that 
when MG is incubated with bovine serum albumin at 37º C, more than 90% is free, i.e. not 
protein bound, up to the first 15 min of incubation (Dhar et al, 2009).  
After MG-17 i.p. the aortic MG increased significantly more compared with the other 
six organs investigated, including the heart and lungs. This increase in MG level was 
attenuated by ALA. The high basal as well as post-MG administration levels of aortic MG are 
of great pathological significance in terms of development of MG-induced AGEs and 
atherogenesis, and endothelial dysfunction over a long term (Thornalley, 1996; Desai and Wu, 
2007; Vlassara and Palace, 2002). There was no significant increase in MG levels in the 
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spleen and the brain as compared to control. The reason for the increased basal as well as 
post-administration MG in the aorta and the uneven organ distribution needs further separate 
studies.  
The plasma levels of MG are around 1 μM in normal SD rats (Fig. 6-2) (Wang et al., 
2008) and 1 μM or less in healthy humans (Wang et al., 2007; McLellan et al., 1994). Under 
physiological conditions, the glyoxalase system rapidly degrades MG into D-lactate which 
minimizes its reaction with proteins and other cellular components to form AGEs. GSH is an 
essential component of the glyoxalase system. (Thornalley, 1996; Baynes and Thorpe, 1999; 
Desai and Wu, 2007). We found reduced GSH levels in rats treated with MG-17 i.p. (Table 6-
2). Also, in hyperglycemia and diabetic patients the plasma MG levels are elevated to between 
2 and 6 μM (Wang et al., 2007; McLellan et al., 1994) with associated oxidative stress and 
reduced GSH levels (Baynes and Thorpe, 1999). The enzymes glutathione reductase and 
glutathione peroxidase play a key role in the recycling of glutathione between its reduced 
(GSH) and oxidized (GSSG) forms. Glutahione peroxidase removes hydrogen peroxide with 
the help of GSH that is in turn oxidized to GSSG. Glutathione reductase acts as an antioxidant 
by converting GSSG to GSH. MG can increase oxidative stress by causing glycation of 
glutathione reductase and glutathione peroxidase and inactivating them (Desai and Wu, 2008). 
MG has also been shown to directly deplete GSH in various cell types so that the cell becomes 
more sensitive to oxidative stress. Reduced availability of GSH will affect the glyoxalase 
system and impair degradation of MG. This establishes a vicious cycle that leads to increased 
levels of MG. (Desai and Wu, 2008). A direct interaction of ALA and GSH has not been 
reported. However, in a recent study ALA given for 16 weeks to aging rats increased 
glutathione peroxidase and reduced oxidative stress (Guo et al., 2009). GSH was not 
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measured in the study by Guo et al. (2009). ALA, by scavenging MG, can potentially prevent 
the interaction between MG and GSH. Thus, ALA can prevent the decrease in GSH caused by 
MG that was observed in our study. An increased availability of GSH in the ALA treated 
group can potentially lead to increased degradation of MG by the glyoxalase system with a 
consequent increase in D-lactate levels. This mechanism can explain the increase in plasma 
and aortic D-lactate levels that was found in MG+ALA treated groups. The elevated D-lactate 
levels observed in MG alone treated groups can be explained by increased metabolism of MG 
by the glyoxalase system until the later gets saturated. 
In chronically fructose-fed SD rats, the serum MG levels are elevated to around 4 μM 
along with development of insulin resistance like syndrome (Jia and Wu, 2007). This raises an 
important question of whether MG is the cause or the effect of type 2 diabetes mellitus. 
Glucose and fructose are the major precursors of MG formation (Dhar et al., 2008; 
Thornalley, 1996; Desai and Wu, 2007). Thus, a regular high intake of carbohydrates in 
normal people can result in increased MG formation, which can eventually lead to the 
development of insulin resistance and type 2 diabetes mellitus. Our results with acute MG-17 
i.p. and the subsequent impaired glucose tolerance (Fig. 6-4A, B) in vivo point to the 
beginnings of insulin resistance. This theory gains weight in that MG-50 i.v. results in higher 
plasma MG levels and causes a greater impairment of glucose tolerance (Fig. 6-4C, D). 
Adipose tissue isolated from rats treated in vivo with MG-17 i.p. and MG-50 i.v. shows 
reduced insulin-stimulated glucose uptake (Fig. 6-5). These results provide further insight into 
the mechanisms behind the in vivo observations. In adipose tissue glucose transport is insulin-
dependent and is mediated by GLUT 4. The acute effects of MG that might have an 
implication for the development of insulin resistance and diabetes have mostly been studied in 
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vitro in cultured cells. Thus, incubation of cultured 3T3-L1 adipocytes with MG (20 μM) 
reduced glucose uptake, decreased insulin-induced insulin-receptor substrate-1 (IRS-1) 
tyrosine phosphorylation, and decreased the activity of phosphatidylinositol 3-kinase (PI3K) 
(Jia and Wu, 2007). Incubation of cultured L6 muscle cells with high concentrations of MG 
(2.5 mM) for 30 min impaired insulin signaling (Riboulet-Chavey et al., 2006). Incubation of 
insulin with MG modifies the structure of the insulin molecule in a way that impairs insulin-
mediated glucose uptake in adipocytes (Jia et al., 2006). To the best of our knowledge the 
effects of acute MG in vivo on glucose tolerance have not been reported previously. In a 
genetic model of diabetes such as the Zucker obese rat a defect of glucose transport in muscle 
has been reported (Sherman et al., 1988). Protein kinase Akt2 (protein kinase B) plays a vital 
role in insulin signaling in muscle and liver and mice lacking Akt2 develop insulin resistance 
and a diabetes mellitus-like syndrome (Cho et al., 2001). Our study reveals reduced insulin-
mediated glucose uptake in adipose tissue from MG treated group, which may possibly be due 
to reduced GLUT4 mediated glucose uptake into the cells as indicated by reduced GLUT4 
protein expression (Fig. 6-7). One or more steps in the insulin signaling pathway may also be 
impaired as indicated by reduced IRS-1 tyrosine phosphorylation (Fig. 6-9) (Jia and Wu, 
2007; Baynes and Thorpe, 1999; Cho et al., 2001; Birnbaum, 2001). Along with plasma 
glucose, the plasma insulin AUC was significantly higher after i.v. glucose load in the MG 
treated rats than its control group (Fig. 6-6B, D), indicating insulin resistance. ALA 
pretreatment attenuated the acute effects of MG on glucose tolerance which cannot be due to 
the AGEs cross-link breaking property of ALA since AGEs are formed by a slow process of 
reactions of MG with certain proteins that ranges from more than 24 h to many weeks (Desai 
and Wu, 2007; Thornalley, 1996). The attenuation of acute effects of MG seems to be most 
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likely due to binding of ALA with MG.  
 Plasma MG levels remained significantly elevated for at least 2 hours after a single 
intravenous or intraperitoneal injection of MG (Fig. 2) indicating a long half-life of more than 
10 h (data not shown), which may lead to cumulative toxicity when MG is given daily (Slavik 
et al., 1983). We have established doses for intraperitoneal and intravenous administration of 
MG that result in pathologically relevant concentrations in the plasma (Fig. 6-2). 
In recent years western diet has increasing amounts of carbohydrates, and the rapid 
rise in the incidence of childhood obesity and type 2 diabetes mellitus has become a major 
health concern (Birnbaum, 2001; Van Dam et al., 2002). In the absence of a genetic 
predisposition the link between high carbohydrate intake and the development of type 2 
diabetes mellitus is unknown from a mechanistic perspective (Van Dam et al., 2002). 
Carbohydrates are a major metabolic source of MG (Dhar et al., 2008; Thornalley, 1996; 
Desai and Wu, 2007) and it would be interesting to examine the effects of ALA on chronic 
administration of high glucose or MG and the development of insulin resistance. The 
attenuation of acute effects of MG on glucose tolerance by ALA can be a promising strategy 
to prevent the chronic harmful effects of high glucose intake. 
Conclusions 
In summary, we have achieved pathologically relevant plasma levels of MG in normal 
SD rats using acute administration of exogenous MG through i.p. or i.v. route. The elevated 
MG induces glucose intolerance. ALA attenuates these effects of MG, an acute in vivo effect 
of ALA against MG, possibly due to scavenging, shown for the first time. Our study suggests a 
pathogenetic mechanism linking high carbohydrate intake and development of glucose 
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intolerance through increased formation of MG.  
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Summary 
Background and purpose: Endothelial dysfunction is a feature of hypertension and diabetes. 
Methylglyoxal (MG) is a reactive dicarbonyl glucose metabolite. MG levels are elevated in 
spontaneously hypertensive rats and in diabetic patients. We investigated if MG induces 
endothelial dysfunction and whether MG scavengers can prevent MG and high glucose-
induced endothelial dysfunction.  
Experimental approach: We used isolated aortic rings from Sprague-Dawley rats for 
endothelium-dependent relaxation studies. We used cultured rat aortic and human umbilical 
vein endothelial cells. MG was measured by HPLC. Western blotting and assay kits were 
used. 
Key results: Incubation of aortic rings with MG (30 μM) or high glucose (25 mM) 
significantly attenuated endothelium-dependent acetylcholine-induced relaxation, which was 
restored by the two different MG scavengers, aminoguanidine (100 μM) and N-acetyl cysteine 
(NAC, 600 µM). Treatment of cultured endothelial cells with MG or high glucose 
significantly increased cellular MG levels to a similar extent, prevented by aminoguanidine 
and NAC. In cultured endothelial cells MG and high glucose reduced basal and bradykinin-
stimulated nitric oxide (NO) production, cyclic guanosine monophosphate levels, and serine-
1177 phosphorylation and activity of endothelial nitric oxide synthase (eNOS) without 
affecting threonine-495 and Akt phosphorylation, and total eNOS protein. These effects of 
MG and high glucose were attenuated by aminoguanidine or NAC.  
Conclusions and implications: Our results show for the first time that MG reduces serine-
1177 phosphorylation and activity of eNOS, reduces NO production, and causes endothelial 
dysfunction similar to high glucose. Specific and safe MG scavengers have the potential to 
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prevent MG and high glucose-induced endothelial dysfunction. 
Keywords: Methylglyoxal, eNOS, hyperglycemia, endothelial dysfunction, aminoguanidine, 
N-acetyl cysteine, methylglyoxal scavengers 
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Introduction 
Endothelial dysfunction, commonly defined as reduced endothelium-dependent 
vascular relaxation, occurs as an early event in atherosclerosis, hypertension (O'Keefe et al., 
2009), the prediabetic stage of insulin resistance (Su et al., 2008), and is a hallmark of type 2 
and type 1 diabetes mellitus (De Vriese et al., 2000, Potenza et al., 2009). Nitric oxide (NO) is 
one of the main vasodilator mediators released from the endothelium (Palmer et al., 1987). It 
is synthesized by endothelial nitric oxide synthase (eNOS) from L-arginine with L-citrulline 
as a co-product (Palmer et al., 1988). NO has a short half-life (6-7 s). Reduced production or 
availability of NO is a common feature of endothelial dysfunction (De Vriese et al., 2000, 
Potenza et al., 2009). 
Methylglyoxal (MG) is a highly reactive dicarbonyl metabolite produced during 
glucose metabolism (Desai and Wu, 2007). The clinical significance of MG lies in the fact that 
it reacts with and modifies certain proteins, lipids and DNA and alters their normal structure 
and/or function (Desai and Wu, 2007, Baynes JW Thorpe SR, 1999). MG is a major precursor 
of advanced glycation endproducts (AGEs), which are implicated in the pathogenesis of 
vascular complications of diabetes (Desai and Wu, 2007, Baynes JW Thorpe SR, 1999). We 
have shown earlier that MG levels are elevated in spontaneously hypertensive rats (Wang et 
al., 2005), in fructose-fed hypertensive rats (Wang et al., 2008), and in diabetic patients (Wang 
et al., 2007a). We have also shown that incubation of vascular smooth muscle cells (VSMCs) 
with 25 mM glucose or fructose for 3 h increases MG production 3.5 or 3.9 fold, respectively, 
and increases oxidative stress (Dhar et al., 2008). The aim of the current study was to examine 
if MG induces endothelial dysfunction and the mechanism involved. Even though high 
glucose has previously been shown to cause endothelial dysfunction (Potenza et al., 2009, 
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Triggle, 2008, Nishikawa et al., 2000, Du et al., 2001) we performed parallel experiments 
with high glucose to see if the functional and molecular changes produced by MG and high 
glucose are similar. We examined whether two different MG scavengers, viz. aminoguanidine 
(Lo et al., 1994, Wang et al., 2007b) and N-acetyl cysteine (NAC) (Vasdev et al., 1998, Jia 
and Wu, 2007), can prevent any deleterious effects of MG and high glucose on endothelial 
function. 
 
Materials and Methods 
Animals 
Male 11-week old Sprague-Dawley (SD) rats from Charles River Laboratories 
(Quebec, Canada) were used according to a protocol approved by the Animal Care Committee 
at The University of Saskatchewan (Protocol No. 20070029), following guidelines of the 
Canadian Council on Animal Care. The rats were acclimatized for one week. The 
investigation conforms with the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). 
 
Isometric tension studies on aortic rings 
A group of 24 SD rats was used. Isometric tension studies were carried out on rat 
aortic rings as described (Wu et al., 1998). Briefly, 3-4 mm thoracic aortic rings from SD rat 
were mounted under a 2 g load in four separate 10 mL organ baths containing Krebs solution 
with 5 mM glucose and maintained at 37° C and bubbled with 95% O2 + 5% CO2. After a 90 
min equilibration period the rings were pre-contracted with phenylephrine (1 µM) and 
cumulative concentration-dependent relaxation in response to acetylcholine (ACh) was 
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obtained before (Control) and 2 h after incubation with either glucose (15 or 25 mM) or MG 
(30 or 100 μM). In initial experiments the responses to ACh were repeated before and 2 h after 
incubation with normal Krebs solution to confirm reproducibility of responses to ACh. Some 
sets of rings were co-incubated with the MG scavenger aminoguanidine (AG, 100 μM) (Lo et 
al., 1994, Wang et al., 2007b), or another MG scavenger, NAC (600 µM) (Vasdev et al., 1998, 
Jia and Wu, 2007), or the NADPH oxidase inhibitor apocynin (100 μM) for 2 h. Treatment 
with each compound was tested in rings from at least 5 different rats. Isometric tension was 
measured with isometric force transducers with the ‘Chart’ software and Powerlab equipment 
(AD Instruments Inc., Colorado Springs, CO, USA).  
 
Cell culture 
Rat aortic endothelial cells (RAECs) were isolated from male SD rats according to the 
method of McGuire et al (McGuire and Orkin, 1987). The cells were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 0.15 
mg/mL endothelial cell growth supplement (Biomedical Technologies Inc., MA, USA). For 
the initial culture MatrigelTM (Sigma-Aldrich, Oakville, ON, Canada) coated culture dishes 
were used. RAECs were identified by their typical cobblestone morphology and positive 
staining for von Willebrand factor. Immunostaining was done as described by us earlier (Dhar 
et al., 2008). Cells between passage 3 and 6 were used for the experiments. Human umbilical 
vein endothelial cells (HUVECs) from American Type Culture Collection were cultured in 
Kaighns F12K medium containing 10% fetal bovine serum (FBS), 0.1 mg/mL heparin and 
0.03-0.05 mg/mL endothelial cell growth supplement.  
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Nitric oxide assay 
Confluent cells were washed twice with Hanks balanced salt solution (HBSS) and 
incubated with MG (3, 10 or 30 μM) or glucose (15 or 25 mM) in HBSS for 3 or 24 h at 37º C 
in an incubator. The supernatant was analyzed for basal NO production. The cells were further 
incubated with bradykinin (BK, 10 μM), an endothelial cell agonist for NO production 
(Palmer et al., 1987), for 15 min and the supernatant was collected and levels of nitrate plus 
nitrite were measured with the Griess assay kit (Caymen Chemicals, Ann Arbor, MI, USA) 
(Dhar et al., 2008). Nitrate in the sample was first converted to nitrite by nitrate reductase. 
One set of HUVECs was also co-incubated with AG (100 μM) or NAC (600 µM), and MG 
(30 μM) or glucose (25 mM) for 24 h following which the basal and BK-stimulated NO 
production were measured. 
 
Cyclic guanosine monophosphate (cGMP) assay 
Briefly, control and test compounds treated cells were treated with the 
phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX, 100 µM), for 30 min before 
agonist stimulation. Cells were harvested into the supplied lysis buffer and subjected to cGMP 
measurement using the cGMP assay kit (R & D Systems, MN, USA) according to the 
manufacturer’s protocol. To normalize cGMP values, protein content in each dish was 
measured by the BCA Protein assay (Bio-Rad, Hercules, CA, USA).  
 
Methlyglyoxal assay 
MG was measured by a specific and sensitive HPLC method as described before (Dhar 
et al., 2008, Dhar et al., 2009). MG was derivatized with o-phenylenediamine (o-PD) to form 
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the specific quinoxaline product, 2-methylquinoxaline. The samples were incubated in the 
dark for 24 h with 0.45 N perchloric acid and 10 mM o-PD at room temperature. The 
quinoxaline derivatives of MG (2-methylquinoxaline) and the quinoxaline internal standard 
(5-methylquinoxaline) were quantified on a Hitachi D-7000 HPLC system (Hitachi, Ltd., 
Mississauga, ON, Canada) via Nova-Pak® C18 column (3.9 ×150 mm, and 4 μm particle 
diameter, Waters, MA, USA). 
 
eNOS activity assay 
The NOS activity assay is based on the biochemical conversion of [3H] L-arginine to 
[3H] L-citrulline by NOS. Briefly, control and test compounds treated cells were washed in 
PBS, harvested and centrifuged for 2 min to pellet the cells. The cells were resuspended in 1x 
homogenization buffer and sonicated briefly. The suspension was centrifuged, the supernatant 
was separated and the resulting protein concentration was adjusted to 5-10 mg/mL. The eNOS 
activity was measured using the Cayman Chemicals NOS activity assay kit (Cayman 
Chemical Company, MI, USA). 
 
Measurement of reduced glutathione (GSH) 
Briefly, monochlorobimane stock (100 µM) was added to endothelial cells treated with 
test compounds. After 30 min, the medium was collected for medium GSH measurement. 
Cells were washed with PBS and harvested in 1 mL of 1% sodium dodecylsulfate (SDS) in 50 
mM Tris buffer (pH 7.5), sonicated and the aliquots (100 µL) of supernatants were read in 
triplicate with an excitation wavelength of 380 nm and an emission wavelength of 470 nm 
(Wu and Juurlink, 2002, Kamencic et al., 2000). 
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 Western blotting 
Cell lysates were prepared as described earlier (Jia and Wu, 2007, Wu and Juurlink, 
2002) and the protein concentration in the supernatant was determined by the BCA Protein 
assay (Bio-Rad, Hercules, CA, USA). Aliquots of cell lysates (50 μg of protein each) were 
separated on 7.5-10% SDS-PAGE, electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane (Bio-Rad), blocked with 5% nonfat milk in TBS-Tween buffer for 1.5 h at room 
temperature, and incubated overnight at 4° C with the primary antibody, eNOS and phospho-
NOS-1177 (both from BD Transduction Laboratories, Mississauga, ON, Canada), phospho-
NOS-495 and GSH-reductase (both from Santa Cruz, CA, USA), anti-Akt, anti-phos-Akt 
(Cell Signaling, MA, USA), and then with horseradish peroxidase conjugated secondary 
antibody (Santa Cruz, CA, USA) for 1 h at room temperature. After extensive washing, the 
immunoreactive proteins were detected with an Enhanced Chemiluminescence Detection 
System (ECL; Amersham Biosciences Corp., Piscataway, NJ, USA) (Jia and Wu, 2007, Wu 
and Juurlink, 2002).  
 
Measurement of reactive oxygen species and NADPH oxidase activity 
Confluent cells were loaded with a membrane-permeable, nonfluorescent probe 2’,7’-
dichlorofluorescin diacetate (CM-H2DCFDA, 5 μM) for 2 h at 37° C in FBS-free medium in 
the dark. The cells treated with MG (30 μM) or glucose (25 mM) for 24 h were assayed for 
fluorescent oxidized dichlorofluorescein (DCF) as an indicator of production of reactive 
oxygen species (ROS) as described earlier (Dhar et al., 2008), and for activity of NADPH 
oxidase (Griendling et al., 1994), which is a key endothelial cell enzyme for the production of 
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superoxide anions (Gao and Mann, 2009). The protein content of the homogenate was 
measured by BCA Protein assay (Bio-Rad, Hercules, CA, USA). NADPH oxidase activity 
was measured by a luminescence assay in a 50-mmol/L phosphate buffer, pH 7.0, containing 1 
mmol/L EGTA, 150 mmol/L sucrose, 500 µmol/L lucigenin as the electron acceptor, and 100 
µmol/L NADPH as the substrate (final volume, 0.9 mL) (Griendling et al., 1994). 
 
Chemicals and Statistical analysis 
All chemicals were of analytical grade. Methylglyoxal, D-glucose, N-acetyl cysteine, 
apocynin and glutathione were purchased from Sigma Aldrich, Oakville, ON, Canada. Cell 
culture media and reagents were purchased from Invitrogen Canada Inc., Burlington, ON, 
Canada. Data are expressed as mean ± SEM and analyzed using one way ANOVA and post 
hoc Bonferroni’s test. The P value was considered significant when it was less than 0.05. 
 
Results 
Methylglyoxal and high glucose reduce acetylcholine-induced relaxation of aortic rings: 
attenuation by MG scavengers 
In rat aortic rings precontracted with phenylephrine (1 µM), MG (30 or 100 µM) 
incubated for 2 h in the bath caused significant inhibition of ACh-induced endothelium-
dependent relaxation, which was prevented by coincubation of AG (100 µM) with MG (100 
μM) (Fig. 7-1A). AG (10 and 30 μM) did not prevent MG (100 μM)-induced reduction of 
relaxation (data not shown). High glucose (15 and 25 mM) incubated for 2 h also attenuated 
ACh-induced relaxation of rat aortic rings that was prevented by coincubation of glucose (25 
mM) with AG (100 µM) (Fig. 7-1B). MG (30 µM) and glucose (25 mM) induced attenuation 
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of relaxation was also restored by another MG scavenger, NAC (600 µM) (Vasdev et al., 
1998, Jia and Wu, 2007) (Fig. 7-1C, D). However, MG and high glucose-induced attenuation 
of relaxation was not restored by the NADPH oxidase inhibitor apocynin (100 μM) (Fig. 7-
1E, F). In washout experiments on aortic rings the reduced relaxation induced by MG (30 
μM) and glucose (25 mM) for 2 h was restored after a further 2 h washout with changes of 
Krebs solution in the bath every 15 min (data not shown). MG and glucose did not affect 
endothelium-independent relaxation of aortic rings induced by sodium nitroprusside (data not 
shown). In preliminary experiments MG (3 and 10 µM) or the osmotic control mannitol (25 
mM) incubated for 2 h did not affect ACh-induced relaxation (data not shown).  
 
High glucose and exogenous methylglyoxal increase methylglyoxal levels in endothelial 
cells 
Incubation of RAECs and HUVECs with MG (30 or 100 µM) for 24 h significantly 
increased the level of cellular MG that was prevented by coincubation with AG (100 µM) or 
NAC (600 μM) (Fig. 7-2A, C). Incubation of cultured RAECs and HUVECs with glucose (25 
mM) for 24 h also significantly increased MG levels in these cells (Fig. 7-2B, D), which was 
also prevented by coincubation of HUVECs with AG (100 µM) or NAC (600 μM) and 
glucose (25 mM) for 24 h (Fig. 7-2B, D). Incubation of RAECs and HUVECs with 25 mM 
glucose for 3 h also significantly increased cellular MG levels (data not shown). 
The increase in cellular MG in RAECs and HUVECs induced by glucose (25 mM) 
and exogenous MG (30 µM) was similar (Fig. 7-2).  
 
Methylglyoxal and high glucose reduce nitric oxide production in RAECs and HUVECs 
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Incubation of RAECs and HUVECs with 3, 10 or 30 µM MG for 3 or 24 h decreased 
basal and BK (10 µM)-stimulated NO production in both cell types to varying degrees 
depending on the concentration of MG and the incubation time (Figs. 7-3A, C & 7-4A, C). 
The inhibition of basal and agonist-stimulated NO production was significant with 30 µM 
MG incubated for 24 h in both RAECs and HUVECs (Figs. 7-3C and 7-4C). The attenuation 
of basal and BK-stimulated NO production by MG (30 μM) incubated for 24 h was restored 
by coincubation with AG (100 μM) or NAC (600 µM) (Fig. 7-3C and 7-4C). 
Similarly, incubation of RAECs and HUVECs with glucose (15 or 25 mM for 3 or 24 
h) decreased basal and BK (10 µM)-stimulated NO production to varying degrees depending 
on the concentration of glucose and the incubation time (Figs. 7-3B, D and 7-4B, D). The 
inhibition of basal and agonist-stimulated NO production in both cell types was significant 
with 25 mM glucose incubated for 24 h (Figs. 7-3D and 7-4D). The attenuation of basal and 
BK-stimulated NO production by glucose (25 mM) incubated for 24 h was restored by 
coincubation with AG (100 μM) or NAC (600 µM) (Fig. 7-3D and 7-4D). AG (100 μM) alone 
for 24 h did not affect basal or BK-stimulated NO production (data not shown). 
 
Methylglyoxal and high glucose reduce agonist-stimulated cGMP increase in RAECs 
and HUVECs 
cGMP is the second messenger of NO-induced activation of soluble guanylate cyclase 
and is a sensitive indicator of NO production (Waldman and Murad, 1987, Papapetropoulos et 
al., 1996). Incubation of RAECs and HUVECs with 30 µM MG or 25 mM glucose for 24 h 
prevented BK (10 µM)-stimulated cGMP increase in both cell types that was restored by 
coincubation with AG (100 μM) or NAC (600 µM) (Fig. 7-5A, B). 
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 Methylglyoxal and high glucose reduce activity of the eNOS enzyme 
To understand the mechanism of reduced NO production with MG and high glucose, 
the activity of the eNOS enzyme was tested in an eNOS activity assay. Incubation of RAECs 
(data not shown), as well as HUVECs, with MG (30 µM) or glucose (25 mM) for 24 h 
reduced NO production catalyzed by eNOS in the eNOS activity assay, which was prevented 
by  coincubation with AG (100 μM) (Fig. 7-6A). At the same time both MG and high glucose 
did not affect the eNOS protein level in HUVECs (Fig. 7-6B) or RAECs (data not shown) 
under the same treatment conditions indicating that the reduced NO production from RAECs 
and HUVECs by MG and glucose was due to reduced activity of the eNOS enzyme and not 
due to reduced eNOS protein expression.  
 
Methylglyoxal and high glucose reduce bradykinin-stimulated serine-1177 
phosphorylation of the eNOS enzyme 
To further elucidate the mechanism of reduced eNOS activity by MG and high 
glucose, we examined the serine-1177 and threonine-495 phosphorylation of eNOS, and 
phsophorylation of Akt, which is a substrate for serine 1177 of eNOS (Fulton et al., 1999, 
Dimmeler et al., 1999). In HUVECs, treatment with MG (30 µM) or glucose (25 mM) for 24 
h reduced BK-stimulated serine-1177 phosphorylation of eNOS that was prevented by co-
incubation with AG (100 μM) (Fig. 7-6C). There was little basal serine-1177 phosphorylation 
of eNOS, which was almost abolished by MG (30 µM) or glucose (25 mM) incubated for 24 
h. The antibody for serine-1177 phosphorylated eNOS did not react well with RAEC eNOS 
and hence that data is not shown. eNOS was phosphorylated basally at threonine-495. BK 
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stimulation reduced the threonine-495 phosphorylation of eNOS (Fig. 7-6C). MG (30 µM) or 
glucose (25 mM) incubated for 24 h did not affect basal or BK-stimulated threonine-495 
phosphorylation of eNOS (Fig. 7-6C). MG and high glucose also did not affect 
phosphorylation of Akt (Fig. 7-6C). 
 
Methylglyoxal and high glucose increase oxidative stress in HUVECs and RAECs  
Incubation of cultured HUVECs and RAECs with MG (30 μM) or glucose (25 mM) 
for 24 h caused a significant increase in oxidized DCF, an indicator of ROS production, in 
both cell types which was attenuated by coincubation with NAC (600 μM) (Fig. 7-7A, B). 
Incubation of RAECs and HUVECs with MG (30 μM) or glucose (25 mM) for 24 h, also 
caused a significant increase in the activity of NADPH oxidase, as measured by superoxide 
anion production in an activity assay, that was prevented by the NADPH oxidase inhibitor 
apocynin, in both cell types (Fig. 7-7C, D). 
 
Methylglyoxal and high glucose decrease GSH levels and glutathione reductase protein 
in RAECs and HUVECs 
MG is degraded by the glyoxalase enzymes that use GSH as a cofactor. Incubation of 
HUVECs (Fig. 7-8A) and RAECs (data not shown) with MG (30 μM) or glucose (25 mM) 
for 24 h significantly reduced GSH levels and also decreased glutathione reductase protein 
expression, which was prevented by coincubation with AG (100 μM) in HUVECs (Fig. 7-
8B).  
180 
 
-8 -7 -6 -5 -4 -3
0
25
50
75
100
Control
MG 30 μM
MG 100 μM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
A
*
*
** ** ** **
**
** ** **
** **
**
**
**
**
MG 100μM+AG 100μM
†
††
††
††† ††† ††† †† †† ††
ACh (log molar concn.)
-8 -7 -6 -5 -4 -3
0
25
50
75
100
Control
Glu 15 mM
Glu 25 mM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
B
*
*
* ****
**
**
**
**
**
*
**
*
** **
*
**
**
*
Glu 25mM+AG 100 μM
††
††
††
††† ††† ††† ††† †††
ACh (log molar concn.)
-8 -7 -6 -5 -4
0
25
50
75
100
Control MG 30 μM
+ NAC 600 μM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
C
*
MG 30 μM
* ** ** ** **
**
**
ACh (log molar concn.)
-8 -7 -6 -5 -4
0
25
50
75
100
Control Glu 25 mM
+ NAC 600 μM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
D Glucose 25 mM
** ** ** **
* ** ** **
ACh (log molar concn.)
-8 -7 -6 -5 -4
0
25
50
75
100
Control MG 30 μM
+Apo 100 μM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
E
*
****
*
*
MG 30 μM
* ** ** ** **
**
**
ACh (log molar concn.)
-8 -7 -6 -5 -4
0
25
50
75
100
Control Glu 25 mM
+Apo 100 μM
%
 re
la
xa
tio
n 
of
 P
E
 to
ne
ACh (log molar concn.)
*
* * *
**
**
**
***
F Glucose 25 mM
** ** ** **
****
**
 
Figure 7-1 Methylglyoxal (MG) scavengers attenuate MG and high glucose induced 
endothelial dysfunction in isolated aortic rings from Sprague-Dawley rats. Dose-related 
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responses were obtained to acetylcholine (ACh) in phenylephrine (PE, 1 μM) precontracted 
rings before (control) and 2 h after incubation with (A, C, E) MG (30 or 100 μM) or (B, D, F) 
glucose (Glu, 15 or 25 mM). In some sets of rings the MG scavenger aminoguanidine (AG, 
100 μM) was co-incubated with (A) MG (100 μM) or (B) glucose (25 mM); the MG 
scavenging antioxidant N-acetyl cysteine (NAC 600 µM) was co-incubated with (C) MG (30 
μM) or (D) glucose (25 mM); or the NADPH oxidase inhibitor apocynin (Apo 100 μM) was 
co-incubated with (E) MG (30 μM) or (F) glucose (25 mM) for 2 h. (n = 5 rings from different 
rats for each test compound). *P<0.05, **P<0.01 vs corresponding control value, †P<0.05, 
††P<0.01, †††P<0.001 vs corresponding (A) MG 100 μM value or (B) glucose (25 mM). 
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Figure 7-2 High glucose and exogenous methylglyoxal (MG) increase cellular MG levels in 
cultured endothelial cells: attenuation by MG scavengers. Confluent rat aortic endothelial cells 
(RAECs) and human umbilical vein endothelial cells (HUVECs) were incubated with normal 
culture medium (Control, Con) or medium containing (A, C) MG (30 or 100 μM), or (B, D) 
glucose (Glu, 25 mM), for 24 h. Aminoguanidine (AG, 100 μM) or N-acetyl cysteine (600 
μM) was coincubated with (A, C) MG (30 or 100 μM), or with (B, D) glucose (25 mM) for 24 
h. Cellular MG was measured by HPLC. n = 4 for each treatment. *P<0.05, **P<0.01, 
***P<0.001 vs corresponding control value, ††P<0.01, †††P<0.001 vs corresponding (A, C) 
MG (30 μM), or (B, D) glucose (25 mM) value, (C) φφφP<0.001 vs MG 100 μM. 
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Figure 7-3 Methylglyoxal (MG) and high glucose reduce nitric oxide production in cultured 
rat aortic endothelial cells (RAECs). RAECs were incubated with (A, C) MG (3, 10 or 30 
μM), or (B, D) glucose (5, 15 or 25 mM) for (A, B) 3 h or (C, D) 24 h. Cells were coincubated 
with (C) MG (30 μM) or (D) glucose (25 mM) and aminoguanidine (AG, 100 μM) or N-acetyl 
cysteine (NAC, 600 μM) for 24 h. The supernatant was collected after the 3 or 24 h incubation 
time (basal) and the cells were further incubated with bradykinin (10 μM) for 15 min to 
stimulate nitric oxide production and the supernatant was analyzed for nitrite+nitrate levels by 
the Griess assay. n = 8 for each group. *P<0.05, **P<0.01, ***P<0.001 vs corresponding (A, 
C) control value or (B, D) glucose (5 mM). †P< 0.05, ††P< 0.01, †††P< 0.001 vs corresponding 
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(C) MG (30 μM) alone or (D) glucose (25 mM) value. 
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Figure 7-4 Methylglyoxal (MG) and high glucose reduce nitric oxide production in cultured 
human umbilical vein endothelial cells (HUVECs). HUVECs were incubated with (A, C) MG 
(3, 10 or 30 μM), or (B, D) glucose (5, 15 or 25 mM) for (A, B) 3 h or (C, D) 24 h. 
Aminoguanidine (AG, 100 μM) or N-acetyl cysteine (NAC, 600 µM) was coincubated with 
(C) MG (30 μM), or with (D) glucose (25 mM) for 24 h in some sets of cells. The supernatant 
was collected after the 3 or 24 h incubation time (basal) and the cells were further incubated 
with bradykinin (10 μM) for 15 min to stimulate nitric oxide production and the supernatant 
was analyzed for nitrite+nitrate levels by the Griess assay. n = 8 for each group. *P<0.05, 
**P<0.01, ***P<0.001 vs corresponding (A, C) control value or (B, D) glucose 5 mM. 
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††P<0.01, †††P<0.001 vs. corresponding (C) MG (30 μM) alone value or (D) glucose (25 mM) 
alone. 
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Figure 7-5 Methylglyoxal (MG) and high glucose reduce cyclic guanosine monophosphate 
(cGMP) production in cultured rat aortic endothelial cells (RAECs) and human umbilical vein 
endothelial cells (HUVECs). (A) RAECs and (B) HUVECs were incubated with MG (30 μM) 
or glucose (25 mM) for 24 h. Aminoguanidine (AG, 100 μM) or N-acetyl cysteine (NAC, 600 
µM) was coincubated with MG (30 μM), or with glucose (25 mM) for 24 h in some sets of 
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cells. Basal and bradykinin (BK, 10 μM)-stimulated cGMP levels were measured with an 
assay kit as described in the methods. n = 8 for each group. **P<0.01 vs corresponding 
control value. †P<0.05, ††P<0.01, †††P<0.001 vs. corresponding MG (30 μM) alone or glucose 
(25 mM) alone value. 
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Figure 7-6 Methylglyoxal (MG) and high glucose reduce serine-1177 phosphorylation and 
activity of endothelial nitric oxide synthase (eNOS). Human umbilical vein endothelial cells 
(HUVECs) were incubated with MG (30 µM) alone or glucose (Glu, 25 mM) alone, or 
coincubated with aminoguanidine (AG, 100 µM) for 24 h following which an eNOS activity 
assay was performed, based on conversion of [3H]-L-arginine to [3H]-L-citrulline, using an 
activity assay kit (A). (B) The total eNOS protein was determined in the same treated cells 
from (A) by western blotting. (C) Basal and bradykinin (BK, 10 µM)-stimulated serine-1177, 
and threonine-495 phosphorylation of eNOS; and Akt and phosphorylated Akt were 
determined with appropriate anti-phospho-eNOS, anti-Akt and anti-phospho-Akt antibodies in 
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cells treated as in (A) by western blotting. n = 5 for each group.  *P<0.05 vs. control, †P<0.05 
vs. MG 30 μM.   
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Figure 7-7 Methylglyoxal (MG) and high glucose increase reactive oxygen species 
production and NADPH oxidase activity in cultured endothelial cells. Incubation of cultured 
(A, C) rat aortic endothelial cells (RAECs) and (B, D) human umbilical vein endothelial cells 
(HUVECs) with MG (30 µM) or glucose (25 mM) for 24 h increased (A, B) reactive oxygen 
species (ROS) production, measured as oxidized dichlorofluorescein (DCF), and (C, D) 
NADPH oxidase activity  that was prevented by co-incubation with (A, B) the antioxidant N-
acetylcysteine (NAC 600 µM) or (C, D) the NADPH oxidase inhibitor, apocynin (Apo, 100 
µM), respectively. NADPH oxidase activity was measured with a luminescence assay. n = 5 
for each group. **P<0.01 vs. corresponding control, †P<0.05 vs. corresponding glucose (25 
mM) alone or MG (30 µM) alone value. 
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Figure 7-8 Methylglyoxal (MG) and high glucose decrease glutathione and glutathione 
reductase in cultured human umbilical vein endothelial cells (HUVECs). Incubation of 
HUVECs with MG (30 µM) or glucose (25 mM) for 24 h decreased (A) cellular reduced 
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glutathione (GSH) levels and (B) glutathione reductase (GSH red) protein levels that was 
prevented by co-incubation with aminoguanidine (AG, 100 µM). GSH was determined with 
the monochlorobimane assay as described in methods. n = 5 for each group. **P<0.01, 
***P<0.001 vs. corresponding control, †††P<0.001 vs. corresponding MG (30 µM) alone, or 
glucose (25 mM) alone value. 
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Discussion 
In this study we provide evidence, for the first time, that MG, a glucose metabolite, 
induces endothelial dysfunction in isolated rat aortic rings as well as in cultured RAECs and 
HUVECs. High glucose (25 mM) increases MG levels in both RAECs and HUVECs, and 
induces endothelial dysfunction in aortic rings and cultured endothelial cells similar to MG. 
The effects of MG and high glucose on aortic rings and cultured endothelial cells are 
attenuated by two different MG scavengers, aminoguanidine (Lo et al., 1994, Wang et al., 
2007b) and NAC (Vasdev et al., 1998, Jia and Wu, 2007). Thus, our results provide a possible 
mechanism linking high glucose and endothelial dysfunction. The effects of MG and high 
glucose to reduce eNOS activity, NO production, and increase oxidative stress are seen in 
endothelial cells of rat and human origin and hence are not limited to one species. We have 
recently shown that MG levels are comparatively higher in the aorta compared to other organs 
such as heart, liver, lungs, kidney etc., and after exogenous MG administration the aortic 
levels increased significantly (Dhar et al., 2010). 
To the best of our knowledge, the effect of MG on endothelium-dependent vascular 
relaxation has not been reported previously. Both, MG (30 and 100 μM) and high glucose (15 
and 25 mM) reduced ACh-induced relaxation to a similar extent. In fact 25 mM glucose 
caused a slightly greater reduction of relaxation. It should be pointed out that exogenous MG 
is not fully absorbed into the cells. In one study as little as 3% of exogenous MG was 
absorbed by cultured L6 muscle cells incubated with 2.5 mM MG (Riboulet-Chavey et al., 
2006).  As shown in Fig. 7-2, 30 μM MG causes a similar increase in cellular MG levels as 25 
mM glucose in endothelial cells, which justifies the use of 30 μM exogenous MG in our study. 
The attenuation of relaxation by both, MG and high glucose, was prevented by two different 
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MG scavengers, aminoguanidine and NAC (Lo et al., 1994, Wang et al., 2007b, Vasdev et al., 
1998, Jia and Wu, 2007) (Fig. 7-1A-D), but not by the NADPH oxidase inhibitor apocynin 
(Fig. 7-1E, F), indicating MG as a possible mediator of the effects of high glucose on 
endothelial dysfunction.  
The reduction of NO production by cultured endothelial cells treated with MG has not 
been reported previously. We measured the production of NO in both cell types as nitrate plus 
nitrite (Fig. 7-3 & 7-4), as well as cGMP accumulation (Fig. 7-5) in response to agonist 
stimulation. cGMP is a sensitive indicator of NO production, which activates soluble 
guanylate cyclase (Waldman and Murad, 1987, Papapetropoulos et al., 1996). Again, both MG 
scavengers, aminoguanidine and NAC, prevented the reduced NO production by both MG and 
high glucose. It should be pointed out here that aminoguanidine is also an inhibitor of 
inducible NOS (Corbett et al., 1992, Misko et al., 1993) but iNOS is not normally expressed 
by endothelial cells. In the case that aminoguanidine was inhibiting eNOS it should further 
reduce the NO production along with MG and high glucose. In our study, aminoguanidine 
actually attenuated the reduction in NO production by MG and high glucose, suggesting a MG 
scavenging effect of aminoguanidine (Lo et al., 1994, Wang et al., 2007b). Moreover, we used 
a relatively lower concentration of aminoguanidine (100 µM) compared to concentrations of 1 
mM and higher reported in the literature (Lo et al., 1994, Misko et al., 1993).  
The mechanism of reduced NO production can be ascribed to reduced eNOS activity 
induced by MG and high glucose with no change in eNOS protein level (Fig. 7-6A, B). The 
reduced eNOS activity is likely due to reduced BK-stimulated serine-1177 [bovine eNOS 
serine-1179] phosphorylation of eNOS (Dimmeler et al., 1999, Fleming et al., 2001) caused 
by MG (30 µM) or glucose (25 mM) (Fig. 7-6C). Serine-1177 is the most common site 
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phosphorylated in activated eNOS (Fulton et al., 1999, Dimmeler et al., 1999). Basal eNOS is 
phosphorylated at threonine-495 and. BK stimulation causes dephosphorylation of threonine-
495 [bovine eNOS threonine-497] (Fleming et al., 2001). MG (30 µM) or glucose (25 mM) 
did not affect threonine-495 phosphorylation of e-NOS (Fig. 7-6C). High glucose (25 mM) 
has been reported to reduce serine-1179 (human serine-1177) phosphorylation of eNOS due to 
activation of inhibitor kappa β kinase (IKKβ), a mediator of inflammation, and reduce NO 
production in cultured bovine aortic endothelial cells (Kim et al., 2005). Since serine-1177 is 
the phosphorylation site for the substrate Akt (Fulton et al., 1999, Dimmeler et al., 1999) we 
looked at Akt phosphorylation itself. MG and hyperglycemia did not affect Akt 
phosphorylation in HUVECs (Fig. 7-6C). Thus, reduced Akt phosphorylation is not 
responsible for reduced eNOS activity. 
One study (Brouwers et al., 2008) has reported a lack of effect of MG and MG-adducts 
(argpyrimidine and 5-hydro-5-methylimidazolone) (1, 10 and 100 µM of each) on eNOS 
activity in whole cell homogenates of HUVECs incubated with MG and its two adducts. Some 
possible reasons for this lack of effect of MG could be the incubation time of 60 min, and use 
of whole cell homogenates instead of intact cultured cells, which provides a different 
experimental condition. Moreover, the authors used 10 µmol/L of total free arginine and since 
MG has high affinity for arginine, it is possible that the added MG bound to arginine in the 
reaction mix and did not affect eNOS. In contrast, Du et al. (Du et al., 2001) have reported 
that hyperglycemia inhibits eNOS activity by activating, the hexosamine pathway, increasing 
superoxide production and reducing serine-1177 phosphorylation of eNOS. We have shown 
that MG also reduces serine-1177 phosphorylation of eNOS and is a possible mediator of 
hyperglycemia-induced dysfunction. 
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Increased superoxide anion can quench NO to form peroxynitrite and thus reduce the 
bioavailability of NO (Pacher et al., 2007). This is the more frequently reported mechanism of 
endothelial dysfunction caused by oxidative stress (Potenza et al., 2009). Hyperglycemia (30 
mM glucose) has been shown to induce endothelial dysfunction by increasing production of 
ROS, oxidative stress and activating protein kinase C and NFκB (Potenza et al., 2009, Triggle, 
2008, Nishikawa et al., 2000). However, in these studies it was not shown if high glucose per 
se or one of its metabolites is responsible for causing endothelial dysfunction. Our results 
show that MG reduces serine-1177 phosphorylation of eNOS in parallel with high glucose, an 
effect prevented by the MG scavenger aminoguanidine, implicating MG as a possible 
mediator of the effect of high glucose on reduced eNOS phosphorylation and activity.  
So how does oxidative stress fit with the data presented in our study? NADPH oxidase 
is a key enzyme responsible for overproduction of superoxide anion and an increase in 
oxidative stress in endothelial dysfunction (Gao and Mann, 2009). We found that both MG 
and high glucose increased NADPH oxidase activity and ROS production that was prevented 
by the NADPH oxidase inhibitor, apocynin, and the MG-scavenging antioxidant, NAC, 
respectively, in RAECs and HUVECs. MG has been shown to increase NADPH oxidase 
activity and superoxide production in other cell types such as vascular smooth muscle cells 
(Chang et al., 2005) and neutrophils (Ward and McLeish, 2004). 
Are the effects of MG or high glucose on eNOS activity and NO production direct or 
through an increase in oxidative stress? Our results with eNOS activity assay (Fig. 7-6A), 
apocynin and NAC indicate the effects to be partly direct on the eNOS enzyme itself. 
Inhibiting superoxide with apocynin did not completely restore the ACh-induced relaxation of 
aortic rings (Fig. 7-1E, F) or BK-stimulated NO production in HUVECs (data not shown) that 
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was attenuated by MG or high glucose. On the contrary NAC, which can also scavenge MG 
(Vasdev et al., 1998), restored ACh-induced relaxation of rings (Figs. 7-1C, D) and BK-
stimulated NO production and cGMP increase in RAECs and HUVECs (Figs. 7-3, 7-4 and 7-
5) that was attenuated by MG and high glucose.  
MG and high glucose also significantly reduced GSH levels and expression of GSH-
reductase, which was prevented by aminoguanidine, in HUVECs (Fig. 7-8) and RAECs (data 
not shown). GSH plays a key role in the degradation of MG by the glyoxalase enzymes 
(Dakin and Dudley, 1913). A reduction in GSH levels would delay the degradation of MG. 
Glutathione reductase replenishes GSH by reducing oxidized glutathione (GSSG) and is an 
antioxidant enzyme (Zhao et al., 2009). MG has been shown to reduce GSH and GSH 
reductase levels in VSMCs (Wu and Juurlink, 2002). It should be pointed out besides MG, 
other reactive aldehydes, viz. glyoxal and 3-deoxyglucosone are formed from degradation of 
glucose (Thornalley et al., 1999). According to one report 2.7 fold more 3-deoxyglucosone 
and 21 fold more glyoxal was formed from glucose in phosphate buffer (Thornalley et al., 
1999). However, of the three aldehydes MG is the most reactive and widely studied as an 
AGEs precursor.  
Thus, our data provides a possible link between hyperglycemia and endothelial 
dysfunction with MG as the mediator of the endothelial dysfunction induced by high glucose. 
Therefore, MG is a potential target for preventive strategies against hyperglycemia-induced 
endothelial dysfunction and its sequelae. The potential of NAC needs to be researched in this 
regard. NAC is already clinically used in patients for conditions such as acetaminophen 
overdose, influenza viral infection, chronic obstructive pulmonary disease and pulmonary 
fibrosis (Millea, 2009).  Aminoguanidine was found to be toxic in clinical trials as an AGEs 
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scavenger (Freedman et al., 1999). However, for experimental studies aminoguanidine is the 
most effective and commonly used MG and AGEs scavenger (Desai and Wu, 2007, Lo et al., 
1994, Wang et al., 2007b), and was a rational choice in our study as an MG scavenger.  
In conclusion, hyperglycemia-induced endothelial dysfunction is receiving increasing 
attention as an early preventable event. High glucose-induced endothelial dysfunction is most 
likely mediated by MG. Development of specific and safe MG scavengers may prove very 
useful in blocking the multiple deleterious effects of hyperglycemia, including endothelial 
dysfunction and vascular complications of diabetes. 
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Abstract 
The incidence of high dietary carbohydrate-induced type 2 diabetes mellitus is 
increasing worldwide. Methylglyoxal (MG) is a reactive glucose metabolite and a major 
precursor of advanced glycation end products (AGEs). MG levels are elevated in diabetic 
patients. It is not known if MG is a causative factor in the pathogenesis of diabetes. We 
investigated the effects of chronic administration of MG on glucose tolerance and β-cell 
insulin secreting mechanism in 12 week old male Sprague-Dawley rats. Synthesis of reduced 
glutathione (GSH), which plays a key role in MG degradation, was inhibited in one group of 
rats with buthionine-l-sulfoximine (BSO). MG was administered by continuous infusion with 
a subcutaneous mini-osmotic pump for 28 days. We measured MG and GSH levels by HPLC, 
performed in vivo glucose tolerance test, glucose uptake in adipose tissue, insulin secretion 
from isolated pancreatic islets, western blotting and mRNA, and apoptosis tests for islet cells. 
In rats treated with MG and MG+BSO, MG levels were significantly elevated in plasma, 
pancreas, adipose tissue and skeletal muscle, fasting plasma glucose was elevated, while 
insulin and GSH were reduced. These two groups also had impaired glucose tolerance, 
reduced insulin-stimulated glucose uptake and GLUT-4 expression in adipose tissue. 
Furthermore, in the pancreatic β-cells MG and MG+BSO reduced insulin secretion, PDX-1 
MafA, and GLUT-2 mRNA or protein expression, increased cEBP/β protein or mRNA, and 
caused apoptosis. Alagebrium, an MG scavenger and an AGE-breaking compound, attenuated 
the effects of MG. Chronic MG induces biochemical and molecular abnormalities 
characteristic of type 2 diabetes and is a possible mediator of high carbohydrate-induced type 
2 diabetes.  
Key words: Methylglyoxal, insulin resistance, glucose intolerance, type 2 diabetes. 
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Introduction 
 Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin 
resistance, and progressive decrease in insulin secretion from the pancreas (Field, 1962). A 
genetic predisposition has been found in many patients. More recently there has been a 
staggering increasing in the incidence of T2DM, many of the cases being reported in children. 
This explosive increase is attributed to a diet high in carbohydrates, fat, and a sedentary 
lifestyle (Schwartz, 2008; van Dam et al., 2002; Weigensberg et al., 2009; Willett et al., 2002; 
Clark 2009). Oxidative stress is associated with diabetes mellitus and has been proposed as 
one of the causative factors of diabetes (Simmons, 2006; Shah et al., 2007). An increase in 
oxidative stress caused the insulin resistance of Zucker obese rats to progress to T2DM in one 
week (Laight et al., 1999).  
Methylglyoxal (MG) is a reactive dicarbonyl metabolite of glucose, and to a much 
lesser extent of fatty acid, and protein metabolism (Desai and Wu, 2007). MG reacts with and 
modifies certain proteins to form advanced glycation end products (AGEs) (Desai and Wu, 
2007; Vander Jagt, 2008). AGEs are implicated in the pathogenesis of vascular complications 
of diabetes (Vander Jagt, 2008; Vlassara et al., 1994). Plasma MG levels in healthy humans 
are 1 μM or less and are elevated 2-4 fold in diabetic patients with a positive correlation to the 
degree of hyperglycemia (Wang et al., 2007; McLellan et al., 1994). Under physiological 
conditions the highly efficient glyoxalase system degrades MG into D-lactate with the help of 
reduced glutathione (GSH) (10, 14) and keeps plasma MG levels at around 1 μM or less 
(Wang et al., 2007; McLellan et al., 1994). We have shown that incubation of vascular smooth 
muscle cells with 25 mM glucose or fructose for 3 h increases MG production 3.5 or 3.9 fold, 
respectively, and increases oxidative stress (Dhar et al., 2008). In vitro incubation of MG with 
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insulin modifies the structure of the insulin molecule, in a way that impairs insulin-mediated 
glucose uptake in adipocytes (Jia et al., 2006). Incubation of cultured L6 muscle cells with 
high concentrations of MG (2.5 mM) for 30 min impaired insulin signaling (Riboulet-Chavey 
et al., 2006). However, the in vitro studies cannot establish whether MG is the cause of 
diabetes or an effect of diabetes.  
The molecular mechanisms of high dietary carbohydrate induced T2DM are not 
entirely clear. It is possible that high carbohydrate-induced chronic elevation of MG causes 
cumulative pathologic changes that contribute to the development of insulin resistance and 
T2DM. We have recently shown that a single acute dose of MG (50 mg/kg i.v.) administered 
to 12 week old male Sprague-Dawley (SD) rats causes insulin resistance and reduced adipose 
tissue insulin-stimulated glucose uptake (Dhar et al., 2010). Here we report the results of a 
comprehensive study on the effects of chronically administered MG on in vivo glucose 
tolerance, adipose tissue glucose uptake and insulin secretion from isolated pancreatic islets, 
and the underlying molecular mechanisms. We administered MG by continuous infusion via 
an osmotic minipump for 28 days, a method used for the first time to administer MG, which is 
expected to closely mimic the supposedly continuous production of MG in the body and avoid 
the excessive peaks in plasma concentrations of MG that can result from daily intraperitoneal 
administration.  
 
METHODS 
 
Animals 
All animal protocols were approved by the Animal Care Committee of the University 
210 
 
of Saskatchewan. Male Sprague Dawley (SD) rats, 12 weeks old, from Charles River 
Laboratories, Quebec, Canada, were treated according to guidelines of the Canadian Council 
on Animal Care.  
The rats were from the same batch and similar in weight. MG (40% solution) was 
administered to 12 week old male SD rats for 28 days by means of an osmotically driven 
infusion minipump (Alzet® 2ML4, Durect Corporation, Cupertino, CA, USA) implanted 
subcutaneously on the back following procedure provided on a video by the company. This 
pump holds a fixed volume (2 ml) of drug and releases a continuous small amount of MG into 
the body at a rate of 2.5 μl/h or 60 μl/day, amounting to 60 mg/kg/day. Control rats were 
administered 0.9% saline (2.5 μl/h) by means of subcutaneously implanted pump. GSH is an 
antioxidant, which also plays a key role in degrading MG. Since oxidative stress has been 
implicated as a possible pathogenetic factor for T2DM (Simmons 2006; Shah et al., 2007) we 
also treated rats with buthionine-l-sulfoximine (BSO), an inhibitor of glutamyl cysteine 
synthetase (Meister, 1983), which prevents GSH synthesis, decreases MG degradation, and 
increases oxidative stress. Alagebrium is a MG scavenger and an AGE-breaking compound 
(Dhar et al., 2010; Wolffenbuttel, 1998).  
After one week of acclimatization the rats were divided into the following treatment 
groups (n = 8 each): 1. Control – 0.9% saline, 2. MG (60 mg/kg/day), 3. MG (60 mg/kg/day) 
+ alagebrium (ALA, 30 mg/kg/day in drinking water), 4. ALA alone (30 mg/kg/day in 
drinking water), 5. MG (60 mg/kg/day) + BSO (30 mg/kg/day in drinking water), 6. BSO 
alone (30 mg/kg/day in drinking water). All the treatments were for 28 days.  
 
Biochemical parameters 
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Blood was collected from anesthetized rats from different treatment groups, the plasma 
was separated and analyzed for total cholesterol, triglycerides, high density lipoprotein 
(HDL), creatine kinase (CK), creatinine, alanine transaminase (ALT) and aspartate 
aminotransferase (AST).  
  
Oral Glucose Tolerance Test (OGTT) 
After overnight fasting, an oral glucose tolerance test (GTT) was performed.  Briefly, 
the trachea, left jugular vein, and right carotid artery were cannulated in anesthetized rats. 
After collecting a basal blood sample an oral glucose load (1 g/kg) was given with a stomach 
tube. Further blood samples were collected at 5, 15, 30, 60 and 120 min from the carotid 
artery. Plasma glucose levels were determined using a glucose assay kit (BioAssay Systems, 
Hayward, CA, USA) and insulin levels were measured with a rat insulin ELISA assay kit 
(Mercodia Inc., Winston Salem, NC, USA).  
 
Insulin release from freshly isolated pancreatic islets 
The pancreatic islets were freshly isolated from SD rats as described previously (Wu et 
al., 2009). Briefly, rats were anesthetized with isoflurane, the pancreatic duct was cannulated 
and injected with ~ 7 ml of ice-cold collagenase (Type IV, 5 mg/ml, Worthington Biochemical 
Corporation, Lakewood, NJ, USA) solution in Krebs buffer. The pancreas was cut out, washed 
in Krebs buffer and finely chopped into small pieces with Mcllwain tissue chopper. The tissue 
was digested with 20 ml collagenase (Type IV) for 20 min at 37 °C in a shaker bath and then 
stopped by addition of 20 ml of calcium-free ice-cold Krebs buffer. The digested tissue was 
then centrifuged at 1000 rpm for 10 min and washed twice with Krebs buffer and thereafter 
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transferred into a petri dish. Islets were separated under a dissection microscope. The identity 
of islets was confirmed under a high power microscope. For each treatment 10-20 islets were 
used in eppendorf tubes. The islets were incubated for 30 min at 37°C in Krebs buffer 
containing either 5 mM or 20 mM glucose.  The incubation medium was collected and 
analyzed for released insulin with insulin assay kit 
 
Glucose uptake 
Adipose tissue was isolated and washed in Dulbecco’s modified Eagle medium 
(DMEM) without glucose and chopped. The chopped tissue was transferred into eppendorf 
tubes, weighed and incubated in DMEM containing collagenase solution (1.5 mg/ml) for 30 
min. Insulin was added at a final concentration of 100 nM and incubated for another 30 min. 
Finally, after the addition of [3H]-2-DOG (0.1 µCi/500 µl) and glucose (50 µM) to the 
medium, the tissue was incubated for another 20 min. All incubations were performed at 
37°C. The incubation was stopped by washing three times with ice-cold phosphate buffered 
saline. The cells were lysed in 0.1% sodium dodecyl sulfate (SDS) and 1 N NaOH and then 
transferred into scintillation vials for counting (Beckman LS 3801 scintillation counter). 
 
MG Assay 
MG was measured by a specific and sensitive HPLC method (Dhar et al., 2009). 
Briefly, MG was derivatized with o-phenylenediamine (o-PD) to form the quinoxaline 
product, 2-methylquinoxaline. The samples were incubated on dark for 24 h with 0.4 N 
perchloric acid (PCA) and 10 mM o-PD at room temperature. Samples were centrifuged at 
12000 rpm for 10 min. The 2-methylquinoxaline and 5-methylquinoxaline, which was added 
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to the samples as the internal standard, were quantified on a Hitachi D-7000 HPLC system 
(Hitachi, Ltd., Mississauga, ON, Canada) via Nova-Pak® C18 column (3.9×150 mm, and 4 
μm particle diameter, Waters Corporation, Milford, MA, USA). 
 
Measurement of reduced glutathione levels 
The GSH levels in the plasma and organs were determined by derivation with 5, 50-
dithio-bis (2-nitrobenzoicacid), and reverse-phase HPLC using ultra-violet Detection, as 
described previously (Kamenic et al., 2000). 
 
Determination of cell apoptosis: 
(i) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay 
The TUNEL assay was done using TUNEL assay kit (Roche Diagnostics, Indianapolis, 
IN, USA). In brief, paraformaldehyde- fixed and optimal cutting temperature (OCT) 
compound-embedded sections of pancreas were cut into 4µM on glass slides. The sections 
were washed twice with PBS. After permeation with 0.1% Triton X-100 for 5 min and two 
washes with PBS, the tissue sections were incubated with blocking solution (3% H2O2 in 
methanol) for 10 min. After washing with PBS the slides were incubated with TUNEL reagent 
for 1h in dark and then converter POD for 30 min. After rinsing with PBS, the DAB reagent 
was added, the sections were mounted under glass cover slips and analyzed under light 
microscope  
DNA was isolated from pancreas using DNA extraction kit (R & D Systems, 
Minneapolis, MN, USA). Equal amount and concentration (1 µg) of DNA was loaded on 1% 
agarose gel and run at 100V for 2h. The gel was visualized on Syngene bio-imaging system 
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(Syngene, Frederick, MD, USA). 
 
Isolation of plasma membrane for GLUT4 
Plasma membrane from adipose tissue was isolated using plasma membrane isolation 
kit (BioVision Inc., MountainView, CA, USA). Briefly, adipose tissue was homogenized in 2-
3 volume of the 1x homogenization buffer, until completely lysed (30-50 times). The sample 
was centrifuged at 700 g for 10 min at 4°C, the supernatant was collected and centrifuged at 
10,000 g for 30 min at 4°C. The supernatant is the cytosol fraction and the pellet is the total 
cellular membrane protein (containing proteins from both plasma membrane and cellular 
organelle membrane). The total membrane protein pellet was resuspended in 200 μl of the 
upper phase solution and an equal volume of lower phase solution was added, mixed well and 
incubated on ice for 5 min. The sample was then centrifuged at 3500 rpm for 5 min. The upper 
phase was carefully transferred to a new tube and extracted by adding 100 μl of the lower 
phase solution. The upper phase was diluted in five volumes of water, kept on ice for 5 min 
and spun at top speed for 10 min at 4°C. The supernatant was removed and the pellet 
containing the plasma membrane protein was used for membrane GLUT4 determination. 
 
Western immunobloting 
Isolated pancreas and adipose tissue were homogenized using polytron homogenizer in 
a homogenization buffer. The supernatants were resolved on 10% SDS-PAGE gel and 
transferred to PVDF membrane. The membranes were blocked with 5% non-fat dry milk 
solution for 1h and incubated overnight with primary antibodies for GLUT4 (plasma 
membrane and total), GLUT2, PDX-1, Maf-A, C/EBPβ, β-actin (Santa Cruz Biotechnology 
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Inc., Santa Cruz, CA, USA) and then with  horse radish peroxidase conjugated secondary 
antibody for 1h. The reactions were visualized using ECL reagent and exposed to X-ray film 
(Kodak scientific imaging film, Eastman Kodak Company, Rochester, NY, USA). 
 
Real time Quantitative PCR (RT-PCR) 
RNA was isolated from the pancreas using RNA isolation kit (Qiagen sciences, 
Germantown, MD, USA). The total RNA was reverse-transcribed in triplicate using 
RevertAidTM H Minus M-MuLV reverse transcriptase (MBI, Fermentas Burlington, ON, 
Canada) in the presence of 5x RT buffer (MBI, Fermentas), Random primer (Invitrogen 
Corporation, Carlsbad, CA, USA), dNTP mixture (Amersham, Pittsburgh, PA, USA) at 42°C 
for 50 min, followed by 72°C for 10 min. The pre-designed primers for PDX-1 and Maf-A 
were from Qiagen Sciences (Germantown, MD, USA). The real-time PCR was carried out in 
an iCycler iQ apparatus (Bio-Rad, Life Science Research, Hercules, CA, USA) associated 
with the ICYCLER OPTICAL SYSTEM software (version 3.1) using SYBR Green PCR 
Master Mix (Bio-Rad, Life Science Research, Hercules, CA, USA). All PCRs were triplicated 
and performed in 96-well optical-grade PCR plates and run for 45 cycles at  95°C for 20 s, 
62°C for 1 min, and 72°C for 30 s. After cycling, melting curves of the PCR products were 
acquired by stepwise increase of the temperature from 62° to 95°C. 
 
Chemicals and Statistical analysis   
All chemicals were of analytical grade. Methylglyoxal and o-phenylenediamine (o-
PD) were purchased from Sigma Aldrich, Oakville, ON, Canada. Alagebrium (formerly 
known as ALT-711) was a generous gift from Synvista Therapeutics, Inc. (Montvale, NJ, 
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USA). Data are expressed as mean ± SEM and analyzed using one way ANOVA and post hoc 
Bonferroni’s test. P value less than 0.05 was considered significant.  
 
RESULTS 
Chronic methylglyoxal treatment significantly alters metabolic characteristics of SD rats 
MG, MG+BSO and BSO treatment for 4 weeks significantly increased fasting plasma 
glucose (Fig. 8-2A inset), total cholesterol and triglycerides (Table 8-1), and decreased fasting 
plasma insulin (Fig. 8-2B inset) and high density lipoprotein (HDL) (Table 8-1) levels as 
compared to the control group. There was no significant difference in the body weight 
between the treatment groups (Table 8-1), and markers indicating tissue or organ damage such 
as serum creatine kinase (CK) for muscle damage, creatinine for kidney function, alanine 
transaminase (ALT) and aspartate aminotransferase (AST) for liver damage (Table 8-1). 
Pretreatment with ALA (30 mg/kg/day) significantly attenuated MG-induced changes in the 
metabolic parameters (Fig. 8-2 insets, Table 8-1).  
 
Methylglyoxal and GSH levels were different among treatment groups 
MG and MG+BSO treated groups had significantly elevated plasma, pancreatic, 
adipose tissue and skeletal muscle MG levels compared to control (Fig. 8-1A, B) that were 
attenuated by pretreatment with ALA in the MG+ALA group. BSO alone also significantly 
elevated plasma, pancreatic, adipose tissue and skeletal muscle MG compared to control (Fig. 
8-1A, B). MG levels were higher in plasma and tissues in the MG+BSO group compared to 
MG and BSO alone groups (Fig. 8-1A, B). MG and MG+BSO treatment significantly reduced 
GSH levels in the plasma, pancreas and skeletal muscle (Fig. 8-1C, D). ALA pretreatment 
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attenuated the decrease in plasma GSH induced by MG (Fig. 8-1C, D). BSO alone also 
reduced plasma, skeletal muscle and pancreatic GSH compared to control (Fig. 8-1C, D). 
Adipose tissue and pancreas had much lower GSH levels compared to skeletal muscle (Fig. 8-
1D). 
 
Chronic methylglyoxal impaired glucose tolerance in SD rats 
 
MG and MG+BSO treatment significantly impaired in vivo glucose tolerance 
determined after an oral glucose load in SD rats (Fig. 8-2A). Plasma glucose levels were 
significantly higher in the MG and MG+BSO group compared to control even 2 h after the 
glucose load. ALA pretreatment attenuated the impaired glucose tolerance induced by MG 
(Fig. 8-2A).  
MG and MG+BSO treated groups had significantly lower plasma insulin levels 
compared to the control group in the oral GTT (Fig. 8-2B). The plasma insulin levels were 
lower in the MG+BSO group compared to the MG alone group. The plasma insulin levels 
were significantly lower than control even 2 h after the glucose load in the MG and MG+BSO 
groups. ALA pretreatment attenuated the reduced insulin levels induced by chronic MG 
treatment (Fig. 8-2B).  
 
Chronic methylglyoxal treatment reduces glucose uptake and plasma membrane GLUT4 
expression in adipose tissue 
Insulin-stimulated glucose uptake was evaluated in adipose tissue freshly isolated from 
rats after different treatments for 28 days. There was a significant decrease in insulin-
stimulated glucose uptake in rats treated with MG or MG+BSO compared to those from 
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control (Fig. 8-3A). ALA attenuated the reduced insulin-stimulated glucose uptake by MG. To 
understand the possible mechanism of MG induced impaired glucose tolerance and reduced 
glucose uptake, the adipose tissue GLUT4 translocation to the plasma membrane was 
determined. There was a significant decrease in plasma membrane GLUT4 in MG and 
MG+BSO treated rats (Fig. 8-3B). ALA attenuated the reduced plasma membrane GLUT4 
induced by MG. BSO alone also reduced plasma membrane GLUT4 (Fig. 8-3B). 
 
Chronic methylglyoxal treatment reduces total insulin content and glucose-stimulated insulin 
release from pancreas 
 The pancreatic insulin content was significantly reduced in MG and MG+BSO treated 
groups compared to control (Fig. 8-4). ALA attenuated the reduction in insulin content by MG 
(Fig. 8-4). We further investigated whether MG inhibits pancreatic insulin release. Basal and 
glucose-stimulated insulin release from isolated pancreatic islets was significantly reduced in 
MG and MG+BSO groups compared to control (Fig. 8-5A). BSO alone also significantly 
reduced glucose-stimulated insulin secretion compared to control but less than MG+BSO 
group (Fig. 8-5A).  ALA significantly attenuated MG-induced decrease in glucose-stimulated 
insulin release from the pancreatic islets (Fig. 8-5A). 
 
Effects of chronic MG on insulin synthesis/secretion pathway in pancreas  
To determine the cause of MG-induced reduction of basal plasma level and glucose-
stimulated insulin release from pancreatic islets we looked at the molecular mechanisms of 
insulin synthesis and secreting pathways. GLUT2 is the transporter for glucose entry into islet 
cells. PDX-1, Maf-A are negative regulators whereas C/EBPβ is a positive regulator of insulin 
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gene transcription. There was a significant decrease in GLUT2 (Fig. 8-5B), PDX-1 and Maf-A 
protein expression in MG and MG+BSO treated rats [Fig. 8-6A(i), A(ii)). There was also a 
significant decrease in mRNA expression of PDX-1 and Maf-A in MG and MG+BSO treated 
rats as compared to control [Fig. 8-6B(i), B(ii)]. ALA attenuated the decrease in GLUT2 (Fig. 
8-5B), PDX-1 and Maf-A protein and mRNA induced by MG [Fig. 8-6A(i), A(ii), 8-6B(i), 
B(ii)]. At the same time there was a significant increase in C/EBPβ protein expression and 
mRNA in MG and MG+BSO treated rats [Fig. 8-6A(iii), B(iii)]. MG-induced increase in 
C/EBPβ protein and mRNA was prevented by ALA [Fig. 8-6A(iii), 8-6B(iii)]. 
 
Chronic methylglyoxal treatment induces apoptosis of pancreatic β-cells 
After chronic MG and MG+BSO administration, there was significant DNA 
fragmentation (Fig. 8-7A) and significant positive BrdUTP staining indicating apoptosis (Fig. 
8-7Bii, iii) of pancreatic β cells as compared to control. ALA significantly attenuated MG 
induced apoptosis and DNA fragmentation in chronic MG treated rats (Fig. 8-7A, Biv). BSO 
alone also partially induced apoptosis (Fig. 8-7Bv) but had no effect on DNA fragmentation 
(Fig. 8-7A). 
220 
 
 
Table 8-1 
 
Plasma levels of different substances in Sprague-Dawley rats treated with methylglyoxal 
(MG). 0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion with a 
subcutaneous osmotic pump for 28 days to all groups of rats (n=6 each). The MG scavenger, 
alagerbium (ALA, 15 mg/kg/day in drinking water) (MG+ALA) or glutathione synthesis 
inhibitor, buthionine-L-sulfoximine (BSO, 30 mg/kg/day in drinking water) (MG+BSO and 
BSO) were administered to some groups of rats. The control group received only saline (0.9% 
by pump). After 28 days basal plasma levels of substances listed in the table were measured.  
 
Parameter 
 
Control MG MG+BSO MG+ALA BSO 
Body weight (g) 558 ± 18 556 ± 9 582 ± 13 588 ± 7 536 ± 33 
Total Cholesterol 1.8±0.1 2.4±0.05*** 2.8±0.05***†† 1.9±0.03†† 2.1±0.1**‡‡‡
HDL 1.2±0.05 0.7±0.06** 0.46±0.05***† 1.0±0.07† 0.78±0.1**‡
Triglycerides 0.2±0.03 0.5±0.04*** 0.7±0.02***†† 0.3±0.02†† 0.4±0.05**‡‡‡
Creatinine 55±5 66±6 75±8 52±2 58±5 
CK 315±20 365±25 378±23 332±15 355±21 
ALT 60±10 65±9 71±10 59±8 63±7 
AST 46±5 50±8 56±9 45±6 48±4 
 
Abbreviations: HDL, high density lipoprotein; CK, creatinine kinase; AST, aspartate 
aminotransferase; ALT, Alanine transaminase  
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Fig. 8-1 Methylglyoxal (MG) levels are elevated and reduced glutathione (GSH) levels 
are decreased in Sprague-Dawley rats chronically treated with MG. 0.9% saline or MG (60 
mg/kg/day) was delivered by continuous infusion with a subcutaneous osmotic minipump for 
28 days to all groups of rats (n=6 each). The MG scavenger, alagerbium (ALA, 30 mg/kg/day 
in drinking water) (MG+ALA) or glutathione synthesis inhibitor, buthionine-L-sulfoximine 
(BSO, 30 mg/kg/day in drinking water) (MG+BSO and BSO) were administered to some 
groups of rats. The control group received only saline (0.9% by pump). After 28 days MG and 
GSH levels were determined by HPLC in (A, C) plasma and (B, D) organs. *P<0.05, 
**P<0.01, ***P<0.001 vs respective control, †P<0.05, ††P<0.01, †††P< 0.001 vs respective 
MG group, ‡P<0.05, ‡‡P<0.01, ‡‡‡P<0.001 vs. respective MG+BSO group. 
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Fig. 8-2 Fasting plasma glucose is elevated, insulin is reduced and oral glucose tolerance test 
is impaired in Sprague-Dawley rats chronically treated with methylglyoxal (MG). 0.9% saline 
or MG (60 mg/kg/day) was delivered by continuous infusion with a subcutaneous osmotic 
minipump for 28 days to all groups of rats (n=6 each). The MG scavenger, alagerbium (ALA, 
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30 mg/kg/day in drinking water) (MG+ALA) or glutathione synthesis inhibitor, buthionine-L-
sulfoximine (BSO, 30 mg/kg/day in drinking water) (MG+BSO and BSO) were administered 
to some groups of rats. The control group received only saline (0.9% by pump). After 28 days 
the rats were fasted overnight, anesthetized and cannulated. A basal zero min blood sample 
was taken from the carotid artery. After that an oral glucose load (1 g/kg body wt) was 
administered and blood samples were collected from the carotid artery at different times up to 
120 min. Plasma was separated and analyzed for (A inset) basal glucose, (B inset) basal 
insulin, and (A) glucose and (B) insulin levels following the glucose load. *P<0.05, 
**P<0.01, ***P<0.001 vs respective control at the same time point, †P<0.05, ††P<0.01, †††P< 
0.001 vs respective MG group at the same time point, ‡‡P<0.01, ‡‡‡P<0.001 vs. respective 
MG+BSO group at the same time point. 
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Fig. 8-3 Adipose tissue glucose uptake and plasma membrane GLUT4 protein are reduced in 
chronic methylglyoxal (MG) treated Sprague-Dawley rats. 0.9% saline or MG (60 mg/kg/day) 
was delivered by continuous infusion with a subcutaneous osmotic minipump for 28 days to 
all groups of rats (n=6 each). The MG scavenger, alagerbium (ALA, 30 mg/kg/day in drinking 
water) (MG+ALA) or glutathione synthesis inhibitor, buthionine-L-sulfoximine (BSO, 30 
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mg/kg/day in drinking water) (MG+BSO and BSO) were administered to some groups of rats. 
The control group received only saline (0.9% by pump). After 28 days the rats were fasted 
overnight, and (A) abdominal visceral adipose tissue was removed and tested for insulin-
stimulated glucose uptake in vitro. (B) The adipose tissue was also subjected to Western 
blotting to determine the plasma membrane and total GLUT4 protein as described in methods. 
*P<0.05, **P<0.01 vs control, †P<0.05 vs MG group. 
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Fig. 8-4 Pancreatic insulin content is reduced in Sprague-Dawley rats chronically treated with 
methylglyoxal (MG). 0.9% saline or MG (60 mg/kg/day) was delivered by continuous 
infusion with a subcutaneous osmotic minipump for 28 days to all groups of rats (n=6 each). 
The MG scavenger, alagerbium (ALA, 30 mg/kg/day in drinking water) (MG+ALA) or 
glutathione synthesis inhibitor, buthionine-L-sulfoximine (BSO, 30 mg/kg/day in drinking 
water) (MG+BSO and BSO) were administered to some groups of rats. The control group 
received only saline (0.9% by pump). After 28 days the rats were fasted overnight, and the 
pancreas was removed and evaluated for insulin content. *P<0.05, **P<0.01 vs respective 
control. 
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Fig. 8-5 Pancreatic GLUT2 and insulin release from isolated pancreatic islets are reduced in 
Sprague-Dawley rats chronically treated with methylglyoxal (MG). 0.9% saline or MG (60 
mg/kg/day) was delivered by continuous infusion with a subcutaneous osmotic minipump for 
28 days to all groups of rats (n=6 each). The MG scavenger, alagerbium (ALA, 30 mg/kg/day 
in drinking water) (MG+ALA) or glutathione synthesis inhibitor, buthionine-L-sulfoximine 
(BSO, 30 mg/kg/day in drinking water) (MG+BSO and BSO) were administered to some 
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groups of rats. The control group received only saline (0.9% by pump). After 28 days the rats 
were fasted overnight, and (A) the pancreatic islets were isolated as described in methods. 
Glucose-stimulated insulin secretion was evaluated in the isolated islets in vitro. (B) The 
pancreatic tissue was removed and processed for determination of GLUT2 protein expression 
by western blotting. *P<0.05, ***P<0.001 vs respective control, ††P<0.01, †††P< 0.001 vs 
respective MG group, ‡‡‡P<0.001 vs. respective MG+BSO group. 
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Fig. 8-6  Insulin gene transcription factors, pancreatic duodenal homeodomain-1 (PDX-
1) and Maf-A protein expression and mRNA are reduced; and CCAAT/Enhancer Binding 
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Protein β (C/EBPβ) protein expression and mRNA are enhanced in Sprague-Dawley rats 
chronically treated with methylglyoxal (MG). 0.9% saline or MG (60 mg/kg/day) was 
delivered by continuous infusion with a subcutaneous osmotic minipump for 28 days to all 
groups of rats (n=6 each). The MG scavenger, alagerbium (ALA, 30 mg/kg/day in drinking 
water) (MG+ALA) or glutathione synthesis inhibitor, buthionine-L-sulfoximine (BSO, 30 
mg/kg/day in drinking water) (MG+BSO and BSO) were administered to some groups of rats. 
The control group received only saline (0.9% by pump). After 28 days the pancreatic tissue 
was removed and processed for determination of (Ai) PDX-1, (Aii) Maf-A and (Aiii) C/EBPβ 
protein expression by western blotting. (B) (i) PDX-1, (ii) Maf-A and (iii) C/EBPβ mRNA 
were also determined by RT-PCR in pancreatic tissue isolated from groups of rats described 
above. *P<0.05, **P<0.01, ***P<0.001 vs respective control, †P<0.05, †††P< 0.001 vs 
respective MG group, ‡P<0.05, ‡‡P<0.01 vs. respective MG+BSO group. 
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Fig. 8-7  Chronic methylglyoxal (MG) induces apoptosis in pancreatic islets in 
Sprague-Dawley rats. 0.9% saline or MG (60 mg/kg/day) was delivered by continuous 
infusion with a subcutaneous osmotic minipump for 28 days to all groups of rats (n=6 each). 
The MG scavenger, alagerbium (ALA, 30 mg/kg/day in drinking water) (MG+ALA) or 
glutathione synthesis inhibitor, buthionine-L-sulfoximine (BSO, 30 mg/kg/day in drinking 
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water) (MG+BSO and BSO) were administered to some groups of rats. The control group 
received only saline (0.9% by pump). After 28 days (A) DNA was isolated and run on agarose 
gel to evaluate DNA integrity. (B) a part of the pancreas was removed and fixed in 4% 
paraformaldehyde. The tissue was processed for sectioning and stained for the terminal 
deoxynucleotidyl gtransferase dUTP nick end labeling (TUNEL) assay. Big black arrows 
show the pancreatic islet. Small black arrows show brown staining of apoptotic cells. 
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DISCUSSION 
In the present study we report for the first time that MG administered by continuous 
infusion with a minipump for 28 days to Sprague-Dawley rats induces metabolic, biochemical 
and molecular abnormalities characteristic of type 2 diabetes mellitus. The most notable 
change induced by MG was an elevation of fasting plasma glucose and reduction of insulin 
level accompanied by a significantly impaired oral glucose tolerance test (Fig 8-1, 8-2). The 
oral GTT revealed abnormally elevated plasma glucose levels and reduced insulin levels. An 
investigation of the mechanisms of elevated plasma glucose revealed reduced insulin-
stimulated glucose uptake in adipose tissue and plasma membrane GLUT-4 protein. At the 
same time the pancreatic islet β-cell insulin secreting machinery was significantly impaired in 
MG and MG+BSO treated rats. Glucose-stimulated insulin secretion was reduced in freshly 
isolated pancreatic islets, GLUT2 protein level was decreased, pancreatic insulin content was 
lower, protein as well as mRNA expression of insulin promoter transcriptional factors PDX-1 
and Maf-A were significantly down-regulated whereas protein expression of C/EBPβ, a 
repressor of insulin gene transcription was significantly up-regulated in MG and MG+BSO 
treated rats. The deleterious effects of MG were attenuated by the MG scavenger and AGEs 
breaking compound, alagebrium (Dhar et al., 2010; Wolffenbuttel, 1998).  
To the best of our knowledge, MG has not been previously administered chronically 
by continuous infusion. This is important because continuous infusion mimics the supposedly 
continuous production of MG in the body and it avoids the excessive peaks in plasma that are 
associated with periodic intraperitoneal or subcutaneous injections, which are necessary in a 
chronic study. The plasma levels of MG were significantly elevated between 2 and 4 fold in 
the MG and MG+BSO groups compared to control (Fig. 8-1A), similar to a range reported in 
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diabetic animals and patients (Wang et al., 2007; McLellan et al., 1994; Jia et al., 2007). MG 
levels were also significantly higher in the pancreas, adipose tissue and skeletal muscle, which 
can explain the metabolic changes observed in these organs/tissues. GSH levels were reduced 
in the plasma, pancreas, adipose tissue and skeletal muscle. GSH plays a central role in the 
degradation of MG by binding MG and making it available for degradation by the glyoxalase 
enzymes (Desai and Wu, 2007; Meister, 1983; Desai and Wu, 2008). A reduction in GSH 
would decrease MG degradation and contribute to its elevated levels, thus setting up a vicious 
cycle. This was observed in groups of rats treated with the GSH synthesis inhibitor, BSO 
(Meister, 1983), which further increased MG levels in the MG+BSO group and aggravated the 
effects of chronic MG. MG itself has been shown to reduce GSH levels (Fig. 8-1C, D) (Dhar 
et al., 2009; Desai and Wu, 2008). Pancreatic β cells have been reported to contain low levels 
of GSH and antioxidant capacity compared to other tissues making it more susceptible to 
oxidative damage (Robertson and Harmon, 2006). Our study supports this view since we also 
found lower GSH levels in pancreas as compared to skeletal muscle (Fig. 8-1D).  
The fasting elevated glucose and low insulin levels in the plasma (Fig. 8-2A, B) are 
features of T2DM (Field, 1962). In the early stages of insulin resistance plasma insulin levels 
are higher than normal, at a stage when the pancreas secretes more insulin to overcome high 
glucose levels. As the disease progresses, the pancreas fails to secrete enough insulin and the 
plasma insulin levels are less than normal with higher plasma glucose levels (Field, 1962; Pick 
et al., 1998). The oral GTT revealed significantly impaired glucose tolerance and reduced 
insulin-response to the glucose load. An impaired GTT is a feature of the prediabetic insulin 
resistance as well as T2DM. One reason for the elevated plasma glucose levels is reduced 
response of insulin sensitive tissues to insulin due to defects in one or more steps of the insulin 
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signaling pathway. In vitro studies have shown that incubation of cultured 3T3-L1 adipocytes 
with MG reduced glucose uptake, decreased insulin-induced insulin-receptor substrate-1 (IRS-
1) tyrosine phosphorylation, and decreased the activity of phosphatidylinositol 3-kinase 
(PI3K) (Riboulet-Chavey et al., 2006; Jia et al., 2007). In a genetic model of diabetes such as 
the Zucker obese rat a defect of glucose transport in muscle has been reported (Friedman et 
al., 1991). We found that MG and MG+BSO reduced membrane GLUT4 in the adipose tissue. 
GLUT4 is the glucose transporter isoform that carries glucose into the adipose and skeletal 
muscle cells in response to insulin. Insulin receptor activation in these tissues results in 
GLUT4 translocation to the cell membrane. We have recently shown that a single dose of MG 
(50 mg/kg i.v.) given to SD rats causes reduced membrane GLUT4 and insulin receptor 
substrate-1 phosphorylation in adipose tissue (Dhar et al., 2010). 
The main reason for the reduced fasting plasma insulin and the reduced insulin 
response to the glucose load could be due to altered function of the pancreatic islets induced 
by MG. We observed that the total pancreatic insulin content was reduced in rats treated with 
MG and MG+BSO (Fig. 8-4). This is likely due to reduced transcription of insulin synthesis 
as indicated by reduced levels of the insulin gene promoters PDX-1 and Maf-A induced by 
MG (Fig. 8-6Bi, ii). PDX-1 is an essential regulator of both pancreatic exocrine and endocrine 
cell development. Inactivation of PDX-1 in the β-cells has been shown to impair β-cell 
function and cause diabetes (Brissova et al., 2005; Leibowitz et al., 2001; Robertson and 
Harmon, 2006). Similarly, Maf-A activates insulin as well as glucagon gene expression in the 
pancreatic islet β and α cells, respectively (Harmon et al., 2005). The expression and/or 
activities of PDX-1 and MafA are reduced in beta-cells in diabetes, resulting in decreased 
insulin synthesis and secretion (Kaneto et al., 2008), which supports our findings of MG as a 
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likely causative factor in T2DM. 
MG and MG+BSO up regulated C/EBPβ in pancreas (Fig. 8-6Biii), which can also be 
responsible for the reduced insulin levels in these rats because C/EBPβ is a repressor of 
insulin gene transcription in β-cells and in diabetes animal models. C/EBPβ deletion reduces 
adiposity, hepatic steatosis and diabetes in Lepr db/db mice (Schroeder-Gloeckler et al., 
2007). We also tested basal and glucose-stimulated insulin secretion from freshly isolated 
pancreatic islets which showed reduced insulin secretion in rats treated with MG and 
MG+BSO. These results support our previous study which showed that acute administration 
of MG (50 mg/kg i.v.) to SD rats reduced glucose-stimulated insulin secretion from isolated 
pancreatic islets (Dhar et al., 2010). GLUT2 is the isoform of the facilitative glucose 
transporters in the pancreatic β cells. GLUT2 is translocated from a cytosolic pool to the 
plasma membrane in response to increased extracellular glucose. GLUT2 also acts as a 
glucose sensor and when the extracellular glucose concentration increases it sends a signal 
inside the cell to cause insulin secretion (Leturque et al., 2009). GLUT2 is reduced in animal 
models of T2DM (Efrat et al., 1994). The reduced secretion of insulin in the MG and 
MG+BSO groups of rats can be partly explained by significantly reduced membrane GLUT2 
in the pancreas (Fig. 8-5B).  
In type I diabetes there is β cell death whereas T2DM is characterized by gradual 
apoptosis of islet β cells which ultimately results in reduced insulin secretion (Pick et al., 
1998; Robertson and Harmon, 2006; Koyama et al., 1998; Efanova et al., 1998). MG has been 
shown to induce apoptosis in other cell types such as neutrophils (Wang et al., 2007), 
Schwann cells (Fukunaga et al., 2004) and Jurkat leukemia T cells (Du et al., 2000). We found 
that MG and MG+BSO had induced DNA fragmentation and cause apoptosis in pancreatic 
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cells (Fig. 8-7A, B). Reduced islet number would also contribute to reduced pancreatic insulin 
content and insulin secretion (Figs. 8-4 and 8-5A) as observed in this study.  
To further elucidate the role of MG in the metabolic and biochemical abnormalities 
described above, one group of rats was treated with MG + ALA. We have recently shown that 
ALA attenuates acute MG-induced glucose intolerance in SD rats (18). Thus, ALA has acute 
MG scavenging action besides being a known AGEs-breaker (Wolffenbuttel et al., 1998; Guo 
et al., 2009; Doggrell, 2001). The attenuation of chronic MG induced deleterious effects by 
ALA strongly supports the role of MG as an inducer of insulin resistance and β-cell 
dysfunction.   
The deleterious effects of MG were not random since there were no significant 
changes in the levels of biomarkers such creatine kinase, an indicator of muscle damage, 
creatinine an indicator of kidney function, and ALT and AST, which are enzyme markers for 
liver damage (Table 8-1). The reason for increased levels of total cholesterol and triglycerides 
and reduced levels of HDL induced by MG and MG+BSO treatment (Table 8-1) are not 
known and require further investigations.  
The results of this study suggest that chronic high dietary carbohydrate may cause 
daily abnormal elevations of MG levels, which leads to cumulative pathologic changes in the 
islet β cell insulin secreting machinery and in the insulin signaling pathway in tissues such as 
the skeletal muscle and adipose tissue. The severity and the time course of progression of 
these pathologic changes to T2DM may depend on the overall health of the individual, any 
underlying oxidative stress, GSH levels and antioxidant defences. 
In summary, we have shown for the first time that chronic administration of MG to SD 
rats induces abnormalities in glucose homeostasis and insulin secretion. The direct 
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involvement of MG in these deleterious effects is supported by the GSH synthesis inhibitor 
BSO, which caused a further increase in MG levels when combined with MG treatment; and 
attenuation of the deleterious effects of MG by the MG scavenger ALA. Our results strongly 
implicate MG as the mediator of high glucose-induced insulin resistance and T2DM that is 
becoming a serious health problem in the Western world (Van dam et al., 2002; Weigensberg 
et al., 2009; Willett et al., 2002; Clark, 2009). Further studies may show that specific and safe 
MG scavengers could be useful in preventing high glucose-induced insulin resistance and 
T2DM. 
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General discussion 
Elevated levels of MG have been reported in diabetic subjects (Wang et al., 2007; 
McLellan et al., 1994) and animals (Jia and Wu, 2007) but the findings have been associative 
so far. In order to prove a direct role of MG in the pathogenesis of diabetes mellitus, T2DM 
specifically, it is necessary to administer MG exogenously to normal animals, such as SD rats 
and perform a battery of tests to see if the biochemical and metabolic abnormalities found in 
T2DM can be reproduced. The rationale for undertaking this project was primarily based on 
several in vitro studies performed in our lab and by other investigators. In in vitro studies, 
treatment of cultured adipocytes, 3T3 cells (Jia et al., 2006) or L6 skeletal muscle cells 
(Ribolet-Chavey et al., 2006), with MG impaired insulin signalling. Similarly, incubation of 
insulin with MG induced modification of the insulin molecule and reduced its ability to induce 
glucose uptake in cultured 3T3-L1 adipocytes (Jia et al., 2006). Fructose-fed SD rats develop 
insulin resistance and have elevated plasma MG levels and reduced adipose tissue insulin-
stimulated glucose uptake (Jia and Wu, 2007). These studies suggest a causative role of MG in 
inducing insulin resistance in insulin sensitive tissues such adipose tissue and skeletal muscle. 
However, there are no studies on any effects of MG on the pancreatic islet insulin secreting β 
cells. Thus, a comprehensive study was planned in normal SD rats to examine the effects of 
exogenous MG when given acutely as a single dose and when given chronically for 4 weeks.  
The project started with an investigation of the relative contribution of some of the 
putative precursors of MG formation to MG generation in cultured A10 VSMCs. As discussed 
in on earlier chapter, aminoacetone, an intermediate of protein metabolism, was the most 
potent precursor in generating MG on an equimolar basis.  After a 3 h incubation, 
aminoacetone produced a 7 fold increase in MG levels above the basal value followed by 
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fructose (3.9 fold) and D-glucose (3.5 fold) (Dhar et al., 2008). Acetol, an intermediate of 
fatty acid metabolism, was comparatively less potent than D-glucose, and produced a 2.8 fold 
increase in MG above the basal value. High fructose, glucose and aminoactone via formation 
of MG increased oxidative stress (Dhar et al., 2008). The study demonstrated that MG 
formation in VSMCs depends on the nature and concentration of the substrate. In order to 
validate the comparison with D-glucose it was necessary to use 25 mM of other substrates, 
despite the knowledge that such high concentrations for these other substrates have not been 
reported in humans or animals in the literature. Thus, while the practical significance of these 
is difficult to gauge without further studies, these findings draw attention to fructose as an 
important source of MG, in view of the fact that diet in Western countries tends to be high in 
fructose, especially in the form of corn syrup.  The potency of aminoacetone may have 
significant implications in subjects with high dietary protein intake or bodily turnover. 
Since measurement of MG levels in various biological samples forms the vital 
parameter for all projects in the lab, it was necessary to ensure a sensitive, reproducible and 
standard method of measurement of samples of plasma, organs/tissues and cultured cells. MG 
is measured by HPLC in most labs, including ours. A project was undertaken to test various 
sample preparation protocols for HPLC. Significant differences were observed in the amount 
of MG detected in a given sample when the sample preparation protocol was altered (Dhar et 
al., 2009). Protocols that yielded consistent and reproducible values in biological samples 
were defined and recommended for other users in the paper that was published (Dhar et al., 
2008). Since many investigators around the world use HPLC to measure MG levels, this was a 
significant and very satisfying achievement for me. 
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Endothelial dysfunction is a feature if early stages of many pathological conditions and 
is a harbinger of severe pathology of disease which can develop. These conditions include 
diabetes mellitus, hypertension, atherosclerosis and many others. More attention is being 
devoted by the scientific community to identify the benefits of treating endothelial 
dysfunction in the hope of preventing more severe cardiovascular pathology later on.  
Typically, endothelial dysfunction is taken as reduced endothelium-dependent 
relaxation. The role of eNOS as a key enzyme generating one of the main vasodilatory 
mediators, viz. NO, is the focus of many studies. Previous studies have reported that 
hyperglycemia induces endothelial dysfunction and the mechanism is commonly ascribed to 
an increase in oxidative stress (Potenza et al., 2009, Triggle, 2008, Nishikawa et al., 2000, 
Brownlee, 2001, Du et al., 2001). It is not yet known how glucose itself triggers the increase 
in ROS production. Since, MG is a well known initiator of oxidative stress, and since it also 
happens to be a reactive metabolite of glucose, it provided a sound rationale for my 
investigation on the possible role of MG as the mediator, or one of the mediators, of 
hyperglycemia induced endothelial dysfunction. Since there have been no reports on the 
involvement of MG itself in endothelial dysfunction, the results of my study showing MG-
induced eNOS-mediated dysfunction were novel and exciting. The results showed that 
incubation of endothelial cells from two different species, viz. human and rat, with high 
glucose for 3 or 24 h increases MG formation in a concentration and time dependent fashion. 
Incubation of HUVECs and RAECs with different concentrations of MG showed that 30 μM 
MG resulted in intracellular MG levels that were comparable to those generated in the cells 
incubated with 25 mM glucose. Both hyperglycemia and MG reduced activity of eNOS, 
reduced serine 1177 phosphorylation and reduced bradykinin-stimulated NO production.  
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Incubation of rat aortic rings with high glucose and MG reduced ACh induced relaxation 
precontracted with phenylepherine. The effect of MG and high glucose on aortic rings, 
HUVECs and RAECs was prevented by MG scavenger, aminoguanidine. The reduced NO 
production is possibly due to reduced eNOS activity without any change in eNOS protein. 
Reduced eNOS activity can be due to reduced BK-stimulated serine-1177 phosphorylation of 
eNOS caused by MG (30 µM) or glucose (25 mM). BK stimulation induces eNOS 
phosphorylation at Ser-1177 and increases NO production. MG and high glucose also 
decreased reduced GSH levels and GSH-reductase protein expression in HUVECs and the 
effect was prevented by MG scavenger, aminoguanidine.  Our study shows for the first time 
that high glucose induced endothelial dysfunction is mediated by MG by reducing eNOS 
phosphorylation/activity, and NO bioavailability. 
In order to undertake a systematic study on the effects of exogenous MG on glucose 
homeostasis in vivo, I started by examining the effects of acute administration of a single dose 
of MG to normal SD rats. Acute administration of MG significantly increased plasma MG 
levels and the levels were still higher at 2 h post MG administration as compared to control 
rats, suggesting a long half life of this dicarbonyl compound. Previous studies have shown 
MG impairs the insulin signalling in vitro by altering the structure and function of the insulin 
molecule (Jia et al., 2006). Interestingly, a single acute dose of MG to normal SD rats 
impaired glucose tolerance and induced insulin resistance (Dhar et al., 2010). After a bolus 
dose of glucose, the glucose tolerance was significantly impaired and insulin levels were 
higher in MG treated rats.  To determine the possible reason of how MG induced insulin 
resistance, insulin stimulated glucose uptake was done in adipose tissue and insulin signalling 
pathway was studied. Our study showed that there was a significant decrease in insulin 
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stimulated glucose uptake, GLUT4 protein expression, IRS-1 tyrosine phosphorylation in 
adipose tissue of MG treated rats. To investigate whether MG induced effects can be 
prevented by MG scavenger, ALA, we gave a single acute dose of alagebrium in one group of 
rats 15 min prior to the administration of MG. ALA significantly attenuated the effects of MG, 
by scavenging it. We also observed significant increase in MG levels in aorta after acute 
administration. These data suggest that even a single acute dose of MG induces glucose 
intolerance and contributes to the development of insulin resistance in normal SD rats. 
The next logical experiment was to examine the effects of chronic administration of 
MG to normal SD rats. The protocol for this study was designed as comprehensively as 
possible to investigate the effects of MG and the underlying molecular mechanisms in detail. 
MG was administered by continuous infusion with an implanted minipump for one month. To 
investigate whether endogenous inhibition of MG detoxification can exacerbate the effect of 
MG, one group of rats was treated with buthionine sulfoximine (BSO) in drinking water along 
with MG. BSO is a GSH synthesis inhibitor. GSH is one of the cofactors involved in the 
metabolism of MG to D-lactate via glyoxalase pathway. One group of rats was treated with 
the MG scavenger, ALA, along with MG. The MG levels were significantly elevated whereas 
GSH levels were significantly decreased in plasma, adipose tissue, skeletal muscle and 
pancreas of MG and MG+BSO treated rats. High plasma glucose levels and impaired glucose 
tolerance were observed in MG treated rats. An investigation of the mechanism of high plasma 
glucose indicated that insulin stimulated glucose uptake in adipose tissue and GLUT4 
translocation to the plasma membrane were significantly reduced in MG treated rats. To 
investigate whether insulin sensitivity was affected, glucose stimulated insulin release from 
freshly isolated pancreatic islets was done in MG treated rats. Glucose stimulated insulin 
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release in islets of MG treated rats was significantly reduced. Moreover GLUT2 protein 
expression was significantly downregulated in MG and MG+BSO treated rats. Apoptosis of 
pancreatic β-cells was also observed in MG and MG+BSO treated rats.  
Mechanism for MG induced T2DM and endothelial dysfunction 
MG induces oxidative stress 
Free radicals are molecules with an unpaired electron. ROS includes both oxygen 
derived free radicals and non radicals which do not have an unpaired electron in their orbit. An 
imbalance between oxidant and antioxidant state in the body creates a condition called 
oxidative stress. Oxidative stress is associated with number of diseases like diabetes mellitus, 
stroke, hypertension and atherosclerosis (Desai, et al., 2010). The most widely used markers 
of oxidative stress are measurement of superoxide, hydrogen peroxide and peroxynitrite in 
biological system. Superoxide is formed by the addition of an electron to the oxygen molecule 
and is mainly formed during mitochondrial electron transport chain reactions. Superoxide is 
cleaved by the enzyme superoxide dismutase into hydrogen peroxide and oxygen molecule 
(Desai, 2008). There are number of methods for the measurement of superoxide in biological 
samples. One of the most widely used is chemiluminescence based lucigenin assay using 
probe bis-N-methylacridinium nitrate (lucigenin). Increased levels of superoxide have been 
found in in vivo and in vitro conditions in association with increased MG, which suggest that 
MG directly induces superoxide generation (Desai, 2008). In 13 week old spontaneously 
hypertensive rats, increased levels of superoxide in aorta are associated with increased aortic 
MG levels (Wang, et al., 2005). Treatment of VSMCs with MG increased superoxide 
formation in a concentration and time dependent manner and the effect was prevented by the 
superoxide scavenger SOD (Wang, et al., 2006). Superoxide formation has also been shown to 
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increase significantly in neutrophils exposed to MG for 60 min. Although it is not a free 
radical, hydrogen peroxide is another highly reactive molecule. Catalase is the main enzyme 
involved in hydrogen peroxide removal. Hydrogen peroxide is measured using the probe 
2’,7’-dichlorofluorescin diacetate (DCFH-DA). Once inside the cell, DCFH-DA is converted 
to DCFH2 and then oxidised to the fluorescent product DCF. DCF is easily detected in cells 
using a fluorescent microscope or spectrofluorometer (Desai & Wu, 2007). When superoxide 
reacts with nitric oxide, it forms peroxunitrite, a reactive molecule with a short half life. 
Peroxynitrite levels can be measured in biological systems using dihydrodichlorofluorescein 
(H2DCF) or dihydrorhodamine 123 (DHR-123). Peroxynitrite oxidizes 
dihydrodichlorofluorescein and dihydrorhodamine to fluorescent dichlorofluorescein or 
rhodamine 123 which can be detected using spectrofluorometer (Mart´ın-Romero et al., 2004) 
 
MG impairs insulin gene transcription 
Insulin resistance is observed in disease conditions like diabetes and obesity. Chronic 
hyperglycemia associated with insulin resistance leads to various diabetic microvascular and 
microvascular complications. Chronic hyperglycemia leads to AGE formation by initiating 
reaction between reducing sugars and free amino groups on proteins. A large body of evidence 
suggests that harmful effects of hyperglycemia are due to the formation of oxoaldehydes, MG, 
glyoxal and 3-deoxyglucosone (Desai et al., 2010). Incubation of VSMCs with high glucose 
increases MG formation. Moreover, CEL, one of the AGEs was also significantly increased in 
VSMCs treated with high glucose (Dhar et al., 2008). MG levels have also been found to be 
elevated in plasma of diabetic patients which correlates with the degree of hyperglycemia 
(Wang et al., 2006). Treatment of L6 muscle cells with MG at a concentration of 5 mM alters 
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IRS-1 phosphorylation and impairs insulin signalling pathway (Riboulet-Chavey et al., 2006). 
MG alters the structure of insulin by modification of B-chain in vitro in a concentration 
dependent manner. The resulting MG-insulin adduct reduces glucose uptake in 3T3 adipocytes 
and impairs the function of insulin molecule (Jia, et al., 2006). Our present study has reported 
for the first time that MG administered by continuous infusion with a minipump for 28 days to 
Sprague-Dawley rats induces molecular abnormalities characteristic of type II diabetes 
mellitus. The elevation of plasma glucose levels is due to reduced insulin-stimulated glucose 
uptake in adipose tissue and plasma membrane GLUT-4 protein. We also observed pancreatic 
islet β-cell insulin secreting machinery was significantly impaired in MG and MG+BSO 
treated rats. Glucose-stimulated insulin secretion was reduced in freshly isolated pancreatic 
islets, GLUT2 protein level was decreased, pancreatic insulin content was lower. The protein 
as well as mRNA expression of insulin promoter transcriptional factors PDX-1 and Maf-A 
were significantly down-regulated whereas protein expression of C/EBPβ, a repressor of 
insulin gene transcription, was significantly up-regulated in MG and MG+BSO treated rats. 
The reduced insulin levels seen in the present study, can be due to impaired function of 
pancreatic islets. We also observed apoptosis and DNA fragmentation of pancreatic islets in 
MG and MG+BSO treated rats. The harmful effects of MG were attenuated by the MG 
scavenger and AGEs breaking compound, ALA. The insulin content in the pancreas was 
reduced in rats treated with MG and MG+BSO. The possible reason is due to reduced 
transcription of insulin synthesis as indicated by reduced levels of the insulin gene promoters 
PDX-1 and Maf-A induced by MG. PDX-1 is an essential regulator of pancreatic cell 
development. Inactivation of PDX-1 in the β-cells has been shown to impair β-cell function 
and cause diabetes. Maf-A , other transcription factor, activates insulin as well as glucagon 
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gene expression in the pancreatic islet β and α cells, respectively. The expression of PDX-1 
and MafA are reduced in beta-cells of diabetes, resulting in decreased insulin synthesis and 
secretion, which clearly supports our findings of MG as a likely causative factor in T2DM. 
The present study indicates that diet high in carbohydrates causes daily abnormal elevations of 
MG levels, which leads to cumulative pathologic changes in the islet β cell insulin secreting 
machinery and in the insulin signalling pathway. The severity and the time course of 
progression of these pathologic changes to T2DM depends on the health of the individual, any 
underlying oxidative stress, GSH levels and antioxidant defences. 
 
MG induces apoptosis 
Apoptosis, also known as programmed cell death, is characterised by nuclear 
fragmentation, cell shrinkage, chromatin condensation and DNA fragmentation. Apoptosis 
differs from necrosis in that necrosis is due to cell injury. The most widely used method to 
check apoptosis is the TUNEL assay. TUNEL detects the DNA fragmentation which results 
from apoptosis. In T1DM, there is a β cell death whereas in case of T2DM as the disease 
progresses there is apoptosis of pancreatic islets which lead to reduced insulin secretion. MG 
has been shown to induce apoptosis in rat mesangial cells by activating p38 mitogen activated 
protein kinases (MAPK) (Liu et al., 2003). Incubation of primary rat retinal pericytes with 400 
µM of MG for 6 h induces apoptosis (Kim et al., 2010). We have shown in our study that 
chronic treatment with MG and MG+BSO induce DNA fragmentation and apoptosis of 
pancreatic islets.  
 
Limitations of the study 
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MG is produced in the body through many metabolic pathways. However, there is no 
report available on the relative amounts produced in different cell types and tissues, and also 
about the sources of MG that contribute to its basal plasma levels. It appears that the 
glyoxalase system and GSH very efficiently metabolize MG under physiological conditions 
and keep plasma MG levels below 10 µM as reported in most studies. Despite this fact, most 
in vitro studies have employed very high concentrations of MG ranging from 100 µM to 5 
mM and more. Such high concentrations possibly do not have any pathophysiological 
relevance. One parameter we tried to observe in our doses and concentrations employed was 
the range of intracellular and plasma concentrations that we achieved, which was within the 
range reported in most studies. It is interesting in this regard that we observed significantly 
much higher basal as well as post exogenous-MG levels in aorta in SD rats. Whether more 
MG is produced basally in the aorta or whether it is deposited from the plasma is a big 
question that we did not address. 
In our studies on cultured VSMCs reported in Chapter 4, we had to use a concentration 
of 25 mM of precursors such as aminoacetone and fructose, despite the fact that such high 
concentrations of these substrates have not been reported in the body. However, in order to 
compare these substrates with D-glucose, the most common precursor, it was necessary to use 
the same concentrations for all substrates. Levels of 25 mM plasma glucose are found in STZ-
induced diabetes and sometimes in human subjects whose diabetes is not controlled. 
In our studies on endothelial dysfunction it should be pointed out that we focused on 
the eNOS-NO system and endothelium-dependent relaxation. It can be argued that a lack of 
other vasodilatory mediators such as prostacyclin and EDHF, or an excess production of 
vasoconstrictors such as endothelin may also contribute to dysfunction. These are avenues for 
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future research. Similarly, the endothelium plays many roles besides regulation of vascular 
tone. Aspects of dysfunction related to these functions of the endothelium were not addressed 
in the present study due to obvious time restraints. These aspects require extensive further 
studies. 
Another problem that is encountered in in vivo administration of MG is the route of 
administration. There have been no systematic reports on the oral absorption and 
pharmacokinetics of MG. We examined the oral administration of MG to SD rats and found 
that even after a high oral dose of 200 mg/kg given as an intragastric bolus by gavage, the 
absorption was limited and the peak level was less than one third of the level achieved with 
100 mg/kg administered by the i.p. route. In such a case, administration of MG in drinking 
water would necessitate doses even higher than 200 mg/kg, which would still cast a doubt on 
how much is or will be absorbed since rats drink water by small sips at a time.  
Another major problem on studies with MG is the lack of absolutely specific 
scavengers for MG. As described in the introduction, the most widely used scavenger, 
aminoguanidine, has other effects such as inhibition of histaminase and iNOS (Desai and Wu, 
2007). Metformin when used as aMG scavenger (Lopez, et al., 1999). , while being safer, has 
actions on insulin-sensitive tissues. NAC, another scavenger, despite being used clinically, e.g. 
for acetaminophen overdose, has direct antioxidant properties. However, we tried different 
concentrations of aminoguanidine initially and selected the lowest effective 
dose/concentration. ALA was developed as an AGE-breaker (Coughlan, et al., 2007; Guo, et 
al., 2009; Wolffenbuttel, et al., 1998)., but we investigated and reported its acute effects as a 
preventive agent against MG (Dhar et al., 2010).  
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CONCLUSIONS 
Our present study strongly implicates MG as one of the causative factors for the 
development of diabetes mellitus and endothelial dysfunction. Numerous studies have 
reported elevated levels of MG under diabetic and hypertensive conditions.  But it was unclear 
whether MG is the cause or effect of these pathological conditions. We have shown in our 
study that incubation of VSMCs, RAECs and HUVECs with glucose increases MG formation 
in a concentration dependent manner. The increase in MG formation is associated with 
increased oxidative stress. Increase in MG levels in HUVECs induces endothelial dysfunction 
by reducing eNOS activity, NO bioavailability and phosphorylation of eNOS at ser-1177. 
 Acute MG administration to normal SD rats for 2 h induces glucose intolerance and 
impairs insulin signalling pathway by reducing tyrosine phosphorylation of IRS-1. We also 
observed reduced insulin stimulated glucose uptake and GLUT4 protein expression in adipose 
tissue of MG treated rats. Chronic MG administration by mini pump for 28 days induced 
pancreatic β- cell dysfunction.  There was a significant increase in MG levels and decrease in 
GSH levels in plasma, pancreas, skeletal muscle and adipose tissue of MG and MG+BSO 
treated rats. Insulin stimulated glucose uptake and GLUT4 translocation was significantly 
impaired in adipose tissue of MG and MG+BSO treated rats. There was also reduced glucose 
stimulated insulin release in freshly isolated pancreatic islets in MG treated rats. Moreover we 
observed impaired insulin content and insulin gene transcription in pancreas of MG treated 
rats. The effects of MG were prevented by MG scavenger and AGE breaking compound 
alagebrium. All of these observations and results strongly implicate MG as one of the 
causative factors for the development of T2DM. 
 In conclusion, MG is one of the causative factors for the development of endothelial 
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dysfunction and T2DM. Development of specific MG scavengers will help prevent the 
progression of high carbohydrate induced diabetes and endothelial dysfunction. 
 
SIGNIFICANCE OF THE STUDY 
Diabetes is one of the leading causes of death next to cancer and heart diseases. 
Currently the number of people affected by diabetes globally is 285 million and the number is 
expected to reach 438 million by the year 2030. In Canada alone 3 million people have 
diabetes and the number will be 3.7 million by the year 2020. It is estimated that economic 
cost for the treatment of diabetes in Canada will be $16.9 billion by the year 2020. The 
incidence of T2DM is rising due to obesity, changing life style and aging. 
 The role of MG in the pathogenesis of diabetes has gained more attention in recent 
years. Exploring the role of MG in the pathogenesis of diabetes will provide new mechanistic 
links and novel upstream therapeutic targets for the treatment and management of diabetes 
mellitus. 
 
FUTURE DIRECTIONS 
 
To further clarify the role of MG in the pathogenesis of diabetes, hypertension and vascular 
remodelling, we are planning to carry out the following experiments in near future: 
1. Treat SD rats with MG for one month, measure blood pressure and do functional 
studies using myograph and organ bath. 
2. Use a specific MG scavengers like SMG08 to attenuate the MG-induced 
endothelial dysfunction and T2DM. 
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3.  Investigate the molecular mechanism of how MG induces hypertension and 
vascular remodelling by determining the protein and mRNA expression of α1, AT1, 
renin and ACE in VSMCs, aorta and kidney. 
4. Find specific MG inhibitors with minimal side effects and check their therapeutic 
effect in different diabetic animal models. This study will help explore alternative 
treatment for the management of diabetes and its complications. 
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